

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT WEST VIRGINIA
CHARLESTON DIVISION

Case No. 2:12-cv-00760

Master File
No. 2:12-MD-02327

JOSEPH R. GOODWIN
U.S. DISTRICT JUDGE

ORAL DEPOSITION OF
CHRISTINA PRAMUDJI, M.D.

MARCH 23, 2016

Christina Pramudji, M.D.

Page 2	Page 4
<p>1 ELIZABETH BLYNN WILSON) Case No. 2:12-cv-01286)</p> <p>2)</p> <p>3 DAPHNE BARKER) Case No. 2:12-cv-00899)</p> <p>4)</p> <p>5 WENDY HAGANS) Case No. 2:12-cv-00783)</p> <p>6)</p> <p>7 MARIA EUGENIA QUIJANO) Case No. 2:12-cv-00799)</p> <p>8)</p> <p>9 SHARON BOGGS) Case No. 2:12-cv-00368)</p> <p>10)</p> <p>11 CAREY COLE) Case No. 2:12-cv-00483)</p> <p>12)</p> <p>13 CATHY WARLICK) Case No. 2:12-cv-00276)</p> <p>14)</p> <p>15 DONNA AMSDEN) Case No. 2:12-cv-00960)</p> <p>16)</p> <p>17 HEATHER LONG) Case No. 2:12-cv-01275)</p> <p>18)</p> <p>19 PENNY RHYNEHART) Case No. 2:12-cv-01119)</p> <p>20)</p> <p>21 NANCY JO WILLIAMS) Case No. 2:12-cv-00511)</p> <p>22)</p> <p>23 MARIA STONE) Case No. 2:12-cv-00652)</p> <p>24)</p> <p>25 TERRI KEY SHIVELY) Case No. 2:12-cv-00379)</p> <p>26)</p> <p>27 CHARLENE LOGAN TAYLOR) Case No. 2:12-cv-00376)</p> <p>28)</p> <p>29 TINA MORROW) Case No. 2:12-cv-00378)</p> <p>30)</p> <p>31 CAROL JEAN DIMOCK) Case No. 2:12-cv-004001)</p>	<p>1 APPEARANCES</p> <p>2</p> <p>3</p> <p>4 FOR THE PLAINTIFFS:</p> <p>5 ANDREW N. FAES, ESQ. Wagstaff & Cartmell LLP 4740 Grand Avenue, Suite 300 Kansas City, Missouri 64112 816.701.1100 afaes@wcllp.com</p> <p>7</p> <p>8</p> <p>9 FOR THE DEFENDANTS:</p> <p>10 WILLIAM M. GAGE, ESQ. Butler Snow, LLP 1020 Highland Colony Parkway, Suite 1400 Ridgeland, Mississippi 39157 601.948.5711 william.gage@butlersnow.com</p> <p>12</p> <p>13 ALSO PRESENT:</p> <p>14 Ms. Tamara Vinson, Court Reporter</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
Page 3	Page 5
<p>1 ORAL DEPOSITION OF CHRISTINA PRAMUDJI, M.D.</p> <p>2 produced as a witness at the instance of the</p> <p>3 PLAINTIFFS, and duly sworn, was taken in the</p> <p>4 above-styled and numbered cause on the 23rd of March,</p> <p>5 2016, from 1:20 p.m. to 4:25 p.m., before Tamara</p> <p>6 Vinson, CSR in and for the State of Texas, reported by</p> <p>7 machine shorthand, at the Westin-Houston Memorial</p> <p>8 City, 945 Gessner Road, Houston, Texas, 77024,</p> <p>9 pursuant to the Federal Rules of Civil Procedure and</p> <p>10 the provisions stated on the record or attached</p> <p>11 hereto.</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1 INDEX</p> <p>2 PAGE</p> <p>3 Appearances.....3</p> <p>4</p> <p>5 CHRISTINA PRAMUDJI, M.D.</p> <p>6</p> <p>7 Examination by Mr. Faes.....8</p> <p>8</p> <p>9 Signature reserved.....136</p> <p>10 Reporter's Certificate.....138</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

Christina Pramudji, M.D.

Page 6	Page 8
<p>1 EXHIBIT INDEX</p> <p>2 PAGE</p> <p>3 Exhibit No. 1.....8</p> <p>4 Notice to Take Deposition of Christina</p> <p>5 Pramudji, M.D.</p> <p>6 Exhibit No. 2.....11</p> <p>7 Expert Report of Christina Pramudji, M.D.</p> <p>8 Exhibit No. 3.....15</p> <p>9 Christina Pramudji Reliance List in</p> <p>10 Addition to Materials Referenced in</p> <p>11 Report - MDL Wave 1</p> <p>12 Exhibit No. 4.....22</p> <p>13 Curriculum Vitae</p> <p>14 Exhibit No. 5.....10</p> <p>15 Placeholder</p> <p>16 Exhibit No. 6.....22</p> <p>17 Curriculum Vitae</p> <p>18 Exhibit No. 7.....41</p> <p>19 Gynecare Proxima</p> <p>20 Exhibit No. 8.....56</p> <p>21 USDA UPDATE on Serious Complications</p> <p>22 Associated with Transvaginal Placement of</p> <p>23 Surgical Mesh for Pelvic Organ Prolapse:</p> <p>24 FDA Safety Communication</p> <p>Exhibit No. 9.....66</p> <p>FDA News Release - FDA strengthens</p> <p>requirements for surgical mesh for the</p> <p>transvaginal repair of pelvic organ</p> <p>prolapse to address safety risks</p>	<p>1 with you today that are responsive to those requests?</p> <p>2 A. Yes.</p> <p>3 Q. What are those materials that you brought</p> <p>4 today?</p> <p>5 A. Well, I brought my CV. I brought all the</p> <p>6 documents in my possession, including the thumb</p> <p>7 drives, the company educational literature, the</p> <p>8 literature in publications, all the documents that I</p> <p>9 would have used in preparation, the patient medical</p> <p>10 records, everything that I could -- that I could find,</p> <p>11 with the exception of some of the materials that were</p> <p>12 produced in prior cases and have been sent back to</p> <p>13 Butler Snow.</p> <p>14 Q. Have you brought any invoices with you today</p> <p>15 regarding your work on the Wave 1 expert reports or</p> <p>16 any of the --</p> <p>17 A. No.</p> <p>18 Q. -- case-specific reports?</p> <p>19 A. No.</p> <p>20 Q. Okay. What I'm -- have you billed for</p> <p>21 those --</p> <p>22 A. No.</p> <p>23 Q. -- those reports yet? No, you have not.</p> <p>24 When do you anticipate billing --</p>
Page 7	Page 9
<p>1 CHRISTINA PRAMUDJI, M.D.,</p> <p>2 having been first duly sworn, testified as follows:</p> <p>3 EXAMINATION</p> <p>4 QUESTIONS BY MR. FAES:</p> <p>5 Q. Dr. Pramudji, good afternoon. My name is</p> <p>6 Andy Faes. I'm here to take your deposition today</p> <p>7 regarding the Proxima device. Do you understand that?</p> <p>8 A. Yes.</p> <p>9 Q. And you understand that you're sworn to tell</p> <p>10 the truth. Correct?</p> <p>11 A. Yes.</p> <p>12 Q. Now, if I ask you -- you've been through this</p> <p>13 process before, I take it, but if I ask you a</p> <p>14 question that you don't understand, just let me know</p> <p>15 and I'll try to rephrase the question. All right?</p> <p>16 A. Sure.</p> <p>17 (Exhibit No. 1 marked.)</p> <p>18 Q. I'm going to hand you what's been marked as</p> <p>19 Exhibit No. 1 to the deposition, which is the</p> <p>20 deposition notice. Let me ask you, Dr. Pramudji, have</p> <p>21 you reviewed that document prior to today?</p> <p>22 A. Yes.</p> <p>23 Q. And attached to that notice there's a number</p> <p>24 of document requests. Have you brought any materials</p>	<p>1 A. Probably --</p> <p>2 Q. -- for those reports?</p> <p>3 A. Probably in the next few days.</p> <p>4 Q. Within the next few days?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. What I'm going to do is -- I know I'm</p> <p>7 throwing off the exhibit numbers, but I'm going to</p> <p>8 mark as Exhibit No. 5 --</p> <p>9 A. Uh-huh.</p> <p>10 Q. -- a placeholder. And if you and William</p> <p>11 could agree that when those bills become available --</p> <p>12 A. Uh-huh.</p> <p>13 Q. -- for your general reports and your</p> <p>14 case-specific reports --</p> <p>15 A. Uh-huh.</p> <p>16 Q. -- that are the subject of this notice of</p> <p>17 deposition, you'll send those to the Court Reporter</p> <p>18 and they'll substitute those out as Exhibit No. 5.</p> <p>19 A. Okay.</p> <p>20 (Exhibit No. 5 marked.)</p> <p>21 MR. GAGE: And I would say, I don't have</p> <p>22 an objection to that, except for I do know I have --</p> <p>23 Andy, I heard some generalized commentary back and</p> <p>24 forth between counsel, not you and me, that there was</p>

3 (Pages 6 to 9)

Christina Pramudji, M.D.

Page 10	Page 12
<p>1 some dispute -- I can't remember the details of it --</p> <p>2 some dispute as to whether or not we had gotten the</p> <p>3 invoices from Plaintiffs and their experts and we</p> <p>4 needed to have some meeting of the minds. I'm</p> <p>5 assuming we're going to ultimately get to a meeting of</p> <p>6 the minds on that. So I don't have an objection to</p> <p>7 producing them, but I do know that there is some</p> <p>8 dispute out there that we're still needing to get some</p> <p>9 from your experts. And so, you know, that's not a</p> <p>10 fight you and I need to discuss or deal with today.</p> <p>11 MR. FAES: No. I agree.</p> <p>12 (Exhibit No. 2 marked.)</p> <p>13 Q. (By Mr. Faes) Doctor, I'm going to hand you</p> <p>14 what's been marked as Exhibit No. 2.</p> <p>15 A. Uh-huh.</p> <p>16 Q. Can you tell me what that is?</p> <p>17 A. Yes. This is my expert report regarding the</p> <p>18 Gynemesh, the Prolift and the Prosima.</p> <p>19 Q. Does this report contain each of the opinions</p> <p>20 that you've reached regarding the Prosima, Prolift and</p> <p>21 Gynemesh PS?</p> <p>22 A. Yes, these are my opinions.</p> <p>23 Q. Is there any particular reason why you chose</p> <p>24 to combine your opinions on those three products into</p>	<p>1 the complication rates for the Prosima device are</p> <p>2 different than the Gynemesh PS flat mesh. Correct?</p> <p>3 A. Are you talking about the Gynemesh PS being</p> <p>4 used as a Prolift or just being used as a --</p> <p>5 Q. No. I'm talking about the Gynemesh just as a</p> <p>6 flat mesh.</p> <p>7 A. Oh, they're -- actually, they're pretty</p> <p>8 similar.</p> <p>9 Q. So it's your --</p> <p>10 A. I -- I'm sorry. Before I thought you were</p> <p>11 talking about the Prolift versus the Prosima, which</p> <p>12 they have slightly different rates. But with the</p> <p>13 Gynemesh and the Prosima they're pretty similar.</p> <p>14 Q. So you believe that the complication rates</p> <p>15 for the Prosima device and the Gynemesh PS flat mesh</p> <p>16 --</p> <p>17 A. Uh-huh.</p> <p>18 Q. -- are similar?</p> <p>19 A. Yes.</p> <p>20 Q. Do you agree that the Prolift device has a</p> <p>21 different safety and efficacy profile than the</p> <p>22 Gynemesh PS flat mesh?</p> <p>23 A. It has a slightly -- slightly different, but</p> <p>24 it's -- it's not a huge -- not a huge difference.</p>
Page 11	Page 13
<p>1 a single report as opposed to separating them out?</p> <p>2 A. Well, because the products are made of</p> <p>3 Gynemesh PS and a lot of the science correlates with</p> <p>4 -- with all the products, it seemed to make more sense</p> <p>5 to just combine it.</p> <p>6 Q. Would you agree that the Prosima, for</p> <p>7 example, has a different safety and efficacy profile</p> <p>8 than the Gynemesh PS flat mesh?</p> <p>9 A. It does have a different efficacy, yes. But</p> <p>10 -- but I think a lot of the general -- the general</p> <p>11 points about the different products come together</p> <p>12 nicely and the opinions can be held.</p> <p>13 Q. So you've answered my question on efficacy.</p> <p>14 A. Uh-huh.</p> <p>15 Q. Do you agree that the Prosima has a different</p> <p>16 safety profile than the Gynemesh PS flat mesh?</p> <p>17 A. It depends on what you're -- what you're</p> <p>18 talking about. There are some differences, yes.</p> <p>19 Q. You'd agree that the Prosima device has some</p> <p>20 unique risks that are unique to the Prosima. Correct?</p> <p>21 A. I don't know if they're unique risks. I'm</p> <p>22 thinking more about the rates may be different when</p> <p>23 you compare the products.</p> <p>24 Q. But as a general principle, we can agree that</p>	<p>1 Q. Well, you'd agree, for example, that the</p> <p>2 Prolift kit has trocars and the Gynemesh PS flat</p> <p>3 mesh and the Prosima mesh do not have trocars.</p> <p>4 Correct?</p> <p>5 A. That's correct, yes.</p> <p>6 Q. Would you agree that the trocars used in the</p> <p>7 Prolift mesh kit can introduce unique risks that are</p> <p>8 not risks of the Gynemesh PS flat mesh or the Prosima</p> <p>9 device?</p> <p>10 A. They -- they can, yes. I don't know that</p> <p>11 they're really significant looking at the literature,</p> <p>12 but that is a theory that's out there.</p> <p>13 MR. FAES: Okay. Object and move to</p> <p>14 strike after the answer "yes."</p> <p>15 Q. (By Mr. Faes) Now, in your report, which</p> <p>16 I've marked as Exhibit 2, you go through various facts</p> <p>17 and discuss facts. Did you discuss the facts that you</p> <p>18 were -- you felt were the most important in drawing</p> <p>19 your opinions in the report?</p> <p>20 A. Yes.</p> <p>21 Q. In terms of your decision making in writing</p> <p>22 the report, why did you choose to cite the articles in</p> <p>23 your report that you cited?</p> <p>24 A. Well, I try to cite as much level one</p>

4 (Pages 10 to 13)

Christina Pramudji, M.D.

Page 14	Page 16
<p>1 literature as I can, which is going to be randomized</p> <p>2 controlled trials and review studies where they're,</p> <p>3 you know, gathering together a lot of large studies</p> <p>4 because that's the highest level of literature and try</p> <p>5 to get a good sampling of the highest level studies</p> <p>6 that there are.</p> <p>7 (Exhibit No. 3 marked.)</p> <p>8 Q. Okay. I'm going to hand you what's been</p> <p>9 marked as Exhibit No. 3 to your deposition.</p> <p>10 A. Uh-huh.</p> <p>11 Q. Can you tell me what that is?</p> <p>12 A. It's the reliance list.</p> <p>13 Q. Now --</p> <p>14 MR. FAES: Do you have something to say,</p> <p>15 William, before I . .</p> <p>16 MR. GAGE: Just don't forget to -- she</p> <p>17 mentioned an updated resume. I didn't want you to</p> <p>18 forget to --</p> <p>19 MR. FAES: Oh.</p> <p>20 MR. GAGE: -- mark that as a separate</p> <p>21 exhibit, which I'm handing to you. I mean, do it</p> <p>22 after you ask the questions on the reliance list.</p> <p>23 MR. FAES: Sure.</p> <p>24 MR. GAGE: I didn't mean to interrupt</p>	<p>1 A. Butler Snow helped me to make the list.</p> <p>2 Q. Does this list contain all of the materials</p> <p>3 that you reviewed and relied upon in forming your</p> <p>4 opinions in this case?</p> <p>5 A. Yes.</p> <p>6 Q. You've mentioned that you've brought a number</p> <p>7 of materials with you.</p> <p>8 A. Uh-huh.</p> <p>9 Q. There's flash drives, there's materials</p> <p>10 stacked in front of you.</p> <p>11 A. Uh-huh.</p> <p>12 Q. Is everything -- is there anything that</p> <p>13 you brought today -- strike that. I'll start over --</p> <p>14 A. Uh-huh.</p> <p>15 Q. -- and ask a new question because you</p> <p>16 look like you're maybe a little confused.</p> <p>17 Is there anything that you brought with you</p> <p>18 today that you've reviewed and relied upon in forming</p> <p>19 your opinions on the Prolift, Prosima or Gynemesh</p> <p>20 PS --</p> <p>21 A. Uh-huh.</p> <p>22 Q. -- that is not listed on Exhibit No. 3?</p> <p>23 A. Not to my knowledge.</p> <p>24 Q. Now, you've combined your reliance</p>
Page 15	Page 17
<p>1 you.</p> <p>2 MR. FAES: Well, I already had a</p> <p>3 different one marked, so. . .</p> <p>4 MR. GAGE: Yeah. Is that -- well, he'll</p> <p>5 ask you -- he'll ask you whether you updated that one</p> <p>6 at the appropriate time. I'm sorry to interrupt. I</p> <p>7 just didn't want to forget. I handed it to you when I</p> <p>8 looked down and I saw it in my lap.</p> <p>9 MR. FAES: I don't see any difference</p> <p>10 between this and the one I have. Anyway. . .</p> <p>11 Q. (By Mr. Faes) Now, Dr. Pramudji --</p> <p>12 A. Uh-huh.</p> <p>13 Q. -- Exhibit 3 --</p> <p>14 A. Uh-huh.</p> <p>15 Q. -- is that the reliance list for both your</p> <p>16 Prosima/Gynemesh PS/Prolift report, as well as your</p> <p>17 TVT and TVTO general report?</p> <p>18 A. Yes.</p> <p>19 Q. And at this time, you haven't issued any</p> <p>20 general reports on any of the TVT products, other than</p> <p>21 the TVT retropubic device and the TVTO device. Right?</p> <p>22 A. That's correct.</p> <p>23 Q. Now, did you make this list or was it</p> <p>24 provided for you?</p>	<p>1 list for the -- we'll call them the pelvic organ</p> <p>2 prolapse products. When I say pelvic organ prolapse</p> <p>3 products, I'm referring from here on out as the</p> <p>4 Prolift, the Prosima and the Gynemesh PS. Can we</p> <p>5 agree to that?</p> <p>6 A. Yes.</p> <p>7 Q. So you combined your opinions -- strike that.</p> <p>8 You've combined your reliance list for your</p> <p>9 report on the pelvic organ prolapse products and your</p> <p>10 general report on the TVT and TVTO products. Correct?</p> <p>11 A. Yes.</p> <p>12 Q. There's one reliance list for both reports.</p> <p>13 Correct?</p> <p>14 A. Yes.</p> <p>15 Q. In forming your opinions, did you rely on</p> <p>16 midurethral slings -- strike that.</p> <p>17 In forming your opinions on the POP products,</p> <p>18 did you rely on midurethral strings [sic] and the TVT</p> <p>19 to form any of your opinions regarding the safety and</p> <p>20 efficacy of the Prolift?</p> <p>21 MR. GAGE: Object to form.</p> <p>22 A. Not for the -- not for the major substance of</p> <p>23 my opinions. I mean, for, you know, peripheral</p> <p>24 knowledge, I think it helps support the safety of the</p>

5 (Pages 14 to 17)

Christina Pramudji, M.D.

Page 18	Page 20
<p>1 mesh, but obviously they're very different products, 2 so you can't draw too many conclusions -- 3 Q. (By Mr. Faes) Okay. So same -- 4 A. -- on the general safety of the mesh. 5 Q. Sorry. I didn't mean to interrupt you. So 6 same question: Prosima and Gynemesh PS, in forming 7 your opinions, did you rely on midurethral slings and 8 the TVT to form any of your opinions regarding the 9 safety and efficacy of the Gynemesh PS or the Prosima? 10 A. I'm sorry. Wasn't that the same question 11 that I just answered? 12 Q. You answered it for Prolift the first time. 13 A. Oh, okay. Well, it would be the same answer. 14 Q. Okay. Thank you. Now, when were you first 15 contacted about being a general expert in this case 16 regarding the Prosima? 17 A. Well, the M -- this M -- this big MDL wave 18 was in November. 19 Q. Okay. 20 A. But there was another Prosima case prior to 21 that, maybe a year, year and a half ago. 22 Q. Right. You're referring to the Caviness 23 case -- 24 A. Right.</p>	<p>1 because it was Texas -- 2 MR. FAES: Right. And you guys -- 3 THE WITNESS: -- Federal court. 4 MR. FAES: And you guys never do any 5 more than that. 6 THE REPORTER: We have to do this one at 7 a time, please. 8 MR. FAES: Sorry. 9 MR. FAES: Okay. So I'll just ask if 10 the -- that -- if one was created for the Caviness 11 case, a written report, that you provide that to us. 12 Q. (By Mr. Faes) How many hours would you 13 -- strike that. I'm going to ask a different 14 question. 15 When were you first contacted about being an 16 expert in this case regarding the Gynemesh PS? 17 A. When you say "this case," you mean -- what do 18 you mean specifically? 19 Q. I mean this Wave 1 general expert report. 20 A. This. Oh, okay. So that all just started in 21 November. 22 Q. Have you -- do you have an estimate of the 23 number of hours that you've spent preparing this 24 report which is marked as Exhibit 3?</p>
Page 19	Page 21
<p>1 Q. -- where you were asked by Butler Snow to be 2 an expert? 3 A. Yes. 4 Q. But you didn't prepare a written report 5 in that case. Correct? 6 A. I honestly can't recall. I don't know. I 7 can't remember. At this point, I'd have to look back 8 at my records. 9 MR. FAES: Okay. And I'd ask if one was 10 -- was created that it be produced to us, but, 11 William, correct me if I'm wrong, I'm pretty sure 12 there wasn't. It was just an expert disclosure. 13 Right? 14 MR. GAGE: Andy -- 15 THE WITNESS: I think -- 16 MR. GAGE: -- I honestly don't know, but 17 I will tell you, my sense is -- 18 THE WITNESS: That's right. 19 MR. GAGE: -- in Texas State court, I 20 think the rule is we only had to do disclosures and 21 not reports. 22 MR. FAES: Yeah. 23 MR. GAGE: And I think you're -- 24 THE WITNESS: Yeah, that's what it --</p>	<p>1 A. Yeah. Probably, I would say -- I would 2 estimate about 50 hours. 3 Q. Now, that 50 hours, is that for the entire 4 report for all three of the pelvic organ prolapse 5 products? 6 A. Yes. 7 Q. How many hours of that 50 would you say you 8 spent actually drafting the report? 9 A. Probably about 20. 10 Q. And how many of those hours would you say you 11 spent reviewing materials that went into the report? 12 A. About 30. A lot of the materials I was 13 already familiar with from previous cases. 14 (Exhibit No. 4 marked.) 15 Q. Okay. I'm going to hand you what's been 16 marked as Exhibit 4, which is the -- your CV that was 17 produced to us. And I'm also going to mark as 18 Exhibit 6 the CV that counsel just gave me, which was 19 represented as your updated CV. At first glance, I 20 couldn't tell my difference to it. We'll refer to 21 Exhibit 6 most of the time. 22 (Exhibit No. 6 marked.) 23 Q. So if you look at Exhibit No. 6, which has 24 been represented as your current updated CV, there's a</p>

6 (Pages 18 to 21)

Christina Pramudji, M.D.

Page 22	Page 24
<p>1 list of publications. Correct?</p> <p>2 A. Correct.</p> <p>3 Q. Do any of the publications listed in your CV</p> <p>4 specifically address the Prosima product?</p> <p>5 A. No.</p> <p>6 Q. Do any of the publications listed in your</p> <p>7 report specifically address the Gynemesh PS products?</p> <p>8 A. No.</p> <p>9 Q. Do any of the publications in your report</p> <p>10 specifically address the transvaginal technique for</p> <p>11 the treatment of prolapse?</p> <p>12 MR. GAGE: Object to form. Your -- the</p> <p>13 -- and I'll object to the form to last two -- the last</p> <p>14 two questions. You've asked the question: Do any of</p> <p>15 the publications listed in your report. I'm thinking</p> <p>16 you're meaning to say listed in your CV.</p> <p>17 MR. FAES: I do mean that, so I'll --</p> <p>18 thank you, William. I'll re-ask the question.</p> <p>19 MR. GAGE: Yeah.</p> <p>20 Q. (By Mr. Faes) Do any of the --</p> <p>21 MR. GAGE: Well, she was giving an</p> <p>22 incorrect answer by saying no and so I felt it was</p> <p>23 important to. . .</p> <p>24 THE WITNESS: Oh, I knew what -- I knew</p>	<p>1 Q. You've never treated -- strike that.</p> <p>2 You've never published any peer-reviewed</p> <p>3 literature in the area of treating mesh complications</p> <p>4 either. Is that correct?</p> <p>5 A. That's correct.</p> <p>6 Q. Now, you've used the Prosima in your</p> <p>7 practice. Correct?</p> <p>8 A. Yes, I have.</p> <p>9 Q. And you've implanted about 75 of them. Is</p> <p>10 that --</p> <p>11 A. That's sounds about right, yes.</p> <p>12 Q. Can you tell me when you first implanted the</p> <p>13 Prosima device?</p> <p>14 A. Let's see. It was shortly after it came out,</p> <p>15 which I believe was in 2008, if I remember correctly.</p> <p>16 So that would have been -- you know -- shortly after</p> <p>17 it was launched I -- was when when I tried it.</p> <p>18 Q. Now, you wrote in your report, I believe,</p> <p>19 that the Prosima didn't have a full launch until -- I</p> <p>20 can't find it. I believe you wrote in your expert</p> <p>21 report that the Prosima device didn't have a full</p> <p>22 launch until later in -- later in 2010. Is that</p> <p>23 correct?</p> <p>24 A. (No response.)</p>
Page 23	Page 25
<p>1 what he meant.</p> <p>2 MR. FAES: That's the one time when I</p> <p>3 appreciate the speaking objection, William.</p> <p>4 MR. GAGE: Yes.</p> <p>5 Q. (By Mr. Faes) Do any of the -- Dr. Pramudji,</p> <p>6 do any of the publications listed in your curriculum</p> <p>7 vitae specifically address the Gynemesh PS product?</p> <p>8 A. No.</p> <p>9 Q. Do any of the publications listed in your</p> <p>10 curriculum vitae specifically address the transvaginal</p> <p>11 technique for the treatment of pelvic organ prolapse?</p> <p>12 A. No.</p> <p>13 Q. Would you agree that the Prosima is an</p> <p>14 alternative surgical treatment -- strike that.</p> <p>15 Would you agree that the Prosima is an</p> <p>16 alternative surgical procedure for the treatment of</p> <p>17 prolapse as compared to other techniques that are</p> <p>18 available to physicians?</p> <p>19 MR. GAGE: Object to form.</p> <p>20 A. Yes.</p> <p>21 Q. (By Mr. Faes) You've never published any</p> <p>22 peer-reviewed literature in the area of mesh</p> <p>23 complications. Correct?</p> <p>24 A. That's correct.</p>	<p>1 Q. It's Page 41 that you said it was not widely</p> <p>2 launched until August of 2010.</p> <p>3 MR. GAGE: Object to form.</p> <p>4 Q. (By Mr. Faes) Broadly launched. And it's</p> <p>5 top of Page 40. My mistake.</p> <p>6 MR. GAGE: Object to form.</p> <p>7 A. Oh, yes, that's correct. I got the dates</p> <p>8 confused. So it would have been after that.</p> <p>9 Q. (By Mr. Faes) So that -- what you said</p> <p>10 earlier was incorrect, you don't believe --</p> <p>11 A. Yeah.</p> <p>12 Q. -- that you first implanted it in 2008?</p> <p>13 A. That's -- yeah, that's incorrect. I got the</p> <p>14 dates confused, yeah.</p> <p>15 Q. So you believe that you -- and actually, I</p> <p>16 was going to ask you later about that date on Page 40</p> <p>17 of your report.</p> <p>18 A. Uh-huh.</p> <p>19 Q. Are you sure that's correct, that it was --</p> <p>20 wasn't widely launched until August of 2010?</p> <p>21 MR. GAGE: Object to form.</p> <p>22 Q. (By Mr. Faes) Do you think it might have</p> <p>23 been August of 2009?</p> <p>24 A. I would have to -- I'd have to look back at</p>

7 (Pages 22 to 25)

Christina Pramudji, M.D.

Page 26	Page 28
<p>1 my references.</p> <p>2 Q. Okay. But, at any rate, you believe you</p> <p>3 didn't begin using the Prosima device until it was</p> <p>4 officially launched in either 2009 or 2010, whatever</p> <p>5 the date may be, by Ethicon. Correct?</p> <p>6 A. That's correct, yes.</p> <p>7 Q. But you know that it -- that the Prosima</p> <p>8 device was actually cleared in 2007?</p> <p>9 A. Yes.</p> <p>10 Q. And was available to a limited number</p> <p>11 of physicians who were conducting trials and studies</p> <p>12 on the device. Is that correct?</p> <p>13 A. Yes.</p> <p>14 Q. So you -- you were not, as far as you know,</p> <p>15 one of the people that was involved in conducting a</p> <p>16 clinical trial on the Prosima or using the Prosima</p> <p>17 prior to its full launch by Ethicon. Is that right?</p> <p>18 A. That's correct.</p> <p>19 Q. Now, you use Gynemesh PS in your medical</p> <p>20 practice, as well. Is that correct?</p> <p>21 A. I have used it in the past on a few</p> <p>22 occasions.</p> <p>23 Q. How many times would you estimate you've used</p> <p>24 the Gynemesh PS?</p>	<p>1 A. Absolutely.</p> <p>2 Q. What mesh -- meshes do you use if you need a</p> <p>3 flat mesh, for example?</p> <p>4 A. Well, I -- I haven't really used just a flat</p> <p>5 mesh. I've used -- I've used -- I use the Elevate.</p> <p>6 Q. Still?</p> <p>7 A. No.</p> <p>8 Q. When did you stop using the Elevate?</p> <p>9 A. Well, they've -- they've now stopped</p> <p>10 producing it, so. . .</p> <p>11 Q. When did they stop producing it?</p> <p>12 A. I think -- I think they're in the process of</p> <p>13 stopping, but they announced a couple of weeks ago</p> <p>14 that they are not going to produce it anymore.</p> <p>15 Q. How did you learn of that announce many?</p> <p>16 A. Through an e-mail from ASTORA.</p> <p>17 Q. From -- was it from your sales rep or. . .</p> <p>18 A. No. It was from corporate.</p> <p>19 Q. Okay. And did they say when in that e-mail</p> <p>20 that they would officially stop --</p> <p>21 A. Yes --</p> <p>22 Q. -- making it available for sale?</p> <p>23 A. -- but I can't remember the date. I think if</p> <p>24 the hospitals still have it, it could be used, but,</p>
Page 27	Page 29
<p>1 A. The free cut Gynemesh PS, is that what you're</p> <p>2 referring to.</p> <p>3 Q. Yes. Yes, the flat -- the Gynemesh PS, the</p> <p>4 flat mesh.</p> <p>5 A. Maybe a dozen times.</p> <p>6 Q. Do you recall during what time period you've</p> <p>7 used the Gynemesh PS?</p> <p>8 A. Going back to 2002 and then going forward to</p> <p>9 probably 2011.</p> <p>10 Q. So when you used the Gynemesh prior to 2005,</p> <p>11 did you just use it where you would cut portions of it</p> <p>12 to help you in treating prolapse when you were doing</p> <p>13 native tissue repair?</p> <p>14 A. That's correct.</p> <p>15 Q. Okay. And why did you stop using it in 2011?</p> <p>16 A. Because of the environment around that</p> <p>17 transvaginal mesh with the patients being more wary of</p> <p>18 it and feeling reluctant to have mesh implants.</p> <p>19 Q. So you would agree that you moved away from</p> <p>20 using mesh for pelvic organ prolapse repair?</p> <p>21 A. Yes. Not completely, but, yes. The</p> <p>22 environment was not conducive to using it.</p> <p>23 Q. So when you -- do you still use mesh</p> <p>24 occasionally for pelvic organ prolapse repair?</p>	<p>1 you know, I think patients might feel uncomfortable</p> <p>2 with that. So next time that I need a transvaginal</p> <p>3 mesh, I'll probably use the Boston Scientific mesh.</p> <p>4 Q. Which Boston Scientific mesh do you believe</p> <p>5 you'd use?</p> <p>6 A. Well, I think they only have one transvaginal</p> <p>7 kit right now and I can't recall the name of it.</p> <p>8 Q. Is it the Uphold product?</p> <p>9 A. Uphold, yes.</p> <p>10 Q. I got a little sidetracked with the Elevate</p> <p>11 stuff.</p> <p>12 A. Okay.</p> <p>13 Q. So if you need a -- if you needed a -- strike</p> <p>14 that.</p> <p>15 When is the last time that you recall using a</p> <p>16 flat mesh that you cut yourself or inserted in whole</p> <p>17 in a pelvic organ prolapse repair?</p> <p>18 A. So not a kit --</p> <p>19 Q. Right.</p> <p>20 A. -- you mean?</p> <p>21 Q. Right. A flat mesh like the Gynemesh PS.</p> <p>22 A. The last time would probably be in 2011,</p> <p>23 because at that point I only used it to supplement a</p> <p>24 to Total Prolift that had a large apical defect. So,</p>

8 (Pages 26 to 29)

Christina Pramudji, M.D.

Page 30	Page 32
<p>1 at that point, I wasn't even using it by itself. I</p> <p>2 used it in conjunction with the Prolift. I would</p> <p>3 fashion a greater apical support with the free mesh,</p> <p>4 if that makes sense. So where the Total Prolift would</p> <p>5 go across the apex, I would supplement with the</p> <p>6 Gynemesh. So the last time that I would have used a</p> <p>7 free cut mesh just to supplement was probably</p> <p>8 pre-Prolift.</p> <p>9 Q. Okay. If you -- let me ask you this: If you</p> <p>10 had a patient with a large defect that you didn't feel</p> <p>11 you could repair using either native tissue or suture</p> <p>12 repair or a biologic mesh, would you consider using a</p> <p>13 synthetic mesh?</p> <p>14 A. Yes.</p> <p>15 Q. What synthetic -- what would be your</p> <p>16 synthetic mesh of choice in that situation?</p> <p>17 A. I don't know. I don't know who -- I don't</p> <p>18 even know if they still make Gynemesh, because I</p> <p>19 haven't used it in so long. I don't even know if that</p> <p>20 product --</p> <p>21 Q. So --</p> <p>22 A. If that product is available, I would use</p> <p>23 Gynemesh.</p> <p>24 Q. So, sitting here today, you don't know</p>	<p>1 Q. Yes.</p> <p>2 A. No, I don't know.</p> <p>3 Q. Do you know what sizes and configurations the</p> <p>4 Gynemesh PS currently is available in?</p> <p>5 A. No.</p> <p>6 Q. You stated earlier that you stopped using the</p> <p>7 Gynemesh PS, I think, because of the environment?</p> <p>8 A. Yes.</p> <p>9 Q. Did you say -- did I get that right?</p> <p>10 A. That's correct.</p> <p>11 Q. What do you mean by that?</p> <p>12 A. Well, when there's, you know, wall-to-wall</p> <p>13 litigation commercials, patients look askew at mesh</p> <p>14 procedures. And so they -- they get scared and they</p> <p>15 want to look at other alternatives.</p> <p>16 Q. When did you first begin to use a mesh kit</p> <p>17 for the treatment of prolapse?</p> <p>18 A. 2005.</p> <p>19 Q. And what was the first kit that you used?</p> <p>20 A. The Prolift.</p> <p>21 Q. And other than that kit, is the only other</p> <p>22 kit you've used on a -- not counting, like, cadaver</p> <p>23 labs --</p> <p>24 A. Uh-huh.</p>
Page 31	Page 33
<p>1 whether or not the Gynemesh PS is still available or</p> <p>2 not?</p> <p>3 A. I do not know.</p> <p>4 Q. Have you ever used the Prolene Soft product?</p> <p>5 A. I always get the different nomenclatures</p> <p>6 confused. Is that the same one as Prolift Plus M?</p> <p>7 Q. No, it is not.</p> <p>8 A. Okay. Is that the Vypro?</p> <p>9 Q. No.</p> <p>10 A. Okay. What is the --</p> <p>11 Q. So -- so let me ask you this: Sitting here</p> <p>12 today, do you know what the Prolene Soft mesh is?</p> <p>13 A. No, I don't.</p> <p>14 Q. Do you know if there is any difference</p> <p>15 between the Prolene Soft mesh and the Gynemesh PS</p> <p>16 mesh?</p> <p>17 A. I can't recall right now.</p> <p>18 Q. So if they're identical, you wouldn't know</p> <p>19 that one way or the other?</p> <p>20 A. I can't recall what Prolene Soft is.</p> <p>21 Q. Okay. So it's probably also fair to say that</p> <p>22 you don't know if there's a price difference between</p> <p>23 the Gynemesh PS or the Prolene Soft mesh?</p> <p>24 A. A price difference?</p>	<p>1 Q. -- but in a -- on a live human woman, is the</p> <p>2 only other kit that you've used the Elevate?</p> <p>3 A. Elevate, the Prosima --</p> <p>4 Q. Oh, yeah, the Prosima and the --</p> <p>5 A. -- and the Uphold.</p> <p>6 Q. You have used the Uphold?</p> <p>7 A. Yes.</p> <p>8 Q. When did you first use that?</p> <p>9 A. I don't recall. It was several years ago.</p> <p>10 Q. And has it -- when's the last time that you</p> <p>11 used the Uphold kit?</p> <p>12 A. I really have only tried it a couple of times</p> <p>13 and that was a few years ago.</p> <p>14 Q. Okay. And you've also used -- I think you</p> <p>15 just forgot to mention it -- you've used the Prolift</p> <p>16 Plus M --</p> <p>17 A. Yes.</p> <p>18 Q. -- kit before, as well.</p> <p>19 A. Yes.</p> <p>20 Q. Correct?</p> <p>21 A. Uh-huh, that's correct.</p> <p>22 MR. GAGE: Let me just remind you --</p> <p>23 THE WITNESS: Yes.</p> <p>24 MR. GAGE: -- the way the Court Reporter</p>

9 (Pages 30 to 33)

Christina Pramudji, M.D.

Page 34	Page 36
<p>1 has to work, Andy -- let Andy really completely fully</p> <p>2 finish his question --</p> <p>3 THE WITNESS: Uh-huh.</p> <p>4 MR. GAGE: -- before you answer, because</p> <p>5 I'm reading the transcript here and a lot of times</p> <p>6 you're answering before Andy is finished. And we want</p> <p>7 to make it nice and clean for the record, so I may</p> <p>8 from time to time nudge you on that point.</p> <p>9 MR. FAES: And the Court Reporter</p> <p>10 appreciates it, too.</p> <p>11 MR. GAGE: Yeah.</p> <p>12 Q. (By Mr. Faes) Now, during the time that you</p> <p>13 were using the Prosima, did you also continue to do</p> <p>14 native tissue repairs with sutures?</p> <p>15 A. Yes, I did.</p> <p>16 Q. Did you view the native tissue repairs with</p> <p>17 sutures as an alternative to the Prosima and vice</p> <p>18 versa?</p> <p>19 A. Yes.</p> <p>20 Q. And you've also done abdominal</p> <p>21 sacrocolpopexy. Correct? I tried to say that</p> <p>22 correct. I don't know if I did or not.</p> <p>23 A. That was close. Yes. I really started doing</p> <p>24 that primarily, though, after 2011 when the</p>	<p>1 A. Y mesh. They're all Y meshes.</p> <p>2 Q. But you don't use the Ethicon Artisyn mesh?</p> <p>3 MR. GAGE: Object. Form.</p> <p>4 A. I tried it a couple times, but I didn't -- I</p> <p>5 didn't prefer it. It was harder to work with in</p> <p>6 surgery than the Restorelle in my hands.</p> <p>7 Q. (By Mr. Faes) So it would be fair to say</p> <p>8 that currently when you do abdominal sacrocolpopexy</p> <p>9 procedure, your mesh of choice is the Coloplast</p> <p>10 Restorelle?</p> <p>11 A. That's correct.</p> <p>12 Q. When you consent a patient for a mesh kit,</p> <p>13 such as the Prosima device, do you -- did you talk to</p> <p>14 them about the specific manufacturer and compared the</p> <p>15 kits with them that were available to use or did you</p> <p>16 just talk about vaginal mesh, in general, and then you</p> <p>17 chose the kit for that patient?</p> <p>18 MR. GAGE: Object to form.</p> <p>19 A. I would talk about the vaginal mesh in</p> <p>20 general and maybe with the Prosima some of the nuances</p> <p>21 compared to the Prolift, but I -- other than that, I</p> <p>22 didn't compare it to different kits. I don't think</p> <p>23 patients would really be able to -- most patients</p> <p>24 would not be able to fully understand or appreciate</p>
Page 35	Page 37
<p>1 transvaginal mesh became controversial.</p> <p>2 Q. When did you first start to perform that</p> <p>3 procedure?</p> <p>4 A. I did a handful prior to 2011, but I really</p> <p>5 started using it more after 2011.</p> <p>6 Q. In terms of an alternative treatment for a</p> <p>7 patient, would you agree that abdominal sacrocolpopexy</p> <p>8 would be one of the alternatives if, in fact, there</p> <p>9 were prolapse in the part of a -- in the part of a</p> <p>10 pelvis that would be appropriate for that treatment?</p> <p>11 MR. GAGE: Object. Form.</p> <p>12 A. I don't understand the last part of your</p> <p>13 question.</p> <p>14 Q. (By Mr. Faes) You know what, I'll strike</p> <p>15 that and ask a new one.</p> <p>16 What meshes have you used for abdominal sacro</p> <p>17 -- I'll just say ASC. Okay? What meshes have you</p> <p>18 used for AFC -- ASC?</p> <p>19 A. I've used the Ethicon product.</p> <p>20 Q. Okay.</p> <p>21 A. The Coloplast product, which is called</p> <p>22 Restorelle, R-E-S-T-O-R-E-L-L-E. And that's what I</p> <p>23 use currently. And I've also used the AMS product.</p> <p>24 Q. The Y mesh or. . .</p>	<p>1 the differences between the different kits.</p> <p>2 Q. (By Mr. Faes) Okay. So that kind of brings</p> <p>3 --</p> <p>4 A. I didn't see much -- I didn't much use for</p> <p>5 that.</p> <p>6 Q. Okay. So that kind of brings me to my next</p> <p>7 question: You -- what's the time period that you</p> <p>8 performed the Prolift device? From 2005 until it</p> <p>9 was no longer available in 2012?</p> <p>10 A. Yes, that's correct.</p> <p>11 Q. And you were performing the Prosima from</p> <p>12 either 2009 or 2010, whenever the launch date was,</p> <p>13 until its discontinuance. Right?</p> <p>14 A. That's correct.</p> <p>15 Q. So during the time when you were implanting</p> <p>16 both Prosima devices and Prolift devices, how did you</p> <p>17 decide which kit to use for which patient?</p> <p>18 A. The Prosima is best suited for a grade 2 or 3</p> <p>19 cystocele or rectocele without loss of apical support.</p> <p>20 If they needed more apical support or they had other</p> <p>21 factors that I thought they needed more support, then</p> <p>22 I would do the Prolift.</p> <p>23 Q. So is it fair to say that the Prosima was</p> <p>24 your device of choice for a patient that had a grade 2</p>

Christina Pramudji, M.D.

Page 38	Page 40
<p>1 or 3 rectocele or cystocele without loss of apical 2 support? 3 A. Yes. 4 Q. And your -- was your Prolift your device of 5 choice for all other patients or was there a specific 6 subset of patients that that was your device of choice 7 for? 8 A. That was definitely my device of choice for 9 the more severe prolapse patients, grade 4s or some 10 grade 3s, as well, just depending on -- all grade 3s 11 are not the same. They can have different angles and 12 different areas that need support and some of those 13 would get a Prolift, as well. 14 Q. Now, like the Prosima device, the Elevate 15 does not have trocar passes. Is that correct? 16 A. That's correct. 17 Q. One significant difference between -- strike 18 that. 19 The fact that there were no external trocar 20 passes with the Elevate or the Prosima, did you see 21 that as a potential benefit from a safety perspective 22 as compared to the Prolift? 23 A. Yes, I did. You -- you do avoid some 24 bleeding that could occur with a trocar pass. I</p>	<p>1 can look at it. 2 (Break.) 3 Q. (By Mr. Faes) Dr. Pramudji, we're back on 4 the record after a short break. Are you ready to 5 proceed? 6 A. Yes. 7 (Exhibit No. 7 marked.) 8 Q. Before I -- before the break, I had asked you 9 whether or not the Prosima IFU states that the device 10 is indicated for grade 2 or 3 rectocele or cystocele 11 and I handed you what's been marked as Exhibit No. 7 12 to your deposition, which is the 2010 Prosima IFU. 13 Are you -- have you reviewed that document and are you 14 prepared to answer the question? 15 A. Yes. I do not see in there where it says 16 that it's indicated for that. 17 Q. Had she -- 18 MR. GAGE: Hang on just a second. Okay. 19 Go ahead. 20 Q. (By Mr. Faes) But you did mention that you 21 believe that it was -- that information was contained 22 in professional education materials? 23 A. Yes. 24 Q. Let me ask you this: Do you know if Ethicon</p>
Page 39	Page 41
<p>1 didn't have any other complications with the trocar 2 passes than bleeding at times, but for that reason it 3 would have a slightly -- a slight advantage to the 4 Prosima. 5 Q. Now, you talked a little bit about -- a 6 minute ago about the Prosima device being best for 7 grade 2 or 3 defects. Is that correct? 8 A. Yes. 9 Q. Is there anything, as you sit here today, 10 that you know of in the IFU that tells physicians that 11 the device is best for those two grades of prolapse? 12 A. I believe it does state that in the IFU and I 13 know that that is what we taught in the prof ed, as 14 well. 15 Q. So you believe it states in the Prolift IFU 16 that it is only indicated for grade 2 or 3 defects? 17 MR. GAGE: Object. Form. 18 A. I know it's in some of the literature that 19 the company put out. I'd have to look and see if it's 20 in the IFU that I'm picturing in my head right now. 21 Can I look at it? 22 Q. (By Mr. Faes) Yeah. 23 MR. FAES: Do you want to go off the 24 record for just a second? I need some water and she</p>	<p>1 keeps track of who those professional materials go to? 2 A. I have no idea. 3 Q. You would agree that the IFU, which is 4 Exhibit No. 7 in front of you, is required by law to 5 be in every Prosima product that is sold to 6 physicians. Is that correct? 7 A. Correct. 8 Q. So we can ensure -- strike that. 9 By contrast, the professional education 10 materials provided by Ethicon are not in every box of 11 the product that goes out to physicians. Is that 12 correct? 13 A. Of course not. 14 Q. Doctor, do you know the clearance date for 15 the Gynemesh PS flat mesh product? 16 A. I think it goes back to 2002. 17 Q. And do you know when the Gynemesh PS product 18 was first launched in the United States? 19 A. No, I don't. 20 Q. And I'll take it, since you don't know what 21 the Prolene Soft product is, you don't know what the 22 clearance date is for that product either? 23 A. Correct. 24 Q. And you don't know when the Prolene Soft</p>

11 (Pages 38 to 41)

Christina Pramudji, M.D.

Page 42	Page 44
<p>1 product was first available for use by physicians in 2 the United States? 3 A. That's right. 4 Q. Do you know the clearance date for the 5 Prosima product? I think we talked about this a 6 little earlier. 7 A. I think it was around 2008. 8 Q. But you don't know any more specific than 9 that -- 10 A. No. 11 Q. -- sitting here today? Do you recall if you 12 -- if you listed that clearance date for either the 13 Gynemesh PS or the Prosima product in your report? 14 A. I think I did. I can -- I'd have to look and 15 see exactly where I put it in here. 16 Q. Okay. I don't -- I don't want to take the 17 time right now, but we'll just -- we'll just have your 18 answer stand that you believe it's in there. 19 Let me ask you this, Doctor: Would you -- 20 have you ever used a medical device for something that 21 it was not indicated for? 22 A. No. 23 Q. Is that something you would consider doing, 24 is using a medical device for something off label or</p>	<p>1 transvaginal use? 2 A. Yes, it is. 3 Q. So you believe, as you sit here today, that 4 the Gynemesh PS mesh is indicated for transvaginal 5 use? 6 A. Yes. 7 Q. Do you recall sitting -- as you sit here 8 today, if you've reviewed the 2013 Gynemesh PS flat 9 mesh IFU? 10 A. I'm sure I have, but I'd have to refresh my 11 memory on that. 12 Q. Okay. Do you recall, as you sit here today, 13 if you've reviewed the 2015 Gynemesh flat mesh IFU 14 that's available on Ethicon's website? 15 A. I'm sure I have, but I'd have to review 16 specifics. 17 Q. Do you agree with the FDA's viewpoint that 18 there is a need for more rigorous studies regarding 19 the safety and efficacy of mesh kits? 20 MR. GAGE: Object to form. 21 A. No, I disagree with them, because I think 22 that we have a very strong body of data showing that 23 the mesh kits are safe and effective. 24 Q. (By Mr. Faes) Have you ever seen the 522</p>
Page 43	Page 45
<p>1 something that was not specifically in its indications 2 for use? 3 A. Absolutely. As a trained surgeon, I use my 4 professional judgment and sometimes there are 5 situations where you use things off label, medications 6 or potentially, devices. I haven't used a device off 7 label that I can recall. I have used a medication off 8 label and discussed that with the patient, but that's 9 within the prerogative of the physician to use their 10 judgment. 11 Q. And I take it -- you understand that surgical 12 mesh is a medical device. Correct? 13 A. Yes. 14 Q. So you've never used a surgical mesh off 15 label in your -- how many years have you been 16 practicing? 17 A. Fifteen years. 18 Q. You've never used a -- so I'll restart the 19 question: You've never used a surgical mesh off label 20 in your 15 years of practice that you can recall. 21 Correct? 22 A. That's correct. 23 Q. Do you know, sitting here today, whether or 24 not the Gynemesh PS flat mesh is indicated for</p>	<p>1 order that was issued by the FDA with regard to the 2 Prosima? 3 A. I'm sure that I have at some point. 4 Q. Do you recall, sitting here today, what it 5 said? 6 A. I can't recall. 7 Q. Have you seen Ethicon's response to the 522 8 order on the Prosima? 9 A. I'm sure that I have, but I couldn't -- I 10 couldn't recite it to you. 11 Q. Do you recall, as you sit here today, if in 12 response to Ethicon's -- strike that. 13 Do you recall, as you sit here today, if in 14 response to the FDA's 522 on the Prosima, Ethicon 15 tried to get the FDA to accept studies that it had 16 already done on the Prosima in lieu of a 522 study? 17 MR. GAGE: Object to form. 18 A. I'm not sure if I know about that or not. I 19 don't recall. 20 Q. (By Mr. Faes) Has anyone ever told you why 21 the Prosima was removed from the market? 22 MR. GAGE: Object to form. 23 A. Not that I recall. 24 Q. (By Mr. Faes) Do you have an understanding,</p>

12 (Pages 42 to 45)

Christina Pramudji, M.D.

Page 46	Page 48
<p>1 as you sit here today, of why the Prosima was removed</p> <p>2 from the market?</p> <p>3 MR. GAGE: Object to form.</p> <p>4 A. My understanding is that it was a calculation</p> <p>5 of being able to sell the product and having the</p> <p>6 resources to do the research that was required for the</p> <p>7 522. That was my understanding. I can't recall who</p> <p>8 told me that.</p> <p>9 Q. (By Mr. Faes) Let me ask you this: Do you</p> <p>10 intend to offer any opinions in this case about why</p> <p>11 the Prosima was removed from the market?</p> <p>12 MR. GAGE: Object to form.</p> <p>13 A. I am not sure.</p> <p>14 Q. (By Mr. Faes) Would you agree that from the</p> <p>15 time that the Ethicon did a full launch of the Prosima</p> <p>16 product until the time they stopped making it and it</p> <p>17 was no longer available, it was less than three years?</p> <p>18 A. That's correct.</p> <p>19 Q. Do you know how many Prosima devices Ethicon</p> <p>20 sold during that time?</p> <p>21 A. No, I don't.</p> <p>22 Q. Do you recall specifically how you found</p> <p>23 out that the Prosima device was no longer going to</p> <p>24 be available for sale?</p>	<p>1 stopped selling the product?</p> <p>2 A. Yes, they did.</p> <p>3 Q. Do you know what they did with those</p> <p>4 products?</p> <p>5 A. They kept them so that I could use them.</p> <p>6 Q. So you used -- continued to use the Prosima</p> <p>7 device after the announcement was made that it was no</p> <p>8 longer going to be available?</p> <p>9 A. Yes.</p> <p>10 Q. How many Prosima devices did you use --</p> <p>11 A. I don't recall.</p> <p>12 Q. -- during that time period?</p> <p>13 A. I don't know.</p> <p>14 Q. Do you recall when the last Prosima device</p> <p>15 you placed was?</p> <p>16 A. No, I don't remember.</p> <p>17 Q. Do you know what the shelf life of the</p> <p>18 Prosima product is?</p> <p>19 A. No.</p> <p>20 Q. Is it your usual practice to check the</p> <p>21 expiration date before you implant the product --</p> <p>22 A. Absolutely.</p> <p>23 Q. -- in a person?</p> <p>24 A. Sorry. Sorry to interrupt. Yes, absolutely.</p>
Page 47	Page 49
<p>1 A. No, I don't recall.</p> <p>2 Q. Do you recall the month or the year when that</p> <p>3 occurred?</p> <p>4 A. No.</p> <p>5 Q. Do you recall if you had, like, a warning</p> <p>6 period -- was -- strike that.</p> <p>7 Was there a time between when you were</p> <p>8 told that the Prosima was going to be -- was no</p> <p>9 longer going to be available for sale and when it</p> <p>10 was actually not available for sale?</p> <p>11 A. Yes.</p> <p>12 Q. Do you recall what hospitals you worked at</p> <p>13 during that time period when -- between when Prosima</p> <p>14 -- the announcement on Prosima was first made that it</p> <p>15 was no longer going to be sold and when it was</p> <p>16 ultimately no longer available?</p> <p>17 A. Yes.</p> <p>18 Q. Which hospitals were those?</p> <p>19 A. Memorial Hermann, Memorial City.</p> <p>20 Q. Okay.</p> <p>21 A. And Memorial Hermann Katy and St. Catherine's</p> <p>22 Hospital.</p> <p>23 Q. Do you know if any of those hospitals still</p> <p>24 had Prosima devices on their shelves after Ethicon</p>	<p>1 Q. And to your knowledge, you've never implanted</p> <p>2 a product that was past the expiration date. Is that</p> <p>3 correct?</p> <p>4 A. Not to my knowledge.</p> <p>5 Q. Did you ask the hospital to buy up or</p> <p>6 stockpile any Prosima devices before it was no longer</p> <p>7 available when the announcement was made?</p> <p>8 A. No, I didn't ask them to do that. I just</p> <p>9 felt like I would use what they already had on hand.</p> <p>10 Q. You didn't do any kind of projection of, I</p> <p>11 think that -- you know -- I anticipate using this many</p> <p>12 products a month and the shelf life is X number of</p> <p>13 years, so I'll need this many products, you didn't do</p> <p>14 that analysis?</p> <p>15 A. No.</p> <p>16 Q. Same question on the Prolift: Do you</p> <p>17 know if any of the hospitals had that device on its</p> <p>18 shelves after Ethicon stopped selling the product?</p> <p>19 A. Yes, they did, and I continued to use it.</p> <p>20 Q. And you used it until they ran out?</p> <p>21 A. That's correct.</p> <p>22 Q. And same question on the Prolift: Did you</p> <p>23 ask any of the hospitals to buy up extra Prolift while</p> <p>24 it was available --</p>

Christina Pramudji, M.D.

Page 50	Page 52
<p>1 A. No.</p> <p>2 Q. -- obviously keeping in mind that there's</p> <p>3 an expiration date on the product and you would need</p> <p>4 to use it before it expired?</p> <p>5 A. No, I didn't go to that extent.</p> <p>6 Q. What about the Prolift Plus M device?</p> <p>7 A. Same story.</p> <p>8 Q. Okay. So you did continue to use the Prolift</p> <p>9 Plus M device up until the time it was no longer</p> <p>10 available?</p> <p>11 A. That's correct.</p> <p>12 Q. We talked a little bit about the selection</p> <p>13 criteria you used for the Prosima versus the Prolift</p> <p>14 device. What was your selection criteria for patients</p> <p>15 on the Prolift Plus M device? What kind of patients</p> <p>16 did you put that into?</p> <p>17 A. Well, once the Prolift Plus M became</p> <p>18 available and I felt -- I saw result -- good results</p> <p>19 in my own patients, I started to transition my Prolift</p> <p>20 patients to Prolift Plus M patients. And so I began</p> <p>21 to use it more -- much more frequently than the</p> <p>22 Prolift. And it would have been basically the same</p> <p>23 patients with the more severe prolapse or loss of</p> <p>24 apical support.</p>	<p>1 A. Absolutely. They're great products.</p> <p>2 Q. Do you believe the Prosima device is still</p> <p>3 cleared by the FDA today?</p> <p>4 A. From a regulatory perspective, I'm not sure.</p> <p>5 I don't know.</p> <p>6 Q. If it were not cleared, would you still</p> <p>7 consider implanting the Prosima in a patient?</p> <p>8 MR. GAGE: Object to form.</p> <p>9 A. You know, it worked so great in -- with my</p> <p>10 patients that I probably would consider it, because</p> <p>11 looking at the data and with my own experience, I</p> <p>12 think it's proven to be very effective and safe and I</p> <p>13 feel very comfortable with it.</p> <p>14 Q. (By Mr. Faes) So do you believe a physician</p> <p>15 would be within the standard of care if he knowingly</p> <p>16 implanted a medical device that was not currently cleared</p> <p>17 or approved by the FDA?</p> <p>18 MR. GAGE: Object to form.</p> <p>19 A. In certain situations, yes. Because our</p> <p>20 knowledge as physicians allows us the leeway to use</p> <p>21 things off label.</p> <p>22 Q. (By Mr. Faes) I'm not talking about things</p> <p>23 that aren't indicated. I'm talking about a device</p> <p>24 that is no longer cleared or approved by the FDA.</p>
Page 51	Page 53
<p>1 Q. For the Prolift Plus M?</p> <p>2 A. Correct.</p> <p>3 Q. Did -- was there a time that the Prolift Plus</p> <p>4 M device became your device of choice over the</p> <p>5 Prolift?</p> <p>6 A. Yes, for a while it was.</p> <p>7 Q. Do you recall about what time period that was</p> <p>8 when that occurred?</p> <p>9 A. No, I can't remember.</p> <p>10 Q. You said that you waited to switch over until</p> <p>11 you saw good results in your own patients. Did you do</p> <p>12 -- do you mean you implanted it in the patients and</p> <p>13 then waited to see what happened or are you referring</p> <p>14 to other physicians in your group?</p> <p>15 A. In my own patients --</p> <p>16 Q. Okay.</p> <p>17 A. -- where I could examine them myself and see,</p> <p>18 see how well it worked.</p> <p>19 Q. If you were able to find a Prosima or a</p> <p>20 Prolift device today that was not already expired,</p> <p>21 would you consider implanting it in a patient?</p> <p>22 A. Absolutely.</p> <p>23 Q. Do you believe it's within the standard of</p> <p>24 care to continue to implant those devices today?</p>	<p>1 A. Uh-huh.</p> <p>2 MR. GAGE: Object to form.</p> <p>3 Q. (By Mr. Faes) Do you understand that?</p> <p>4 A. I see the distinction that you're talking</p> <p>5 about. I think strictly legally there could be some</p> <p>6 -- some problems if you implant something that's not</p> <p>7 FDA approved, but whether that's outside the standard</p> <p>8 of care, I think -- I think it could still be within</p> <p>9 the standard of care.</p> <p>10 Q. Backtracking a little bit to the Gynemesh PS</p> <p>11 flat mesh product, have you ever seen the 522 order</p> <p>12 that was issued by the FDA with regard to that</p> <p>13 product?</p> <p>14 A. I believe I have.</p> <p>15 Q. Do you recall, sitting here, what it said?</p> <p>16 A. No, I don't recall.</p> <p>17 Q. Do you know what Ethicon did in response to</p> <p>18 the 522 order on the Gynemesh PS flat mesh?</p> <p>19 A. No, I don't.</p> <p>20 Q. Have you ever used the standard, traditional</p> <p>21 Prolene mesh in your medical practice?</p> <p>22 A. What do you mean by standard, traditional</p> <p>23 Prolene mesh?</p> <p>24 Q. I'm talking about the standard mesh that's</p>

14 (Pages 50 to 53)

Christina Pramudji, M.D.

Page 54	Page 56
<p>1 for hernia repair, not Prolene Soft, not Gynemesh.</p> <p>2 A. No.</p> <p>3 Q. Standard traditional Prolene mesh.</p> <p>4 A. No, I have not.</p> <p>5 Q. Is that a mesh that you would consider using</p> <p>6 in your practice?</p> <p>7 A. I don't know. I'm not familiar with it.</p> <p>8 Q. Let me ask you this: Do you believe it would</p> <p>9 be a reasonable decision for a doctor to stop using</p> <p>10 the Prosima device following the July 2011 FDA public</p> <p>11 health notification?</p> <p>12 A. Sure.</p> <p>13 Q. The same question: Do you believe it would</p> <p>14 be a reasonable decision for a doctor to stop using</p> <p>15 the Prosima -- strike that.</p> <p>16 Do you believe it would be a reasonable</p> <p>17 decision for a doctor to stop using the Prolift or</p> <p>18 Prolift Plus M device following the July 2011 FDA</p> <p>19 public health notification?</p> <p>20 A. If they're uncomfortable with it, that's</p> <p>21 their prerogative.</p> <p>22 Q. Would you agree that surgical complications</p> <p>23 associated with surgical mesh for transvaginal repair</p> <p>24 of pelvic organ prolapse are not rare?</p>	<p>1 Is that correct?</p> <p>2 A. Yes, that's correct.</p> <p>3 Q. Let me ask you this: When you consulted</p> <p>4 patients after this public health notification was</p> <p>5 issued, did you talk to them about this notice?</p> <p>6 A. Absolutely.</p> <p>7 Q. Did you tell your patients that you disagreed</p> <p>8 with the public health notification, that you</p> <p>9 disagreed with the FDA that the complications were not</p> <p>10 rare?</p> <p>11 A. Yes, I did, because in my hands and the</p> <p>12 literature, they are rare.</p> <p>13 Q. Do you believe that a physician, when they --</p> <p>14 a physician who consents is -- strike that.</p> <p>15 If a physician consents his patients for a</p> <p>16 pelvic organ prolapse kit procedure and tells that</p> <p>17 patient that serious complications associated with</p> <p>18 surgical mesh are rare, do you believe that that</p> <p>19 physician has appropriately consented the patient?</p> <p>20 MR. GAGE: Object to form.</p> <p>21 A. Yes.</p> <p>22 Q. (By Mr. Faes) Do you agree or disagree that</p> <p>23 there is no evidence that transvaginal mesh repair</p> <p>24 with mesh provides any added benefit compared to</p>
Page 55	Page 57
<p>1 A. How are you defining "rare"? Or what do you</p> <p>2 mean by "rare"? Can you clarify that?</p> <p>3 Q. Well, you're a physician. How do you</p> <p>4 understand the word "rare" when it relates to</p> <p>5 complications?</p> <p>6 A. In my opinion, and looking at the literature</p> <p>7 and with my own experience, I think that the surgical</p> <p>8 complications are rare, meaning that they're less than</p> <p>9 ten percent.</p> <p>10 (Exhibit No. 8 marked.)</p> <p>11 Q. I'm going to hand you what's been marked as</p> <p>12 Exhibit No. 8 to your deposition. This is the 2011</p> <p>13 public health notification.</p> <p>14 A. Uh-huh.</p> <p>15 Q. If I could have you turn to the second page.</p> <p>16 A. Uh-huh.</p> <p>17 Q. I'm just going to read the -- one, two,</p> <p>18 three, four -- fifth paragraph down. It says: The</p> <p>19 FDA is issuing this update to inform you that serious</p> <p>20 complications associated with surgical mesh for</p> <p>21 transvaginal repair of POP are not rare.</p> <p>22 Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. So you disagree with the FDA in this regard.</p>	<p>1 traditional surgery without mesh?</p> <p>2 A. I disagree, because I think the literature</p> <p>3 bears it out, but the transvaginal mesh repair is more</p> <p>4 effective than traditional repair. There's multiple</p> <p>5 studies that reinforce that.</p> <p>6 Q. And you know --</p> <p>7 A. And I saw that in my own experience.</p> <p>8 Q. And if you turn to Page 3, you see that that</p> <p>9 statement is contained within the public health</p> <p>10 notification, as well.</p> <p>11 A. (No response.)</p> <p>12 Q. It's the third bullet point. I'll read it</p> <p>13 again for you. There is no evidence that transvaginal</p> <p>14 repair to support the top of the vagina, parentheses,</p> <p>15 (apical repair or back wall of the vagina),</p> <p>16 parentheses, posterior repair with mesh provides any</p> <p>17 added benefit compared to traditional surgery without</p> <p>18 mesh.</p> <p>19 Do you see that?</p> <p>20 A. Yes, I do.</p> <p>21 Q. And you disagree with that statement from the</p> <p>22 FDA?</p> <p>23 A. When you narrow in on the posterior wall, it</p> <p>24 is not as much of a benefit as it is on the anterior</p>

15 (Pages 54 to 57)

Christina Pramudji, M.D.

Page 58	Page 60
<p>1 wall, which is what I was referring to previously.</p> <p>2 Q. So I'm not sure if I got an answer to my</p> <p>3 question. Are you saying you agree with this</p> <p>4 statement from the FDA or disagree with it or you</p> <p>5 can't answer?</p> <p>6 A. I would agree with that bullet point --</p> <p>7 Q. When you --</p> <p>8 A. -- about the posterior wall.</p> <p>9 Q. When you consented patients for pelvic organ</p> <p>10 prolapse procedures after July of 2013 --</p> <p>11 A. Uh-huh.</p> <p>12 Q. -- did you tell them that there was no</p> <p>13 evidence that using mesh provides any added benefit as</p> <p>14 compared to traditional surgery without a mesh?</p> <p>15 MR. GAGE: Object to form.</p> <p>16 A. What I told patients -- we're speaking of a</p> <p>17 posterior repair right now. And what I told patients</p> <p>18 is that there is a slight benefit with the mesh and</p> <p>19 there is definitely a benefit with decreased pain with</p> <p>20 the posterior mesh versus a traditional posterior</p> <p>21 plication repair. Does that answer your question?</p> <p>22 Q. (By Mr. Faes) Yes. Do you agree that mesh</p> <p>23 used in transvaginal pelvic organ prolapse repair</p> <p>24 introduces risks not present in traditional non-mesh</p>	<p>1 20th, 2008 public health notification.</p> <p>2 So at least according to this, both the FDA</p> <p>3 and the medical literature believed that mesh</p> <p>4 contraction or shrinkage does exist. Is that correct?</p> <p>5 MR. GAGE: Object to form.</p> <p>6 A. Yes, they do believe that, but I respectfully</p> <p>7 disagree, because the mesh does not contract. It's</p> <p>8 the scar tissue around it. And you can see wound</p> <p>9 contraction and vaginal shortening, tightening, pain</p> <p>10 with any pelvic floor correction.</p> <p>11 Q. (By Mr. Faes) So you would disagree with</p> <p>12 both the FDA and the medical literature that mesh</p> <p>13 can contract or shrink?</p> <p>14 MR. GAGE: Object to form.</p> <p>15 A. Yes, the mesh does not contract or shrink.</p> <p>16 The wound and the scarring is what contracts and</p> <p>17 shrinks. The mesh, itself, does not.</p> <p>18 Q. (By Mr. Faes) When the wound or scar</p> <p>19 contracts and shrinks --</p> <p>20 A. Uh-huh.</p> <p>21 Q. -- if the mesh is encapsulated --</p> <p>22 A. Uh-huh.</p> <p>23 Q. -- can the mesh shrink, as well, along with</p> <p>24 the wound or scar tissue?</p>
Page 59	Page 61
<p>1 surgery for pelvic organ prolapse repair?</p> <p>2 A. The only additional risk that it introduces</p> <p>3 is a mesh exposure.</p> <p>4 Q. So was my -- the answer to my question, yes,</p> <p>5 you agree with that statement?</p> <p>6 A. (No response.)</p> <p>7 Q. Do you want me to read the question again?</p> <p>8 MR. GAGE: No. She can look at it here.</p> <p>9 A. No. It only introduces that one risk. All</p> <p>10 the other risks are going to be potential with any</p> <p>11 pelvic floor surgery.</p> <p>12 Q. (By Mr. Faes) So is it your testimony that</p> <p>13 mesh contraction is a risk of any other pelvic</p> <p>14 surgery?</p> <p>15 A. Wound contraction is. Mesh doesn't contract.</p> <p>16 The wound contracts and the scarring contracts.</p> <p>17 Q. You don't believe that mesh contracts?</p> <p>18 A. No. The wound and the scar contract.</p> <p>19 Q. If you go down to the second paragraph below</p> <p>20 the bullet point it says: Mesh contraction,</p> <p>21 parenthesis, (shrinkage) is a previously unidentified</p> <p>22 risk of transvaginal POP repair with mesh that has</p> <p>23 been reported in the scientific literature in an</p> <p>24 adverse event reports to the FDA since the October</p>	<p>1 A. I mean, it's a matter of semantics. The</p> <p>2 mesh, itself, is not shrinking or contracting. If you</p> <p>3 take it out, it's going to be the same Prolene caliber</p> <p>4 fibers. They're not going to be shrunken.</p> <p>5 Q. There not going to be shrunken or deformed as</p> <p>6 the wound or the scar tissue which completely</p> <p>7 surrounds it contracts?</p> <p>8 A. The pores will be -- the pores of the mesh</p> <p>9 maybe shrunken or deformed and pulled together by the</p> <p>10 scar tissue, but the Prolene, itself, is not shrunken.</p> <p>11 Q. Do you degree -- strike that.</p> <p>12 Do you agree or disagree that mesh placed</p> <p>13 abdominally for pelvic organ prolapse repair results</p> <p>14 in lower rates of mesh complications compared to</p> <p>15 transvaginal pelvic organ prolapse surgery with mesh?</p> <p>16 A. Actually, the mesh erosion rates are similar</p> <p>17 with the transabdominal and the transvaginally placed</p> <p>18 mesh looking at the sacrocolpopexy studies. They have</p> <p>19 similar rates.</p> <p>20 Q. So if you turn to Page 4 of exhibit -- the</p> <p>21 exhibit that I just handed you.</p> <p>22 A. (Complying.)</p> <p>23 Q. You go under the bullet point: Consider</p> <p>24 these factors before placing surgical mesh. The last</p>

16 (Pages 58 to 61)

Christina Pramudji, M.D.

Page 62	Page 64
<p>1 bullet point you see, it reads: Mesh placed</p> <p>2 abdominally for pelvic organ prolapse repair may</p> <p>3 result in lower rates of mesh complications compared</p> <p>4 to transvaginal pelvic organ prolapse surgery with</p> <p>5 mesh.</p> <p>6 Is it fair to say that you disagree with the</p> <p>7 FDA on this statement?</p> <p>8 A. Well, it says it may result. They're not</p> <p>9 saying it does result in lower rates. And I think, if</p> <p>10 we look at the literature, we can see they're very</p> <p>11 similar rates.</p> <p>12 Q. So you -- does that mean you agree with the</p> <p>13 statement from the FDA that it may result in lower</p> <p>14 rates of mesh complications compared to transvaginal</p> <p>15 pelvic organ prolapse surgery with mesh?</p> <p>16 A. As they've written it here, may result, I</p> <p>17 can't really disagree with that. I think, as -- as</p> <p>18 time has borne out and as we've seen further studies</p> <p>19 with sacrocolpopexy, we're seeing that this -- the</p> <p>20 mesh exposure rate is very similar or suture exposure</p> <p>21 rate. And with abdominally placed mesh you also have</p> <p>22 the risk of bowel obstruction and adhesions,</p> <p>23 intraabdominal adhesions.</p> <p>24 Q. I think you've answered my question. I'll</p>	<p>1 which studied whether or not the product was effective</p> <p>2 for -- strike that.</p> <p>3 Do you agree that native tissue repairs have</p> <p>4 similar outcomes to synthetic mesh without the risks</p> <p>5 inherent in mesh use?</p> <p>6 MR. GAGE: Object to form.</p> <p>7 A. (No response.)</p> <p>8 Q. (By Mr. Faes) Why don't I ask a better</p> <p>9 question? Do you agree that native tissue repairs for</p> <p>10 the repair of pelvic organ prolapse have similar</p> <p>11 outcomes to synthetic mesh used for pelvic organ</p> <p>12 prolapse without the risks inherent in mesh use?</p> <p>13 A. No.</p> <p>14 MR. GAGE: Object to form.</p> <p>15 A. I think the -- in my opinion, the literature</p> <p>16 is clear that the outcomes are better with mesh</p> <p>17 augmentation and the risks are similar. The only</p> <p>18 additional risk is mesh exposure or erosion.</p> <p>19 Q. (By Mr. Faes) Do you agree or disagree that</p> <p>20 native tissue repair remains the standard of care for</p> <p>21 the treatment of pelvic organ prolapse in the typical</p> <p>22 patient?</p> <p>23 A. I disagree. The standard of care is</p> <p>24 sacrocolpopexy at this point.</p>
Page 63	Page 65
<p>1 object to move to strike after the word "that" just</p> <p>2 for the record.</p> <p>3 If a synthetic graft product like the Prosima</p> <p>4 does not do better than native tissue repair, in terms</p> <p>5 of safety and efficacy, do you think it should be</p> <p>6 introduced to the market?</p> <p>7 A. That's a hypothetical question.</p> <p>8 Q. It is.</p> <p>9 A. If any product doesn't show improved safety</p> <p>10 or efficacy, I don't know why they would want to --</p> <p>11 why anyone would want to release it or market it.</p> <p>12 What would be the point?</p> <p>13 Q. Okay. Do you agree or disagree with the</p> <p>14 following statement: There is no authoritative --</p> <p>15 authoritative paper to support the Prosima outcomes</p> <p>16 are superior or even comparable to a colporrhaphy?</p> <p>17 A. I disagree with that statement.</p> <p>18 Q. So if the investigator of a -- on a Prosima</p> <p>19 trial were to make that statement to Ethicon, you</p> <p>20 would disagree with that statement?</p> <p>21 A. Yes. I think we've got some good literature</p> <p>22 that shows that it is efficacious and safe. And</p> <p>23 that's also what I saw in my own experience.</p> <p>24 Q. If a primary investigator for a Prosima trial</p>	<p>1 Q. What exhibit are we on, Doctor? Are we on 9?</p> <p>2 A. 8. It's 9.</p> <p>3 MR. GAGE: This was one 8.</p> <p>4 A. That's correct.</p> <p>5 MR. GAGE: So 9 would be next.</p> <p>6 (Exhibit No. 9 marked.)</p> <p>7 Q. (By Mr. Faes) Doctor, I'm going to hand you</p> <p>8 what's been marked as Exhibit 9 to your deposition.</p> <p>9 MR. FAES: I actually got one of these</p> <p>10 for you, too, William.</p> <p>11 Q. (By Mr. Faes) Give you a second to review</p> <p>12 that. And my first question is: Have you seen this</p> <p>13 document before?</p> <p>14 A. Yes, I have.</p> <p>15 Q. Is this a document that you reviewed and</p> <p>16 relied upon in forming your opinions in this case?</p> <p>17 A. Yes.</p> <p>18 Q. Do you agree that -- let me read this. This</p> <p>19 is a document titled FDA strengthens -- strengthens</p> <p>20 requirement for surgical mesh for the transvaginal</p> <p>21 repair of pelvic organ prolapse to address safety</p> <p>22 risks. And it's dated January 4th, 2016.</p> <p>23 Do you see that?</p> <p>24 A. Yes.</p>

17 (Pages 62 to 65)

Christina Pramudji, M.D.

Page 66	Page 68
<p>1 Q. It says beginning in the first paragraph, 2 second sentence: The FDA issued one order to 3 reclassify these medical devices from class II, which 4 generally includes moderate-risk devices, to class 5 III, which generally includes high-risk devices. 6 Do you see that? 7 A. Yes. 8 Q. Do you agree that surgical mesh to repair 9 pelvic organ prolapse are high-risk devices? 10 A. No, I don't agree. 11 Q. So do you disagree with the FDA's decision to 12 reclassify surgical mesh to a high-risk device? 13 A. Yes, I do. 14 Q. Do you believe that the Prosima is a 15 high-risk device? 16 A. No, not at all. 17 Q. Do you believe that the Prolift is a 18 high-risk device? 19 A. No, not at all. 20 Q. Do you believe the Gynemesh PS flat mesh is a 21 high-risk device? 22 A. No. 23 Q. Do you know whether or not the Prolift is now 24 classified as a class III -- strike that.</p>	<p>1 Q. And you don't know obviously, then, if the 2 number of this residual risk score correlates to the 3 device being low risk, moderate risk or high risk? 4 A. I don't know. 5 Q. And, again, since you've never seen these, 6 you don't know what Ethicon's assessment was for the 7 Prolift, Prosima or the Gynemesh PS flat mesh with 8 regards to whether it was a low, moderate or high-risk 9 device. Is that correct? 10 A. That's correct. 11 Q. Now, if you look again at Exhibit No. 9, on 12 the very first paragraph it says: Surgical mesh has 13 been used by surgeons since the 1950s to repair 14 abdominal hernias; in the 1970s, gynecologists began 15 implanting surgical mesh for abdominal repair of 16 pelvic organ prolapse and, in the 1990s, for 17 transvaginal repair of pelvic organ prolapse. In 18 2002, the first flat mesh device with this indication 19 was cleared for use as a class II moderate risk 20 device. 21 Do you see that? 22 A. Yes. 23 Q. Do you know whether or not that the first 24 mesh device with this indication that was cleared in</p>
Page 67	Page 69
<p>1 Do you know whether or not the Gynemesh PS 2 flat mesh is now classified as a class III or class II 3 device? 4 A. I don't know. 5 Q. Do you think that would be important in -- or 6 something you'd like to consider in forming your 7 opinions regarding the Gynemesh PS? 8 A. No. I feel very comfortable with it with my 9 experience and with the literature. 10 Q. Do you know whether or not Ethicon does 11 internal risk analysis to determine risk scores for 12 those devices -- strike that. I think I phrased that 13 wrong. 14 Do you know whether or not Ethicon does 15 internal risk analysis to determine risk scores for 16 the medical devices they sell? 17 A. I'm not sure. 18 Q. You've never seen a residual risk analysis 19 for the Prosima, Prolift or Gynemesh PS device? 20 A. I don't think I have. 21 Q. So you don't recall, sitting here today, 22 whether or not Ethicon assigns a residual risk score 23 when they do these analyses. Is that correct? 24 A. That's correct.</p>	<p>1 2002 that it's referring to is the Gynemesh PS? 2 A. I don't know. 3 Q. So you don't know, sitting here today, 4 whether or not the Gynemesh PS flat mesh was the first 5 mesh device which was cleared with a transvaginal use 6 indication? 7 A. I know it -- I think that was the year that 8 it was approved and cleared, but I don't know if it 9 was the first one. 10 Q. Good enough. Do you know if Ethicon wanted 11 to sell the Gynemesh PS flat mesh with a transvaginal 12 use indication today, if they would have to submit a 13 premarket approval indication to the FDA because it's 14 now a class III device? 15 A. Can you repeat your question, please? 16 Q. You know what, I'm going to strike that -- 17 A. Okay. 18 Q. -- and move on. Doctor, on Page 3 of your 19 report -- and feel free to refer back to it if you 20 want. It's already marked as an exhibit. -- you 21 state that the data in women does not support that the 22 Gynemesh Prolene Soft degrades. Is that an opinion 23 you intend to offer in this case? 24 A. Absolutely. I feel very strongly about that.</p>

18 (Pages 66 to 69)

Christina Pramudji, M.D.

Page 70	Page 72
<p>1 Q. Would you agree that you are not an expert in 2 polymer chemistry?</p> <p>3 A. No, I would not agree with that. I mean, I 4 have dealt with polymers all these years as a surgeon 5 and I was a chemical engineering undergrad and studied 6 polymer science there, so I feel comfortable with 7 polymers and I understand how Gynemesh works in 8 patients in over 2000 patients.</p> <p>9 Q. So you hold yourself out as an expert in 10 polymer chemistry. Is that right?</p> <p>11 A. Yes, as far as it -- as far as it relates to 12 my practice, I certainly do.</p> <p>13 Q. Have you ever done any chemical testing with 14 the Prolene Soft mesh or the mesh in the Prolift or 15 the Prosima to see if it degrades?</p> <p>16 A. No, I haven't done that.</p> <p>17 Q. Have you ever done a microscopic analysis of 18 the Prolene Soft mesh or the mesh that's in the -- 19 which is the mesh that's in the Prolift or in Prosima 20 to determine if it degrades?</p> <p>21 A. No, I haven't.</p> <p>22 Q. Do you -- strike that.</p> <p>23 In support of your opinion regarding mesh 24 degradation you state that the reoperation rates for</p>	<p>1 A. For mesh failure -- what do you mean by "mesh 2 failure"? Do you mean that the prolapse occurred?</p> <p>3 Q. Yes.</p> <p>4 A. In that same compartment or in another 5 compartment?</p> <p>6 Q. Well, let's -- both questions. What 7 do you believe the reoperation rates are for Prolift 8 for prolapse recurring in the same compartment, 9 different compartment, and then both combined?</p> <p>10 A. It's going to be -- for the -- the -- it's 11 going to be around 20 percent per compartment.</p> <p>12 Q. So I'm not sure if that answered my question, 13 so I'll break it down. What do you believe are 14 reoperation rates for Prosima for failures in the same 15 compartment?</p> <p>16 A. For a recurrent -- I don't call it a mesh 17 failure, first of all, because it's not necessarily a 18 fault of the mesh. It's just the way that the pelvis 19 is. There's going to be a certain degree of recurrent 20 prolapse no matter what technique you use.</p> <p>21 Q. Let me see if I can re-ask the question in a 22 way that you can answer with a straight percentage. 23 What do you believe the reoperation rates are for the 24 Prosima for treatment failure in the same compartment?</p>
Page 71	Page 73
<p>1 recurrence are low and that cure rates and patient 2 satisfaction is high. Is there anything else you 3 believe supports your opinion?</p> <p>4 A. Well, the literature definitely supports it 5 when we don't see problems that can be related back to 6 degradation in the literature.</p> <p>7 Q. What do you believe the reoperation rates are 8 for the Prosima device?</p> <p>9 A. Oh, five percent, ten percent. And most of 10 those are just small erosions that need to be 11 repaired.</p> <p>12 Q. What do you --</p> <p>13 MR. GAGE: Object to form of the last 14 question. I think you asked a question and the 15 witness give a different answer, so that's all I'm 16 saying.</p> <p>17 Q. (By Mr. Faes) What do you believe the --</p> <p>18 MR. FAES: Yeah, I think she answered 19 about complications, not reoperation, so maybe I asked 20 a bad question.</p> <p>21 Q. (By Mr. Faes) What do you believe the 22 reoperation rates -- strike that.</p> <p>23 What do you believe the reoperation rates are 24 for Prosima for mesh failure?</p>	<p>1 A. Okay. So it's somewhere between ten to 20 2 percent.</p> <p>3 Q. What do you believe the reoperation rates are 4 for the Prosima for treatment failure in a different 5 compartment?</p> <p>6 A. About the same.</p> <p>7 Q. What do you believe the reoperation rates are 8 for the Prosima for treatment failure either in the 9 same compartment or a different compartment?</p> <p>10 A. It would be --</p> <p>11 MR. GAGE: Object the form.</p> <p>12 A. -- about the same, around that --</p> <p>13 Q. (By Mr. Faes) Ten to 20 percent?</p> <p>14 A. Around that range, yeah.</p> <p>15 Q. And I think you already anticipated my 16 question and answered it, but what do you believe the 17 reoperation rates are for Prosima for mesh extrusion 18 or -- strike that. I'm going to ask it a little bit 19 different question.</p> <p>20 What do you believe the reoperation rates are 21 for the Prosima to treat complications, all 22 complications, excluding treatment failure?</p> <p>23 A. Excluding treatment failure, somewhere 24 between five and ten percent.</p>

19 (Pages 70 to 73)

Christina Pramudji, M.D.

Page 74	Page 76
<p>1 Q. What do you believe the reoperation rates are</p> <p>2 for the Prosima to treat complications or treatment</p> <p>3 failure in any compartment?</p> <p>4 A. So somewhere between five and 20 percent.</p> <p>5 That's looking at the literature, looking at my own</p> <p>6 experience.</p> <p>7 Q. So you -- as you sit here today, you don't</p> <p>8 believe that a reoperation rate for treatment failure</p> <p>9 of ten to 20 percent and a reoperation rate for</p> <p>10 complications of five to ten percent is evidence that</p> <p>11 the Gynemesh PS mesh in the Prosima degrades?</p> <p>12 A. No, not at all. There's no correlation</p> <p>13 there.</p> <p>14 Q. Is there a number it would reach -- it could</p> <p>15 reach in order for you to change or reconsider your</p> <p>16 opinion that the data in women doesn't support that</p> <p>17 the Gynemesh PS degrades?</p> <p>18 A. I can't -- I can't even conceive of that,</p> <p>19 because it does not even -- it does not degrade in any</p> <p>20 way, so it's just a hypothetical question. So, yes,</p> <p>21 there's no --</p> <p>22 Q. So if there --</p> <p>23 A. There's nothing you could tell me that would</p> <p>24 make me say, oh, that's because of degradation,</p>	<p>1 support of your opinion that the data in women does</p> <p>2 not support that the Gynemesh PS degrades, you state</p> <p>3 that the reoperation rates for recurrence are low,</p> <p>4 that the cure rates and patient satisfaction are high.</p> <p>5 Is there anything else that you're relying on to</p> <p>6 support your opinion that the data in women does not</p> <p>7 support that the Gynemesh PS degrades?</p> <p>8 A. Well, also, apart from these, sort of, side</p> <p>9 studies where they show, quote, unquote, degradation,</p> <p>10 which I think is just probably the biofilm, in other</p> <p>11 studies, where they -- where they remove the mesh, the</p> <p>12 mesh is there. You know, it's not -- it doesn't</p> <p>13 disappear. It doesn't degrade over time. I mean, if</p> <p>14 Prolene degraded, they would not use it in cardiac</p> <p>15 surgery to rely on sewing together arteries. So this</p> <p>16 whole theory of degradation is just -- just bogus in</p> <p>17 my opinion.</p> <p>18 Q. So if I understand you correctly, you're</p> <p>19 relying on literature to support your opinion that the</p> <p>20 Gynemesh PS doesn't degrade?</p> <p>21 A. And my own clinical experience, my own</p> <p>22 clinical experience with my patient success and</p> <p>23 satisfaction with it. And in the cases where I've</p> <p>24 removed mesh, you know, grossly examining the mesh --</p>
Page 75	Page 77
<p>1 because it doesn't happen.</p> <p>2 Q. But if I understand you correctly, you're</p> <p>3 using the -- you rely on the fact that reoperation</p> <p>4 rates for recurrence are low and cure rates and</p> <p>5 patient satisfaction is high is the basis for</p> <p>6 your opinion that the mesh doesn't degrade.</p> <p>7 Right?</p> <p>8 A. Right.</p> <p>9 Q. So you're saying -- telling me that there's</p> <p>10 no number that that -- that those reoperation rates</p> <p>11 could rise to that would cause you to reconsider your</p> <p>12 opinion?</p> <p>13 A. No. I mean, that's part of the basis.</p> <p>14 That's not the whole basis. That's just -- first of</p> <p>15 all, we're starting with the fact that it doesn't</p> <p>16 degrade and then this is the supportive reason to show</p> <p>17 that it doesn't. But the converse is not necessarily</p> <p>18 true. If this happens, that doesn't mean that it</p> <p>19 degrades, if that makes sense.</p> <p>20 Q. So, again, I think I asked you this</p> <p>21 question earlier -- maybe I didn't or maybe I've</p> <p>22 already forgotten the experts that your -- strike</p> <p>23 that. I'm just babbling now.</p> <p>24 So let me just ask you a new question: In</p>	<p>1 yeah, I didn't do a microscopic electron microscopy on</p> <p>2 the mesh, but, you know, it's not like you see it</p> <p>3 disintegrating. It's not falling apart in front of</p> <p>4 your eyes.</p> <p>5 Q. Have -- or do you believe that the mesh has</p> <p>6 to be disintegrating for falling apart in front of</p> <p>7 your eyes in order to have a clinical impact on the</p> <p>8 patient? Do you believe -- strike that. Let me ask a</p> <p>9 different question.</p> <p>10 Do you believe that -- actually, let me start</p> <p>11 over.</p> <p>12 Do you believe that polypropylene doesn't</p> <p>13 degrade at all or do you just believe that the</p> <p>14 polypropylene mesh in the pelvic organ prolapse</p> <p>15 products that you're offering opinion on -- opinions</p> <p>16 on don't grade?</p> <p>17 MR. GAGE: Object to form.</p> <p>18 A. I don't think it degrades at all. If it does</p> <p>19 degrade, microscopically, there's absolutely no</p> <p>20 clinical effect on patients --</p> <p>21 Q. (By Mr. Faes) So your --</p> <p>22 A. -- and there's no implication to it.</p> <p>23 Q. Your opinion is that no polypropylene</p> <p>24 anywhere degrades?</p>

20 (Pages 74 to 77)

Christina Pramudji, M.D.

Page 78	Page 80
<p>1 A. Like I said, if it does degrade, 2 microscopically, there's no clinical impact, so it's a 3 nonissue. 4 Q. I'm not sure if I got an answer to my 5 question, though. Is it your opinion that no 6 polypropylene anywhere degrades or do you agree that 7 some polypropylene can degrade under the right 8 circumstances? 9 A. I think it potentially could degrade under 10 the right circumstances. Anything can degrade under 11 the right circumstances. But does it clinically have 12 any impact, no. 13 Q. Do you believe that when polypropylene mesh 14 degrades, it can become -- strike that. 15 Do you believe that when polypropylene 16 degrades one of the things that can occur is that the 17 polypropylene can become brittle? 18 MR. GAGE: Object to form. 19 A. No. 20 Q. (By Mr. Faes) Do you know what fishing line 21 is made out of? 22 A. No, I don't. 23 Q. You don't know that fishing line is made out 24 of polypropylene?</p>	<p>1 A. Not to the same degree. 2 Q. (By Mr. Faes) Do you know whether peroxides 3 have an effect on polypropylene degradation? 4 A. I believe that they can, yes. 5 Q. So, just so I understand your answer, you do 6 believe that peroxides can accelerate or cause 7 polypropylene to degrade? 8 A. In the right concentration, yes. 9 Q. What do you believe the patient satisfaction 10 rates are for the Prosima device? 11 A. They're very high. They're 80 to 90 percent. 12 Q. And where are you getting that information 13 from? 14 A. From multiple studies. 15 Q. What do you believe the reoperation rates are 16 for the Prolift device for complications? 17 A. It's around the same as the Prosima, five to 18 20 percent. 19 Q. That's a pretty big range, isn't it, Doctor? 20 A. Yeah, and the studies are -- that's pretty 21 much the range that you're going to find in the 22 studies. 23 Q. Would you agree that the erosion or extrusion 24 rate for the Prolift can range from 15 to 20 percent?</p>
Page 79	Page 81
<p>1 A. No, I didn't know that. 2 Q. Have you ever gone fishing? 3 A. Yes. 4 Q. Have you ever had to replace your fishing 5 line because the line got brittle from the previous 6 year? 7 A. Yes. But that's a completely different 8 circumstance than something that's implanted in the 9 body. 10 Q. Well, I wasn't asking about things that were 11 implanted in the body. I'm asking -- so you'd agree 12 with that example, that polypropylene under the right 13 circumstances can degrade? 14 A. Yeah, sure. 15 Q. You also talked about the fact that 16 polypropylene sutures are used -- or Prolene sutures, 17 rather, are used in cardiac surgery. Do you believe 18 that the environment in the vagina is the same as the 19 environment in the cardiac cavity? 20 A. No. It's different. 21 Q. In fact, you know that there are peroxides 22 present in the vagina and there are not peroxides 23 present in the cardiac cavity. Right? 24 MR. GAGE: Object to form.</p>	<p>1 A. Some studies show that, but most studies it's 2 closer to the five to ten percent range. Eight 3 percent seems to be the number that comes up a lot. 4 Q. So you did -- if someone were to tell you 5 that the overall erosion or exposure or extrusion 6 rates for the Prolift was in the 15 to 20 percent 7 range, you'd disagree with that? 8 A. Yeah. That's -- that's high. I know some 9 studies have shown that and have shown even higher in 10 small studies, but -- but looking at the large 11 database studies, the rates are not that high. 12 Q. Do you know Dr. Joe Carbone? 13 A. Yes. 14 Q. You've met Dr. Joe Carbone -- 15 A. I have. 16 Q. -- before. Right? In fact, you both 17 attended the 2011 Ethicon Pelvic Floor Summit in 18 Sonoma together? 19 A. Yes. 20 Q. Where there was wine tasting and dinner? 21 A. Yes. 22 Q. So if Dr. Carbone told me last week that he 23 believes the overall erosion or extrusion rates for 24 the Prolift device is 15 to 20 percent, would you</p>

21 (Pages 78 to 81)

Christina Pramudji, M.D.

Page 82	Page 84
<p>1 disagree with him?</p> <p>2 A. With all due respect to Dr. Carbone, I think</p> <p>3 -- I don't think the literature bears out that -- that</p> <p>4 high a rate. And my personal experience certainly is</p> <p>5 not that high. And I think, talking to my colleagues,</p> <p>6 it's not that high.</p> <p>7 Q. But you do agree that, at least in some</p> <p>8 studies, the erosion or exposure rate can be as high</p> <p>9 as 20 percent with the Prolift. Right?</p> <p>10 A. I have seen studies that show that yes.</p> <p>11 Q. And you're familiar with the Iglesia study?</p> <p>12 A. Yes.</p> <p>13 Q. And you know that the exposure and erosion</p> <p>14 rate for the Prolift in that study was greater than 15</p> <p>15 percent?</p> <p>16 A. Yes, as well as the suture exposure rate was</p> <p>17 also 15 percent in the native tissue repairs.</p> <p>18 MR. FAES: I'm going to object and move</p> <p>19 to strike after the answer "yes." I didn't ask</p> <p>20 anything about suture exposure rates.</p> <p>21 Q. (By Mr. Faes) And you know that that study</p> <p>22 was stopped by Dr. Iglesia and her colleagues because</p> <p>23 of their concern about the erosion and exposure rates.</p> <p>24 Correct?</p>	<p>1 literature with my own experience and that's where I</p> <p>2 form my opinions, so I would have to disagree with</p> <p>3 them on that.</p> <p>4 Q. (By Mr. Faes) Yeah. I'm going to have to</p> <p>5 re-ask it, because there's a lot of nonresponsive</p> <p>6 information in there. I'm going to ask a</p> <p>7 hypothetical: Assuming that the FDA said that they</p> <p>8 did not consider Dr. Iglesia an outlier, if they did</p> <p>9 indeed say that, that's another instance in which you</p> <p>10 would disagree with the FDA. Is that correct?</p> <p>11 A. That's correct.</p> <p>12 MR. GAGE: Object to form.</p> <p>13 Q. (By Mr. Faes) What do you believe are the</p> <p>14 patient satisfaction rates with the Prolift device?</p> <p>15 A. Again, very high, 75 to 90 percent.</p> <p>16 Q. At what time frame? Are you calculating</p> <p>17 patient satisfaction rates at one year, three years?</p> <p>18 A. Well, the -- you know -- studies go -- most</p> <p>19 -- a lot -- most of the studies are one to two years,</p> <p>20 but there are some studies that go out further to</p> <p>21 seven years.</p> <p>22 Q. What's the longest study that you're aware</p> <p>23 of, the longest follow-up study you're aware of that</p> <p>24 utilized the Gynemesh PS mesh, whether it be in the</p>
Page 83	Page 85
<p>1 A. That's correct.</p> <p>2 Q. Do you consider Dr. Iglesia an outlier?</p> <p>3 A. Yes, I do.</p> <p>4 Q. Do you know whether the FDA considers Dr.</p> <p>5 Iglesia and outlier?</p> <p>6 A. I don't know what they think about</p> <p>7 Dr. Iglesia.</p> <p>8 Q. So you've never seen records from meetings</p> <p>9 that Ethicon had with the FDA regarding the 522 orders</p> <p>10 where the FDA told Ethicon that they did not consider</p> <p>11 Dr. Iglesia an outlier. Is that fair?</p> <p>12 MR. GAGE: Object to form.</p> <p>13 A. You know, I've seen so many documents. As I</p> <p>14 sit here today, I'm not sure if I saw that or not. I</p> <p>15 probably did.</p> <p>16 Q. (By Mr. Faes) So I'm going to ask a</p> <p>17 hypothetical: Assuming that the FDA said that they</p> <p>18 did not consider Dr. Iglesia an outlier, that's</p> <p>19 another instance in which you would agree with --</p> <p>20 disagree with the FDA. Correct?</p> <p>21 MR. GAGE: Object the form.</p> <p>22 A. With all due respect to the FDA and</p> <p>23 Dr. Iglesia, I look at the full body of literature. I</p> <p>24 don't look at one study. I compare the full body of</p>	<p>1 Prolift or the Prosima or as a flat mesh?</p> <p>2 A. I believe it's seven years.</p> <p>3 Q. Do you recall what study or studies go out to</p> <p>4 seven years?</p> <p>5 A. I would have to take a minute to refresh my</p> <p>6 memory.</p> <p>7 Q. Do you recall, without refreshing your</p> <p>8 memory, whether it's more than one or if it's. . .</p> <p>9 A. I believe there were two studies.</p> <p>10 Q. Do you believe that if polypropylene mesh</p> <p>11 were to break down or degrade, it could lead to an</p> <p>12 erosion or an exposure?</p> <p>13 A. We're talking hypothetically. And I would</p> <p>14 think that if it were degrading, then it would be just</p> <p>15 disappearing. And so I'm not sure how that could</p> <p>16 cause an erosion or an exposure.</p> <p>17 Q. Do you believe that mesh degrading or</p> <p>18 breaking down could lead to an unintended tissue</p> <p>19 reaction?</p> <p>20 A. Again, hypothetically, because as I stated</p> <p>21 before, I don't think it does degrade, but if there's</p> <p>22 some product that did degrade, then, yes, that could</p> <p>23 cause an inflammatory reaction.</p> <p>24 Q. Can an inflammatory reaction or unintended</p>

22 (Pages 82 to 85)

Christina Pramudji, M.D.

<p style="text-align: right;">Page 86</p> <p>1 tissue reaction cause the body to push the mesh out of</p> <p>2 the body causing it to be eroded or exposed?</p> <p>3 A. Hypothetically, if there's an inflammatory</p> <p>4 reaction, you could have a tissue breakdown and have a</p> <p>5 mesh exposure. I wouldn't say it's pushing it out of</p> <p>6 the body, but there could -- if there's a tissue</p> <p>7 breakdown, you could have an exposure of the mesh.</p> <p>8 Q. If polypropylene were to become brittle, as</p> <p>9 we discussed with the fishing line example, could that</p> <p>10 lead to an erosion?</p> <p>11 A. I think it would depend on how it how it --</p> <p>12 how it were oriented. And, again, I'm not conceding</p> <p>13 that it degrades or becomes brittle in the body. But</p> <p>14 hypothetically, if it were poking out towards the</p> <p>15 tissue, something could break down, I suppose.</p> <p>16 Q. You'd agree that sharp edges of the mesh</p> <p>17 could cause an erosion?</p> <p>18 A. If the mesh is not oriented properly and not</p> <p>19 placed properly, that could cause an erosion from a</p> <p>20 sharp edge. It's not because of the mesh. It's the</p> <p>21 way that it's put in.</p> <p>22 Q. If the mesh becomes -- hypothetically, again,</p> <p>23 if the mesh becomes brittle, could that lead to</p> <p>24 patient discomfort?</p>	<p style="text-align: right;">Page 88</p> <p>1 Gynemesh, Prolift and Prosima.</p> <p>2 Q. So, approximately, how many studies did you</p> <p>3 determine had been done on the Vypro mesh in pelvic</p> <p>4 reconstructive surgery?</p> <p>5 A. I don't -- I don't have a number, but it's</p> <p>6 not many at all.</p> <p>7 Q. How many studies did you find where PD</p> <p>8 -- PVDF mesh had been studied in pelvic reconstructive</p> <p>9 surgery?</p> <p>10 A. I don't have a number.</p> <p>11 Q. How many Ultrapro studies did you find that</p> <p>12 had been studied in pelvic reconstructive surgery?</p> <p>13 A. I don't have a number for that.</p> <p>14 Q. How many Elevate studies did you find that</p> <p>15 had been studied in pelvic reconstructive surgery?</p> <p>16 A. I'm sorry. I don't have an exact number.</p> <p>17 Q. So you can't quote a number as you're sitting</p> <p>18 here today, but you believe it's less?</p> <p>19 A. Yes.</p> <p>20 Q. Do you know if it's 50 percent less, 25</p> <p>21 percent less?</p> <p>22 A. It's a lot less.</p> <p>23 Q. How did you determine it was less? What</p> <p>24 methodology did you use?</p>
<p style="text-align: right;">Page 87</p> <p>1 A. I'm not sure.</p> <p>2 Q. On Page 3 of your report you state that</p> <p>3 Gynemesh PS has been the most studied mesh in pelvic</p> <p>4 reconstructive surgery. Is that an opinion you intend</p> <p>5 to offer in this case?</p> <p>6 A. Yes.</p> <p>7 Q. When you say that it's the most studied mesh</p> <p>8 in pelvic reconstructive surgery, what do you mean by</p> <p>9 that? Do you mean that it's had the most number of</p> <p>10 studies performed or that the -- had the most number</p> <p>11 of patients studied in those studies or both, if that</p> <p>12 makes sense? It's kind of an ineloquent question.</p> <p>13 MR. GAGE: Object to form.</p> <p>14 A. Both, the most studies, the most number of</p> <p>15 patients, the most randomized controlled studies.</p> <p>16 Q. (By Mr. Faes) So what other meshes did you</p> <p>17 compare it to to make that determination that it was</p> <p>18 the most studied --</p> <p>19 A. Well --</p> <p>20 Q. -- in pelvic reconstructive surgery?</p> <p>21 A. The Vypro, the PVDF, Ultrapro. And then</p> <p>22 there's other kits, as well, that are also</p> <p>23 polypropylene mesh, like the Elevate, that have been</p> <p>24 studied quite a bit, as well, but not as much as the</p>	<p style="text-align: right;">Page 89</p> <p>1 A. Well, you can just do a PubMed search.</p> <p>2 Q. Did you keep any documentation of your PubMed</p> <p>3 searches in terms of how many studies for these other</p> <p>4 four meshes?</p> <p>5 A. No, I did not.</p> <p>6 Q. Did you compare the Prolene -- actually, I'm</p> <p>7 going to strike that.</p> <p>8 Different question: Did you do any kind of</p> <p>9 systematic review of the literature on those four</p> <p>10 meshes to determine whether the quality of those</p> <p>11 studies was better or worse than the quality of the</p> <p>12 studies on the Gynemesh PS mesh?</p> <p>13 A. I just did sort of a survey of the studies.</p> <p>14 I didn't go in depth.</p> <p>15 Q. So you'd agree that it wasn't any kind of a</p> <p>16 systematic review?</p> <p>17 A. No.</p> <p>18 Q. Did you compare -- in regards to this</p> <p>19 opinion, that it's the most studied mesh in pelvic</p> <p>20 reconstructive surgery, did you do any comparison to</p> <p>21 the traditional Prolene mesh, see how many studies</p> <p>22 there were where that had been used?</p> <p>23 A. No, I didn't.</p> <p>24 Q. Same question: The IntePro Lite mesh?</p>

23 (Pages 86 to 89)

Christina Pramudji, M.D.

Page 90	Page 92
<p>1 A. No.</p> <p>2 Q. What about the Marlex mesh, which is now</p> <p>3 called the Bard mesh?</p> <p>4 A. Uh-huh.</p> <p>5 MR. GAGE: You need to say "yes," not --</p> <p>6 THE WITNESS: No. Yeah. I'm just</p> <p>7 acknowledging that I understood the question. Sorry.</p> <p>8 A. No, I didn't.</p> <p>9 Q. (By Mr. Faes) Would you agree that native</p> <p>10 tissue repair of pelvic organ prolapse is more studied</p> <p>11 than the Gynemesh PS has been in pelvic reconstructive</p> <p>12 surgery?</p> <p>13 A. I am not sure about that. My gut feeling is</p> <p>14 that the Gynemesh is more studied, but I'd have to --</p> <p>15 I'd have to -- I'd have to look at that.</p> <p>16 Q. So -- but it's fair to say, as you sit here</p> <p>17 today --</p> <p>18 A. Uh-huh.</p> <p>19 Q. -- you've never looked at that and you don't</p> <p>20 know, one way or the other, whether native tissue</p> <p>21 repair for repair of pelvic organ prolapse is more</p> <p>22 studied than the Gynemesh PS has been in pelvic</p> <p>23 reconstructive surgery?</p> <p>24 A. I don't know.</p>	<p>1 Q. Is that something you intend to do prior to</p> <p>2 trial?</p> <p>3 A. Perhaps.</p> <p>4 MR. FAES: I would ask counsel, if such</p> <p>5 a demonstrative is ever created, that that be produced</p> <p>6 to us.</p> <p>7 Q. (By Mr. Faes) Do you know how many out of</p> <p>8 those hundred are randomized controlled trials?</p> <p>9 A. I don't have a number off the top of my head.</p> <p>10 Numerous.</p> <p>11 Q. Do you know how many of those studies are</p> <p>12 Gynemesh PS flat mesh by itself?</p> <p>13 A. I don't have a number.</p> <p>14 Q. Do you know if there have been any randomized</p> <p>15 controlled trials of Gynemesh PS flat mesh comparing</p> <p>16 it to comparator device or procedure?</p> <p>17 A. I can't recall right now.</p> <p>18 Q. Do you know if there are any randomized</p> <p>19 controlled trials comparing the Prosima device to an</p> <p>20 alternative device or procedure?</p> <p>21 A. Yes, absolutely.</p> <p>22 Q. How many of those -- how many randomized</p> <p>23 controlled trials do you believe there are that</p> <p>24 compare the Prosima device to a different device</p>
Page 91	Page 93
<p>1 Q. You haven't looked at that question?</p> <p>2 A. I haven't looked at that.</p> <p>3 Q. Okay. You also state in your report that</p> <p>4 there are numerous randomized controlled trials and</p> <p>5 over a hundred studies which demonstrate that the</p> <p>6 Gynemesh PS when used by itself or in the Prolift and</p> <p>7 Prosima devices -- I think I said that wrong. Strike</p> <p>8 that and I'll ask a new question.</p> <p>9 You say in your report that there are</p> <p>10 numerous randomized controlled trials and over a</p> <p>11 hundred studies which demonstrate that the Gynemesh PS</p> <p>12 when used by itself or in the Prolift or Prosima</p> <p>13 devices. Is that correct?</p> <p>14 A. That's correct.</p> <p>15 Q. Do you know what the exact number is?</p> <p>16 A. No, I don't.</p> <p>17 Q. Do you have any documentation that you have</p> <p>18 or a list that you intend to refer to at trial as to</p> <p>19 what those greater than a hundred studies are?</p> <p>20 A. None other than my reliance materials.</p> <p>21 Q. But you've never separately broken them out,</p> <p>22 those hundred out of your reliance list for use as</p> <p>23 a demonstrative at trial or anything like that?</p> <p>24 A. No.</p>	<p>1 or procedure?</p> <p>2 A. I believe there's about five or six.</p> <p>3 Q. In the hundred studies that you say</p> <p>4 demonstrate the use of Gynemesh PS, when used by</p> <p>5 itself or in the Prolift or Prosima devices, do you</p> <p>6 know how many of those studies use Gynemesh PS</p> <p>7 abdominally rather than transvaginally?</p> <p>8 A. I don't recall. Not very many.</p> <p>9 Q. In your report you state that there -- you</p> <p>10 don't believe that there is any evidence that the</p> <p>11 Prolene mesh is cytotoxic. Is that correct?</p> <p>12 A. That's correct.</p> <p>13 Q. Is that an opinion you intend to offer in</p> <p>14 this case?</p> <p>15 A. Yes.</p> <p>16 Q. Have you studied what happens to tissue when</p> <p>17 it is exposed to a cytotoxic substance?</p> <p>18 A. I'm sure in biology or in medical school we</p> <p>19 studied, you know, cytotoxicity and what happens to</p> <p>20 tissue in that circumstance.</p> <p>21 Q. As you sit here today, can you tell me what</p> <p>22 the clinical effect would be to tissue if it were</p> <p>23 opposed [sic] to a cytotoxic substance?</p> <p>24 A. Necrosis. Inflammation, necrosis.</p>

24 (Pages 90 to 93)

Christina Pramudji, M.D.

Page 94	Page 96
<p>1 Q. Would you agree that necrotized or -- strike</p> <p>2 that.</p> <p>3 Would you agree that necrotized tissue</p> <p>4 surrounding a mesh could lead to erosion or exposure</p> <p>5 of the mesh?</p> <p>6 A. Yes.</p> <p>7 Q. So isn't one clinical manifestation --</p> <p>8 potential clinical manifestation of -- strike that.</p> <p>9 So if you agree that one potential effect of</p> <p>10 being exposed to a cytotoxic substance is that the</p> <p>11 tissue can undergo necrosis and you agree that</p> <p>12 necrotized tissue surrounding the mesh can lead to an</p> <p>13 erosion or exposure of the mesh, isn't a study that</p> <p>14 shows an erosion or exposure rate of 15 to 20 percent</p> <p>15 evidence that the mesh is, indeed, cytotoxic?</p> <p>16 MR. GAGE: Object to form.</p> <p>17 A. No, not at all. The necrosis around the</p> <p>18 wound can be due to tissue handling, the state of the</p> <p>19 tissue, cautery of the edges, improper sewing</p> <p>20 technique, history of smoking, diabetes, poor blood</p> <p>21 flow. There's just innumerable reasons for necrosis.</p> <p>22 And most of the erosions are right in the suture line,</p> <p>23 so that's a wound healing issue. If it -- if mesh</p> <p>24 were cytotoxic, you would see erosions all over the</p>	<p>1 Q. -- if you want to keep going, I won't cut you</p> <p>2 off. So you've listed multiple potential causes</p> <p>3 of tissue necrosis. We can agree that there are</p> <p>4 multiple potential causes of tissue necrosis.</p> <p>5 Correct?</p> <p>6 A. Yes.</p> <p>7 Q. And we can also agree that one potential</p> <p>8 cause of tissue necrosis is the tissue being exposed</p> <p>9 to a cytotoxic substance. Is that correct?</p> <p>10 A. That's correct.</p> <p>11 Q. On Page 4 of your report you state that</p> <p>12 plaintiffs' experts have said that there are safer or</p> <p>13 better meshes, that these meshes have not been</p> <p>14 demonstrated to be more efficacious based on reliable</p> <p>15 scientific literature like the Gyne -- the Gynemesh</p> <p>16 PS. Is that correct?</p> <p>17 A. That's correct.</p> <p>18 Q. Is that an opinion you tend to offer in this</p> <p>19 case?</p> <p>20 A. Yes.</p> <p>21 Q. Now, specifically, in your report, you</p> <p>22 mention DynaMesh, Vypro and Ultrapro. Is that right?</p> <p>23 A. Correct.</p> <p>24 Q. Are there any other meshes that you have</p>
Page 95	Page 97
<p>1 place and you don't see that. You see them -- the</p> <p>2 vast majority are right in the suture line.</p> <p>3 Q. You don't think a study that shows an erosion</p> <p>4 rate of 15 to 20 percent is an erosion all over the</p> <p>5 place?</p> <p>6 A. No. No. I'm talking about -- I'm talking</p> <p>7 about erosion on the side of the vagina, you know, not</p> <p>8 just in the suture line. If it's in the suture line,</p> <p>9 that's a wound healing problem. If it -- if the mesh</p> <p>10 were cytotoxic, you would see holes on this side of</p> <p>11 the vagina and over here, not just in the incision</p> <p>12 line.</p> <p>13 Q. So is it your testimony that you've never</p> <p>14 seen an erosion any place other than in the incision</p> <p>15 line?</p> <p>16 A. No, I'm not saying that. I'm not saying that</p> <p>17 at all. I have seen that on the sides. Usually an</p> <p>18 arm that was not placed properly through the sulcus,</p> <p>19 but --</p> <p>20 Q. I think you've you've answered my question.</p> <p>21 A. Okay.</p> <p>22 Q. I'm going to move to strike everything after</p> <p>23 that anyway, but --</p> <p>24 A. Okay.</p>	<p>1 studied that you believe have not been demonstrated to</p> <p>2 be more efficacious based on reliable scientific</p> <p>3 literature like the Gynemesh PS?</p> <p>4 A. No.</p> <p>5 MR. GAGE: Just take a quick bathroom</p> <p>6 break.</p> <p>7 MR. FAES: Same here. Let's do it real</p> <p>8 quick.</p> <p>9 THE WITNESS: Yeah.</p> <p>10 (Break.)</p> <p>11 Q. (By Mr. Faes) Dr. Pramudji, we're back on</p> <p>12 the record after a short break. Are you ready to</p> <p>13 proceed?</p> <p>14 A. Yes.</p> <p>15 Q. Before the break we were talking about meshes</p> <p>16 that you believe have not been demonstrated to be</p> <p>17 safer and more efficacious based on the reliable</p> <p>18 scientific literature like Gynemesh PS. Did you study</p> <p>19 the Restorelle mesh?</p> <p>20 A. No, I did not.</p> <p>21 Q. And that's currently your mesh of choice for</p> <p>22 ASC. Correct?</p> <p>23 A. Yes, that's correct.</p> <p>24 Q. Did you study the IntePro mesh?</p>

25 (Pages 94 to 97)

Christina Pramudji, M.D.

Page 98	Page 100
<p>1 A. No, I did not.</p> <p>2 Q. Did you study the IntePro Lite mesh?</p> <p>3 A. No.</p> <p>4 Q. Did you study the Elevate mesh?</p> <p>5 A. No.</p> <p>6 Q. What about the Uphold mesh?</p> <p>7 A. No.</p> <p>8 Q. No. Did you know that Ethicon was developing</p> <p>9 a Prosima Plus M device which would have used the</p> <p>10 Ultrapro mesh, rather than the Gynemesh PS mesh just</p> <p>11 like the Prolift Plus M?</p> <p>12 A. Yes, I was aware of that.</p> <p>13 Q. When were you made aware of that?</p> <p>14 A. Pretty early on, because we were -- we were</p> <p>15 asking for it, because we liked the Prolift Plus M</p> <p>16 mesh and we were wondering why the new product was</p> <p>17 made with the Gynemesh PS versus the Prolift Plus M</p> <p>18 mesh.</p> <p>19 Q. Do you anticipate that if the Prosima Plus M</p> <p>20 had been made available with the Ultrapro mesh, do you</p> <p>21 believe that would have become your device of choice</p> <p>22 over the traditional Prosima, just like the Prolift</p> <p>23 Plus M became your device of choice over the Prolift?</p> <p>24 MR. GAGE: Object to form.</p>	<p>1 MR. GAGE: Object to form.</p> <p>2 A. I'm sorry to interrupt. Yes, that's correct.</p> <p>3 Q. (By Mr. Faes) Do you know what the weight in</p> <p>4 grams per meter squared of the Gynemesh PS mesh is?</p> <p>5 A. I can't remember at this moment. I used to</p> <p>6 know. I'd have the look it up.</p> <p>7 Q. On Page 5 you state -- of your report you</p> <p>8 state that the Prosima is minimally invasive compared</p> <p>9 to the abdominal -- abdominal sacrocolpopexy and less</p> <p>10 morbid. Is that an opinion you intend to offer in</p> <p>11 this case?</p> <p>12 A. Yes.</p> <p>13 Q. First of all, let me ask you this: What do</p> <p>14 you mean by less morbid?</p> <p>15 A. Less effect on the body. With the</p> <p>16 sacrocolpopexy, you have more dissection, you have</p> <p>17 more risk of bowel complications compared to Prosima.</p> <p>18 Q. Is there anything else about the ASC</p> <p>19 procedure that you believe is more morbid than the</p> <p>20 Prosima procedure?</p> <p>21 A. It also has a risk of hernia, injury to major</p> <p>22 vessels, bowel obstruction, adhesions.</p> <p>23 Q. Do you believe that the Prosima device</p> <p>24 doesn't carry with it a risk of hernia?</p>
Page 99	Page 101
<p>1 A. I'm not sure. I would have to try it out and</p> <p>2 see if I got similar results with it.</p> <p>3 Q. (By Mr. Faes) Do you know why the Prosima</p> <p>4 Plus M device ultimately never came to market?</p> <p>5 A. I don't know why.</p> <p>6 Q. Can you -- well, this is going to be an easy</p> <p>7 question because there's hardly any kits left on</p> <p>8 the market, but can you point to a kit for the</p> <p>9 repair of pelvic organ prolapse which is on the market</p> <p>10 today which uses a mesh that is heavier in weight than</p> <p>11 the Gynemesh PS mesh?</p> <p>12 MR. GAGE: Object to form.</p> <p>13 A. No, I can't.</p> <p>14 Q. (By Mr. Faes) In fact, as you sit here</p> <p>15 today, do you know that all of the mesh kits still on</p> <p>16 the market have mesh that are lighter in weight than</p> <p>17 the Gynemesh PS mesh?</p> <p>18 MR. GAGE: Object to form.</p> <p>19 A. I think they're very similar, maybe slightly</p> <p>20 lighter.</p> <p>21 Q. (By Mr. Faes) But, certainly, none are</p> <p>22 heavier than the --</p> <p>23 A. That's correct.</p> <p>24 Q. -- Gynemesh PS mesh?</p>	<p>1 A. I'm talking about abdominal wall hernia, to</p> <p>2 be clear.</p> <p>3 Q. Okay.</p> <p>4 A. So because of the trocars or the incision for</p> <p>5 an abdominal sacrocolpopexy, there's going to be a</p> <p>6 risk of abdominal wall hernia.</p> <p>7 Q. And is that a risk that -- is that not a risk</p> <p>8 of the Prosima device in your opinion?</p> <p>9 A. Right, because there's no abdominal wall</p> <p>10 incision for a Prosima.</p> <p>11 Q. Can -- is -- can the Prosima device cause</p> <p>12 other hernias, such as an inguinal hernia.</p> <p>13 A. No, it cannot cause that.</p> <p>14 Q. Do you believe the Prosima device doesn't</p> <p>15 have a risk of bowel injury?</p> <p>16 A. It's a very small risk. If you have apical</p> <p>17 dissection into an enterocele, it could happen. Or if</p> <p>18 you're doing a posterior Prosima, you have a risk of</p> <p>19 rectal injury, but it's a very small risk.</p> <p>20 Q. Do you believe it's a --</p> <p>21 A. And it's --</p> <p>22 Q. -- smaller risk than the risk of bowel injury</p> <p>23 with the ASC?</p> <p>24 A. Yes, much smaller risk.</p>

26 (Pages 98 to 101)

Christina Pramudji, M.D.

Page 102	Page 104
<p>1 Q. Now, you state that the Prosima device is</p> <p>2 less invasive. Would you agree that a doctor or</p> <p>3 patient might choose a more invasive surgery to avoid</p> <p>4 potentially life complications of a less invasive</p> <p>5 device or procedure?</p> <p>6 A. What are "life complications"?</p> <p>7 Q. Did I say life com -- I meant life-changing</p> <p>8 complications.</p> <p>9 A. Oh, okay.</p> <p>10 Q. So let me -- did -- is that not what I said?</p> <p>11 MR. GAGE: Yeah, I'm going to -- if</p> <p>12 you're going to rephrase -- if you'll withdraw and</p> <p>13 rephrase the question.</p> <p>14 MR. FAES: Yeah, I'll withdraw it and</p> <p>15 rephrase it.</p> <p>16 MR. GAGE: Thank you.</p> <p>17 Q. (By Mr. Faes) Would you agree that a doctor</p> <p>18 or patient might choose a more invasive surgery to</p> <p>19 avoid potentially life-changing complications of a</p> <p>20 less invasive device or procedure?</p> <p>21 A. Yes, I agree with that statement.</p> <p>22 Q. Would you agree that a doctor and patient</p> <p>23 should know about all of the potentially life-changing</p> <p>24 complications of the device or the procedure, so they</p>	<p>1 placed?</p> <p>2 A. I can agree with that, although I would say</p> <p>3 that I've never seen that or heard of it, but</p> <p>4 hypothetically, that -- I would agree with that</p> <p>5 statement.</p> <p>6 Q. You've never seen or heard of a vaginal</p> <p>7 support device that needed to be removed prior to the</p> <p>8 21 days elapsing because of an apparent infection?</p> <p>9 A. No.</p> <p>10 Q. That's not cited on Page 41 of your report in</p> <p>11 an article?</p> <p>12 A. Oh, I was talking about my own experience.</p> <p>13 Sorry.</p> <p>14 Q. Oh, okay.</p> <p>15 A. Yeah.</p> <p>16 Q. Okay. So you're aware that that --</p> <p>17 A. Yes.</p> <p>18 Q. -- that can occur?</p> <p>19 A. Yes.</p> <p>20 Q. Now, you've testified before that you're</p> <p>21 familiar with the ProteGen project -- ProteGen</p> <p>22 product. Correct?</p> <p>23 A. Correct.</p> <p>24 Q. And you testified that you know that the</p>
Page 103	Page 105
<p>1 can make an informed choice about what device or</p> <p>2 procedure they would like to have performed on them?</p> <p>3 A. I think a doctor and their patient need to</p> <p>4 know about potential complications that can occur with</p> <p>5 any surgery that they're going to have, knowing</p> <p>6 realistically that you may not be able to anticipate</p> <p>7 rare complications.</p> <p>8 Q. But even if a complication is rare, you would</p> <p>9 -- if it's potentially life-changing or devastating,</p> <p>10 you would agree that it's important for both the</p> <p>11 doctor and patient to know about that, in order to</p> <p>12 make an informed choice about whether they want to</p> <p>13 proceed with that surgery?</p> <p>14 A. Yes, that's fair.</p> <p>15 Q. Would you agree that if a -- even if a</p> <p>16 Prosima device is placed correctly by a surgeon, the</p> <p>17 vaginal support device can fall out on its own before</p> <p>18 the 21-day prescribed healing period has lapsed?</p> <p>19 A. That can happen, yes, depending on how their</p> <p>20 body handles the micral suture.</p> <p>21 Q. Would you agree that if an infection occurs</p> <p>22 around the vaginal support device, removal of that</p> <p>23 vaginal support device is indicated and necessary even</p> <p>24 if the prescribed 21 days had not passed since it was</p>	<p>1 ProteGen was removed from the market because the</p> <p>2 erosion rates were unacceptably high?</p> <p>3 A. That's correct.</p> <p>4 Q. Do you know what the reported rates of</p> <p>5 erosion were for the ProteGen?</p> <p>6 A. I can't recall right now.</p> <p>7 Q. How high would the erosion and exposure rates</p> <p>8 for the Prosima need to be in order for you to say the</p> <p>9 erosion rate was unacceptably high?</p> <p>10 A. I think I would feel uncomfortable if I were</p> <p>11 seeing an erosion rate upwards of 30 percent.</p> <p>12 Q. So if the erosion rate for the Prosima were</p> <p>13 25 percent, you wouldn't say that that was</p> <p>14 unacceptably high?</p> <p>15 A. No.</p> <p>16 Q. One in four patients had an erosion or</p> <p>17 exposure?</p> <p>18 A. I would -- I would think twice about it and</p> <p>19 it would depend on how bad the erosions were and what</p> <p>20 kind of treatment they needed and who -- who they are,</p> <p>21 because as you know from the literature a lot of</p> <p>22 patients can live their -- with an erosion, a small</p> <p>23 erosion. So there's a few factors to take into</p> <p>24 consideration. That's kind of a gray area. You have</p>

27 (Pages 102 to 105)

Christina Pramudji, M.D.

Page 106	Page 108
<p>1 to take everything into consideration.</p> <p>2 Q. But anything 30 percent or higher --</p> <p>3 A. Yeah.</p> <p>4 Q. -- with the Prosima you would find</p> <p>5 unacceptably high?</p> <p>6 A. I think, if I had one in three, that would --</p> <p>7 that would be a little bit high.</p> <p>8 Q. Is your answer the same for the Prolift</p> <p>9 device?</p> <p>10 A. Yes.</p> <p>11 Q. Is it the same for the Gynemesh PS flat mesh?</p> <p>12 A. Yes.</p> <p>13 Q. Do you intend to offer an opinion in this</p> <p>14 case as to whether the warnings in the Prosima IFU</p> <p>15 were sufficient to apprise doctors of the risks of</p> <p>16 this product?</p> <p>17 A. Yes, I believe they were sufficient.</p> <p>18 Q. Do you know what the standards were that</p> <p>19 Ethicon applied in terms of what needed to be included</p> <p>20 in the warnings about the Prosima?</p> <p>21 A. Yes.</p> <p>22 Q. And what standards do you believe Ethicon</p> <p>23 applied regarding what needed to be included in the</p> <p>24 warnings about Prosima?</p>	<p>1 just read it for the first time?</p> <p>2 A. That's correct.</p> <p>3 Q. If something in the IFU changes, is there any</p> <p>4 way that you would know if the information in the IFU</p> <p>5 had changed?</p> <p>6 A. Not unless someone told me about it.</p> <p>7 Q. In all your years implanting products for --</p> <p>8 strike that.</p> <p>9 In all of your years of implanting products</p> <p>10 manufactured by Ethicon, has any Ethicon</p> <p>11 representative or sales rep or anybody whoever -- who</p> <p>12 works for Ethicon ever came to you and told you that</p> <p>13 the IFU for a product had been updated?</p> <p>14 A. Not that I can recall.</p> <p>15 Q. Do you know if the Prosima IFU was ever</p> <p>16 updated?</p> <p>17 A. I'm not sure about that one.</p> <p>18 Q. Do you know if the Gynemesh PS IFU was ever</p> <p>19 updated?</p> <p>20 A. I can't recall.</p> <p>21 Q. Do you know if the Gynemesh PS IFU was</p> <p>22 updated this year?</p> <p>23 A. Not that I can recall right now.</p> <p>24 Q. When you read an IFU, do you assume that the</p>
Page 107	Page 109
<p>1 A. I think they were -- you know -- excuse me --</p> <p>2 complications that had a certain degree of frequency</p> <p>3 and severity and anything that could potentially be</p> <p>4 life changing that they would try to include.</p> <p>5 Q. I apologize if you've been asked these next</p> <p>6 couple questions before, but you've been deposed,</p> <p>7 what, five times and I can't remember everything you</p> <p>8 said.</p> <p>9 MR. GAGE: Perfect. Perfect.</p> <p>10 Q. (By Mr. Faes) Have you ever in your career</p> <p>11 been involved in writing or preparing writings for a</p> <p>12 medical device?</p> <p>13 A. No.</p> <p>14 Q. That's wrong in my outline. Have you ever</p> <p>15 been in your career involved in writing or preparing</p> <p>16 IFUs for a medical device?</p> <p>17 MR. GAGE: Object to form.</p> <p>18 A. No, I have not.</p> <p>19 Q. (By Mr. Faes) In your practice, do you</p> <p>20 typically read the IFU for each mesh kit or device</p> <p>21 that you use before using it?</p> <p>22 A. Yes, I do.</p> <p>23 Q. You don't read -- do you -- you don't read</p> <p>24 the IFU every time you use the device. Correct? You</p>	<p>1 IFU is disclosing to you each of the risks and</p> <p>2 complications the company knew could occur with the</p> <p>3 kit or device that you're using?</p> <p>4 A. No, because I also take into consideration my</p> <p>5 surgical training and I know that there's some risks</p> <p>6 of surgery that aren't going to be -- aren't going to</p> <p>7 be included there, so I don't rely on the IFU to tell</p> <p>8 me all the risks.</p> <p>9 Q. Do you assume that when you read an IFU from</p> <p>10 a company regarding a mesh kit or medical device that</p> <p>11 the company is disclosing to you those complications</p> <p>12 and risks that could be significant for the patient</p> <p>13 and known to the company?</p> <p>14 A. Again, not necessarily because there's some</p> <p>15 that you just apply your surgical training to and you</p> <p>16 take that into consideration and assume that those are</p> <p>17 going to be some of the risks.</p> <p>18 Q. Do you assume that when you read an IFU for a</p> <p>19 medical device that the company was disclosing any</p> <p>20 risks and complications that would be inherent to the</p> <p>21 mesh material, so that you would know what those risks</p> <p>22 are?</p> <p>23 A. Yes, I would assume that they would -- they</p> <p>24 would include -- include those sorts of things</p>

Christina Pramudji, M.D.

Page 110	Page 112
<p>1 specific to the device.</p> <p>2 Q. Do you know whether or not -- strike that.</p> <p>3 Do you know whether or not one of the</p> <p>4 purposes of the IFU is to disclose each of the risks</p> <p>5 and complications that can occur with the use of that</p> <p>6 mesh kit in a woman's body?</p> <p>7 MR. GAGE: Object to form.</p> <p>8 A. I think it's to -- to communicate the risks,</p> <p>9 but it's not meant to be comprehensive and I don't</p> <p>10 think surgeons take it to be comprehensive either.</p> <p>11 Q. (By Mr. Faes) As you sit here today, do you</p> <p>12 have an understanding of any standard whatsoever as to</p> <p>13 what risks and complications are supposed to be</p> <p>14 disclosed in an IFU?</p> <p>15 A. I believe there are some guidelines from the</p> <p>16 FDA that help guide companies in what they should put</p> <p>17 into the IFU.</p> <p>18 Q. Do you know what those guidelines are called?</p> <p>19 A. No, I don't know what they're called.</p> <p>20 Q. Do you know if you've reviewed those</p> <p>21 guidelines before?</p> <p>22 A. I have seen them before, yes.</p> <p>23 Q. Would you agree that your background and</p> <p>24 experience is not necessarily the same as other</p>	<p>1 A. I think it would depend on what -- you</p> <p>2 know -- what you're talking about, what sort of</p> <p>3 situation you're talking about.</p> <p>4 Q. So you'd agree that it's possible that a --</p> <p>5 there could be a situation where a physician wouldn't</p> <p>6 know about a potential risk or complication of the</p> <p>7 Prosima or Prolift that you did know about and that</p> <p>8 doctor could still be a reasonable and prudent</p> <p>9 physician and be doing his work within the standard of</p> <p>10 care?</p> <p>11 MR. GAGE: Object to form.</p> <p>12 A. I think people have, you know, different</p> <p>13 training in their residency, different experience, so</p> <p>14 it's possible, but I think it's unlikely, because I</p> <p>15 think any reasonable pelvic surgeon would be able to</p> <p>16 anticipate the potential complications of pelvic --</p> <p>17 any pelvic surgery, whether it's with a kit or native</p> <p>18 tissue or whatever technique that you're using.</p> <p>19 Q. (By Mr. Faes) So is --</p> <p>20 A. I don't think you would be surprised by</p> <p>21 pelvic pain or be surprised by poor wound healing.</p> <p>22 That should be anticipated.</p> <p>23 Q. So is it your testimony that if there was a</p> <p>24 risk or complication of the Prosima or Prolift device</p>
Page 111	Page 113
<p>1 doctors who use medical devices or might consider</p> <p>2 using the Prosima?</p> <p>3 MR. GAGE: Object to form.</p> <p>4 A. Well, of course, there's going to be a wide</p> <p>5 range of doctors that might use medical devices.</p> <p>6 There's going to be some that are very -- more</p> <p>7 experienced than others.</p> <p>8 Q. (By Mr. Faes) You'd agree that you might</p> <p>9 know about a complication from a particular mesh</p> <p>10 device or kit from your own experience that another</p> <p>11 doctor might not know about?</p> <p>12 A. I don't know if I would agree with that. I</p> <p>13 think that if you're a pelvic surgeon, if you're --</p> <p>14 you're doing operations and you've been through</p> <p>15 residency, then you would be aware of the potential</p> <p>16 complications. You may not have experienced it. The</p> <p>17 more surgery you do, the more you're bound to have</p> <p>18 complications along the way, but you would be aware of</p> <p>19 it.</p> <p>20 Q. So if you knew about a potential risk or</p> <p>21 complication from the Prosima or Prolift device that</p> <p>22 another physician didn't know about, would you</p> <p>23 consider that physician to not be a diligent and</p> <p>24 reasonable physician for not knowing about that?</p>	<p>1 that a physician didn't know about, that that</p> <p>2 physician wasn't reasonable and prudent, using your</p> <p>3 words?</p> <p>4 A. I don't think I used those words, but. . .</p> <p>5 Q. I think you said reasonable, so let me --</p> <p>6 A. Okay.</p> <p>7 Q. -- let me strike that and I'll ask it again.</p> <p>8 A. Okay.</p> <p>9 Q. So is it your testimony that if there is a</p> <p>10 risk or complication of the Prosima or Prolift device</p> <p>11 that an implanting physician didn't know about, that</p> <p>12 that physician wasn't reasonable in his treatment and</p> <p>13 care?</p> <p>14 MR. GAGE: Object to form.</p> <p>15 A. I would have to say that they're missing --</p> <p>16 they may be missing some knowledge or experience.</p> <p>17 Q. (By Mr. Faes) Yeah. My question is actually</p> <p>18 a little different than that.</p> <p>19 A. Okay.</p> <p>20 Q. My question isn't whether their -- whether</p> <p>21 they're missing knowledge and experience. My question</p> <p>22 is whether you consider them to not be reasonable in</p> <p>23 their treatment and care of a physician -- of a</p> <p>24 patient if there was a risk or complication of the</p>

Christina Pramudji, M.D.

Page 114	Page 116
<p>1 Prosima or Prolift device that they didn't know about.</p> <p>2 MR. GAGE: Object to form.</p> <p>3 A. No, I disagree because they could still be</p> <p>4 reasonable, they could still be giving the patient</p> <p>5 good treatment and care even if they didn't know about</p> <p>6 that risk or complication.</p> <p>7 Q. (By Mr. Faes) In doing your work on this</p> <p>8 case, have you ever been curious as to what the</p> <p>9 regulatory affairs professionals department in</p> <p>10 Ethicon, the professionals who are required to make</p> <p>11 sure an IFU complies with FDA regulations, are you --</p> <p>12 have you been curious about what they thought needed</p> <p>13 to be in an IFU?</p> <p>14 MR. GAGE: Object to form.</p> <p>15 A. Not really.</p> <p>16 Q. (By Mr. Faes) That's not something that you</p> <p>17 thought would be helpful in forming your opinions in</p> <p>18 this case, that the Prosima and Prolift and Gynemesh</p> <p>19 PS IFUs are adequate?</p> <p>20 A. No, because I think they're adequate. I</p> <p>21 think that they did adequately warn about potential</p> <p>22 complications, so I think they did a fine job putting</p> <p>23 it together.</p> <p>24 Q. Would you agree with me that if Ethicon</p>	<p>1 and start over.</p> <p>2 Do you agree that mesh shrinkage or</p> <p>3 contraction can lead to severe pelvic pain?</p> <p>4 A. No.</p> <p>5 Q. Do you believe that wound contraction can</p> <p>6 cause -- strike that.</p> <p>7 Do you agree that wound contraction or scar</p> <p>8 contraction around a mesh can lead to severe pelvic</p> <p>9 pain?</p> <p>10 A. Yes.</p> <p>11 Q. Do you agree that -- strike that.</p> <p>12 Do you agree that wound contraction or scar</p> <p>13 contraction surrounding mesh can lead to painful</p> <p>14 sexual intercourse?</p> <p>15 A. (No response.)</p> <p>16 Q. Do you want me to restate it since you can't</p> <p>17 read it?</p> <p>18 MR. GAGE: It's hard to read on the</p> <p>19 screen here.</p> <p>20 MR. FAES: Yeah.</p> <p>21 A. Please.</p> <p>22 Q. (By Mr. Faes) Do you agree that wound</p> <p>23 contraction or scar contraction surrounding the mesh</p> <p>24 can lead to painful sexual intercourse?</p>
Page 115	Page 117
<p>1 medical affairs knew that there was a potential risk</p> <p>2 or complication attributable to the Gynemesh PS mesh,</p> <p>3 itself, which, if occurred, could cause severe</p> <p>4 permanent injury to a woman, that risk should be</p> <p>5 disclosed in the IFU? Would you agree with that</p> <p>6 statement?</p> <p>7 A. No, because they're going to have multiple</p> <p>8 discussions and opinions and bouncing things back and</p> <p>9 forth and I think that what they put in the IFU is</p> <p>10 perfectly adequate and reliable.</p> <p>11 Q. Have you ever studied the question of what</p> <p>12 risks and complications were known to doctors across</p> <p>13 the country with various backgrounds and levels of</p> <p>14 experience with regard to the use of the Prosima?</p> <p>15 A. No, I have not studied that.</p> <p>16 Q. Same question: Gynemesh PS?</p> <p>17 A. No.</p> <p>18 Q. Same question: Prolift?</p> <p>19 A. No.</p> <p>20 Q. Same question: Prolift Plus M?</p> <p>21 A. No.</p> <p>22 Q. I know you're not giving an opinion on,</p> <p>23 but . . . Do you agree that -- well, actually, I think</p> <p>24 I know your answer to this. I'm going to strike that</p>	<p>1 A. Yes. And it can also occur with wound</p> <p>2 contraction without mesh. It occurs in native tissue</p> <p>3 repairs, as well.</p> <p>4 MR. FAES: Object and move to strike</p> <p>5 after the answer "yes."</p> <p>6 Q. (By Mr. Faes) Same question: Inability to</p> <p>7 -- with regard to inability to engage in sexual</p> <p>8 intercourse?</p> <p>9 MR. GAGE: Object to form.</p> <p>10 Q. (By Mr. Faes) Since he's going to object to</p> <p>11 the form, I'll withdraw that and ask the whole</p> <p>12 question. Would you agree that wound contraction or</p> <p>13 scar contraction surrounding the mesh can lead to</p> <p>14 inability to engage in sexual intercourse?</p> <p>15 A. I don't think that there would be a case</p> <p>16 where that would -- would occur, where they would be</p> <p>17 unable to engage in sexual intercourse.</p> <p>18 Q. But you did agree that it can cause painful</p> <p>19 sexual intercourse?</p> <p>20 A. Yes, pelvic -- pelvic surgery scarring can</p> <p>21 cause painful intercourse.</p> <p>22 Q. Would you agree that intercourse can be so</p> <p>23 painful to where a person is unable to engage in</p> <p>24 sexual intercourse?</p>

30 (Pages 114 to 117)

Christina Pramudji, M.D.

Page 118	Page 120
<p>1 A. Uninterested, unwilling, but not unable.</p> <p>2 It's not as if the vagina is completely closed, but if</p> <p>3 it's -- if you're saying because of pain, then, yes,</p> <p>4 where they would be un -- unwilling, uninterested.</p> <p>5 Physically, they would be able to have intercourse,</p> <p>6 but it would be too painful.</p> <p>7 Q. So you make a distinction between someone who</p> <p>8 is unable to have sexual intercourse because it's too</p> <p>9 painful versus someone who is just physically unable</p> <p>10 to have intercourse?</p> <p>11 A. Well, yes. I mean, there are -- especially</p> <p>12 with native tissue repairs, there are situations where</p> <p>13 the vagina is so scared and contracted where they are</p> <p>14 physically unable to have intercourse, not just</p> <p>15 because of pain, because they -- their vagina is</p> <p>16 absolutely too small.</p> <p>17 Q. Okay. So you're --</p> <p>18 A. And I don't --</p> <p>19 Q. -- you're making a distinction, not to be</p> <p>20 indelicate, but between someone who is physically</p> <p>21 unable to be penetrated and someone who --</p> <p>22 A. Has --</p> <p>23 Q. -- prefers not to be because it's too</p> <p>24 painful.</p>	<p>1 A. Yes, as in all pelvic surgery.</p> <p>2 Q. Would you agree that one of the risks of the</p> <p>3 pelvic organ prolapse products is that they can lead</p> <p>4 to dyspareunia?</p> <p>5 A. Yes, as in all pelvic surgery.</p> <p>6 MR. FAES: Move to strike after the</p> <p>7 answer "yes."</p> <p>8 Q. (By Mr. Faes) Would you agree that one of</p> <p>9 the risks of the pelvic organ prolapse products is</p> <p>10 that they can lead to multiple surgical interventions</p> <p>11 to treat the complications?</p> <p>12 A. Yes, that can occur.</p> <p>13 Q. Would you agree that one of the risks of the</p> <p>14 pelvic organ prolapse products is that a woman can</p> <p>15 sustain life-changing complications as a result of</p> <p>16 those products?</p> <p>17 A. Yes, that can occur.</p> <p>18 Q. Would you agree that one of the risks of the</p> <p>19 pelvic organ prolapse products is erosions at multiple</p> <p>20 sites?</p> <p>21 A. Yes.</p> <p>22 Q. Would you agree that with the pelvic organ</p> <p>23 prolapse products, most women who have erosions or</p> <p>24 extrusions require surgical intervention?</p>
Page 119	Page 121
<p>1 A. Right.</p> <p>2 Q. Is that right?</p> <p>3 A. Yes.</p> <p>4 Q. Would you agree that one of the risks of the</p> <p>5 -- I'm going to strike that and ask if we can agree</p> <p>6 to something, so I don't have to re-ask these</p> <p>7 questions three different times. For the purposes</p> <p>8 of these questions, as we discussed earlier, when</p> <p>9 I refer to the pelvic organ prolapse products,</p> <p>10 I'm referring to the Prolift, the Prosima and the</p> <p>11 Gynemesh PS, which are the three products that you're</p> <p>12 offering an opinion on. If you can't answer the</p> <p>13 question the same way for all three products, let me</p> <p>14 know and then I'll have to go through each three</p> <p>15 separately. Can we agree to that?</p> <p>16 A. Yes.</p> <p>17 Q. Would you agree that one of the risks of the</p> <p>18 pelvic organ prolapse products is that they can lead</p> <p>19 to complex mesh erosions?</p> <p>20 MR. GAGE: Object to form.</p> <p>21 A. Yes, that is a risk.</p> <p>22 Q. (By Mr. Faes) Would you agree that one of</p> <p>23 the risks with the pelvic organ prolapse products is</p> <p>24 that they can lead to chronic pain syndrome?</p>	<p>1 A. Yes.</p> <p>2 Q. Would you agree that with the Pros -- or</p> <p>3 strike that.</p> <p>4 Would you agree that with the pelvic organ</p> <p>5 prolapse products multiple attempts to excise the mesh</p> <p>6 may be required?</p> <p>7 A. Yes.</p> <p>8 Q. Would you agree with the pelvic organ</p> <p>9 prolapse that one of the risks is life-changing</p> <p>10 complications?</p> <p>11 MR. GAGE: Object to form.</p> <p>12 A. Yes.</p> <p>13 Q. (By Mr. Faes) Would you agree that one of</p> <p>14 the risks of the pelvic organ prolapse products is</p> <p>15 incapacitating pelvic pain?</p> <p>16 A. Yes, as in all pelvic surgery.</p> <p>17 MR. FAES: Move to strike after the</p> <p>18 answer "yes."</p> <p>19 Q. (By Mr. Faes) Would you agree that one of</p> <p>20 the risks of the pelvic organ prolapse products is</p> <p>21 large scale erosions that are not easy to resolve?</p> <p>22 A. There's a very remote risk.</p> <p>23 Q. But is the answer yes?</p> <p>24 A. Yes.</p>

31 (Pages 118 to 121)

Christina Pramudji, M.D.

Page 122	Page 124
<p>1 Q. It is risk. The list of complications and</p> <p>2 risks that I just asked you about, do you know whether</p> <p>3 or not Ethicon knew about all those risks on the day</p> <p>4 the pelvic organ prolapse products first went on the</p> <p>5 market?</p> <p>6 A. I can't recall.</p> <p>7 Q. So you don't know, one way or the other,</p> <p>8 sitting here today?</p> <p>9 A. I don't -- yes, I don't know.</p> <p>10 Q. If they did know, do you agree that those</p> <p>11 risks should have been in the IFU?</p> <p>12 A. I think those are risks that pelvic surgeons</p> <p>13 would anticipate, because as I stated, most of those</p> <p>14 risks, with the exception of the erosion, are risks of</p> <p>15 pelvic surgery.</p> <p>16 Q. Okay. I didn't ask about whether they were</p> <p>17 risks that pelvic surgeons would anticipate. My</p> <p>18 question was very specific. My question was: If</p> <p>19 Ethicon did know about those risks, do you agree that</p> <p>20 those risks should have been put in the IFU?</p> <p>21 MR. GAGE: Object to form.</p> <p>22 A. I don't think they needed to be in the IFU,</p> <p>23 because the surgeons with their knowledge and being</p> <p>24 professionals would be able to anticipate that.</p>	<p>1 MR. FAES: Yeah, I think -- yeah, yeah,</p> <p>2 yeah, yeah. That's fine.</p> <p>3 MR. GAGE: Because you might be entitled</p> <p>4 to a few more minutes. I don't know.</p> <p>5 MR. FAES: Yeah, I think ten.</p> <p>6 Anyway. . .</p> <p>7 Q. (By Mr. Faes) Would you agree with the way</p> <p>8 -- strike that.</p> <p>9 Would you agree that compared to the way the</p> <p>10 mesh was used before the Prolift, the Prolift provided</p> <p>11 for more mesh to be put in a woman's pelvis than had</p> <p>12 been previously used?</p> <p>13 MR. GAGE: Object to form.</p> <p>14 A. I think it depended on how that surgeon was</p> <p>15 configuring the Gynemesh supplementation, so it could</p> <p>16 be the same, it could be more, it could be less.</p> <p>17 Q. (By Mr. Faes) Do you believe that there is a</p> <p>18 sheet of Gynemesh PS flat mesh available as a single</p> <p>19 sheet that is more area than the mesh in the entire</p> <p>20 Prolift kit?</p> <p>21 A. Oh, in the Total Prolift?</p> <p>22 Q. Yes.</p> <p>23 A. No. I think the Total Prolift is probably</p> <p>24 more. I'm thinking about one compartment at a time.</p>
Page 123	Page 125
<p>1 MR. FAES: Move to strike after the word</p> <p>2 "IFU."</p> <p>3 Q. (By Mr. Faes) And that's your opinion for</p> <p>4 all of the risks that we just went through today?</p> <p>5 A. Yes.</p> <p>6 Q. When the Prosima first came onto the market,</p> <p>7 surgeons were not experienced on any long-term basis</p> <p>8 with implanting mesh with a vaginal support device.</p> <p>9 Correct?</p> <p>10 A. That's correct.</p> <p>11 Q. Do you know the area of the -- do you know</p> <p>12 the square area of the mesh used in the Prosima kits?</p> <p>13 A. Not off the top of my head, no.</p> <p>14 MR. GAGE: Object. Form.</p> <p>15 Q. (By Mr. Faes) And I think you've already</p> <p>16 answered this question: You don't know what sizes and</p> <p>17 configurations the Gynemesh PS mesh is offered in.</p> <p>18 Correct?</p> <p>19 A. That's correct.</p> <p>20 MR. GAGE: I show about eight minutes</p> <p>21 before she needs to go.</p> <p>22 MR. FAES: Okay.</p> <p>23 MR. GAGE: And we can sort out at 4:20</p> <p>24 how much -- did you get three hours in, did you not.</p>	<p>1 I think if you combine -- you -- you know -- combined</p> <p>2 an anterior and posterior Gynemesh, it would probably</p> <p>3 be more than a Prolift, Total Prolift.</p> <p>4 Q. Okay. What about just one Prolift, just the</p> <p>5 anterior or just the posterior, do you believe that</p> <p>6 there's a sheet of Gynemesh PS that's available that</p> <p>7 would be more mesh, in terms of total square area than</p> <p>8 either the anterior Prolift with the arms included or</p> <p>9 the posterior Prolift with the arms included?</p> <p>10 A. Yeah. I think it would probably be very</p> <p>11 similar once you added it together. And whenever you</p> <p>12 do a Prolift, you usually trim a lot of the mesh --</p> <p>13 Q. What --</p> <p>14 A. -- on the tail or on the sides.</p> <p>15 Q. What size Gynemesh PS would that be that</p> <p>16 would greater than the Prolift?</p> <p>17 A. I mean, I think one size was, I think, ten by</p> <p>18 ten centimeters, if I remember correctly. And so it</p> <p>19 just depends on how the surgeon fashioned it. So it</p> <p>20 could be more, it could be less.</p> <p>21 Q. Do you know if there's more mesh in an</p> <p>22 anterior or posterior Prolift than what would be</p> <p>23 contained in a ten by ten centimeter strip of Gynemesh</p> <p>24 PS?</p>

32 (Pages 122 to 125)

Christina Pramudji, M.D.

Page 126	Page 128
<p>1 A. It's less, the anterior Prolift? The</p> <p>2 anterior Prolift is bigger than a posterior, yeah.</p> <p>3 Q. What do you believe the area of the posterior</p> <p>4 Prolift is?</p> <p>5 A. I don't know off the top of my head. I mean,</p> <p>6 I'm just picturing it from having used it. It's not</p> <p>7 ten by ten centimeters.</p> <p>8 Q. So you don't --</p> <p>9 A. It's much less than that, even if you add the</p> <p>10 arms.</p> <p>11 Q. You don't know the total area with the arms,</p> <p>12 but you -- but you believe it's less than ten by ten</p> <p>13 centimeters?</p> <p>14 A. Absolutely.</p> <p>15 Q. You believe it's less than a hundred square</p> <p>16 centimeters?</p> <p>17 A. Absolutely.</p> <p>18 Q. Is the same -- is the answer --</p> <p>19 A. Because you trim it. You don't use the whole</p> <p>20 thing. And you trim the arms.</p> <p>21 Q. Do you know if when physicians use a</p> <p>22 ten-by-ten sheet of Gynemesh PS, whether or not they</p> <p>23 typically trim it or typically use the entire square</p> <p>24 of mesh?</p>	<p>1 depended on how that surgeon used the Gynemesh. So if</p> <p>2 they're using a Total Prolift, they would have</p> <p>3 potentially used two Gynemesh grafts on that same</p> <p>4 woman previously, so it could still be the same, more</p> <p>5 or less, depending on how they cut their Gynemesh and</p> <p>6 how they utilize it.</p> <p>7 Q. Okay. Let me ask you this question --</p> <p>8 A. Okay.</p> <p>9 Q. -- would you agree that compared with the way</p> <p>10 mesh was used for the repair of pelvic organ prolapse</p> <p>11 before the transvaginal mesh technique with the</p> <p>12 Gynemesh Prolene Soft, the Prolene Soft provided for</p> <p>13 more mesh -- strike that.</p> <p>14 Would you agree with me that compared with</p> <p>15 the way mesh was used for the repair of pelvic organ</p> <p>16 prolapse before the transvaginal mesh technique using</p> <p>17 the Gynemesh Prolene Soft was developed, the</p> <p>18 transvaginal technique with Gynemesh Prolene Soft</p> <p>19 provided for more mesh to be put in a woman's pelvis</p> <p>20 than had been previously used for pelvic organ</p> <p>21 prolapse repair?</p> <p>22 MR. GAGE: Object to form.</p> <p>23 A. I can't really answer that, because there was</p> <p>24 no standardized way to do that surgery before.</p>
Page 127	Page 129
<p>1 A. They typically trim it. That's what I said</p> <p>2 earlier, it could be the same, it could be more, it</p> <p>3 could be less.</p> <p>4 Q. So you disagree that, compared with the way</p> <p>5 the mesh was typically used before the Prolift, the</p> <p>6 Prolift provides for more mesh to be put in a woman's</p> <p>7 pelvis than had been previously used before Prolift</p> <p>8 kits were available?</p> <p>9 MR. GAGE: Object to form.</p> <p>10 A. Correct, I disagree with that.</p> <p>11 Q. (By Mr. Faes) But only with -- only if just</p> <p>12 the anterior or posterior is used by itself?</p> <p>13 A. Well, if -- okay. If you -- yeah, comparing</p> <p>14 one compartment to one Gynemesh graft, yeah, comparing</p> <p>15 one. But if you did a Gynemesh graft in each</p> <p>16 compartment --</p> <p>17 Q. Right. So --</p> <p>18 A. -- that would be the comparison. I wouldn't</p> <p>19 compare one Gynemesh graft to a Total Prolift.</p> <p>20 Q. So would you agree that, compared to the way</p> <p>21 the mesh was used before the Total Prolift, the Total</p> <p>22 Prolift provided for more mesh to be put in a woman's</p> <p>23 pelvis than had generally previously been used?</p> <p>24 A. I feel like we're going in circles. It just</p>	<p>1 Q. (By Mr. Faes) So is the answer to my</p> <p>2 question you can't -- you can't answer one way or</p> <p>3 another, you just don't know?</p> <p>4 A. It's a question that cannot be answered</p> <p>5 because it was not a standardized technique.</p> <p>6 Q. If Ethicon medical affairs believed that a</p> <p>7 caution needed to be taken by a doctor before using</p> <p>8 Prosima in a particular class of women, should that</p> <p>9 have been put in the IFU?</p> <p>10 A. I would say yes to that.</p> <p>11 Q. If Ethicon -- I think I'll ask two more</p> <p>12 questions and then you probably gotta get out of here.</p> <p>13 Right? Okay. Unless you need to get out of here</p> <p>14 right now. Two more questions --</p> <p>15 MR. GAGE: The real clock is faster than</p> <p>16 my watch yes.</p> <p>17 MR. FAES: Okay.</p> <p>18 MR. GAGE: Yeah.</p> <p>19 Q. (By Mr. Faes) If Ethicon medical affairs</p> <p>20 believed that a caution should be used before putting</p> <p>21 a Prosima into a woman based on some fact about her</p> <p>22 demographics or her age or her level of prolapse or</p> <p>23 comorbidities or anything that was specific that could</p> <p>24 be related to specific patients, should that</p>

Christina Pramudji, M.D.

Page 130	Page 132
<p>1 information have been in the IFU, so that doctors</p> <p>2 would have that information when deciding to do with</p> <p>3 their patients?</p> <p>4 MR. GAGE: Object to form.</p> <p>5 A. I don't --</p> <p>6 Q. (By Mr. Faes) Deciding -- I think I</p> <p>7 flubbed the end of that question. I meant to say</p> <p>8 deciding what to do with their patients. I don't</p> <p>9 know if the realtime is wrong or I'm wrong, but do you</p> <p>10 want me to answer the -- re-ask the question? It's a</p> <p>11 long one.</p> <p>12 A. Please.</p> <p>13 Q. We'll make this the last question then.</p> <p>14 A. Yeah.</p> <p>15 Q. If Ethicon medical affairs believed that a</p> <p>16 caution should be used before putting a Proxima into a</p> <p>17 woman based on some fact about her demographics or her</p> <p>18 age or her level of prolapse or comorbidities or</p> <p>19 anything like that was specific that could be related</p> <p>20 to specific patients, should that information</p> <p>21 have been in the IFU, so doctors would have</p> <p>22 that information when deciding what to do with</p> <p>23 their patients?</p> <p>24 MR. GAGE: Object to form.</p>	<p>1 A. Not necessarily.</p> <p>2 Q. (By Mr. Faes) You say not necessarily. Are</p> <p>3 there --</p> <p>4 A. Uh-huh.</p> <p>5 Q. -- are there situations where you believe it</p> <p>6 would be appropriate to not include a warning or</p> <p>7 precaution that medical affairs thought should be in</p> <p>8 the IFU for marketing reasons?</p> <p>9 MR. GAGE: Object to form.</p> <p>10 A. It depends on -- it depends on what it was.</p> <p>11 You know, when they're coming up with these things,</p> <p>12 they're taking in numerous considerations, so it would</p> <p>13 -- it would just depend on what it was. It would --</p> <p>14 it would give me some pause if that was the only</p> <p>15 reason for marketing reasons, but I would have to know</p> <p>16 more specifics before I drew a conclusion about it.</p> <p>17 Q. (By Mr. Faes) So if medical affairs said, I</p> <p>18 think this warning or precaution is really important</p> <p>19 and marketing comes in and says, yeah, but it's going</p> <p>20 to hurt the sales of our product, so we're not going</p> <p>21 to put it in, you believe that there are situations</p> <p>22 where that would not be wrongful?</p> <p>23 MR. GAGE: Object to form.</p> <p>24 A. Right, because as I've said before, there's</p>
Page 131	Page 133
<p>1 A. Again, it goes back to, what do you need to</p> <p>2 put in the IFU, because that's why we're physicians.</p> <p>3 We're professionals. We're trained to make these</p> <p>4 judgment calls. I mean, I think it -- I think that</p> <p>5 the IFU is perfectly adequate. I don't think anything</p> <p>6 was left out, so I can't think of what they would come</p> <p>7 up with that would change that opinion that I would</p> <p>8 say -- I would say no to that question, because,</p> <p>9 again, they're going to be discussing things back and</p> <p>10 forth and bouncing ideas off of each other. That</p> <p>11 doesn't all need to go into the IFU.</p> <p>12 Q. (By Mr. Faes) But if Ethicon medical affairs</p> <p>13 believed that that caution should be put in there, you</p> <p>14 believe that that information doesn't need to be</p> <p>15 included, even if Ethicon medical affairs believes</p> <p>16 it needs to be put in there?</p> <p>17 MR. GAGE: Object to form.</p> <p>18 A. As I already answered, I would say no.</p> <p>19 Q. (By Mr. Faes) If Ethicon medical affairs</p> <p>20 believed that a particular warning or caution should</p> <p>21 be added to the IFU, but that caution or warning</p> <p>22 wasn't added due to marketing reasons, would you agree</p> <p>23 that that would be wrongful?</p> <p>24 MR. GAGE: Object to form.</p>	<p>1 some risks that are not in an IFU for any product that</p> <p>2 surgeons are aware of, like death. Death is a risk of</p> <p>3 any surgical device with surgery. You know, surgery</p> <p>4 has a risk of death, so they may not want to put that</p> <p>5 in there for marketing reasons.</p> <p>6 Q. (By Mr. Faes) So you believe that there are</p> <p>7 situations where it's appropriate for marketing to</p> <p>8 override the judgment of medical affairs?</p> <p>9 MR. GAGE: Object to form.</p> <p>10 A. I don't -- I don't -- I don't want to agree</p> <p>11 with that. I mean, I don't want to disagree with that</p> <p>12 because medical affairs should be the priority, but</p> <p>13 there are so many considerations that go into it.</p> <p>14 MR. FAES: I'll object and move to</p> <p>15 strike after the word "priority." And Doctor, I'll</p> <p>16 let you go, because --</p> <p>17 THE WITNESS: Okay.</p> <p>18 MR. FAES: -- I'm sorry. I asked way</p> <p>19 more questions than I intended to. We got into a --</p> <p>20 THE WITNESS: I know. We were on a roll</p> <p>21 there.</p> <p>22 MR. FAES: We got into a thing there.</p> <p>23 THE WITNESS: Yeah.</p> <p>24 MR. GAGE: All right. So we're off the</p>

34 (Pages 130 to 133)

Christina Pramudji, M.D.

<p style="text-align: right;">Page 134</p> <p>1 record now. 2 (Deposition concluded at 4:25 p.m.) 3 (Signature reserved.) 4 * * * * * 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>	<p style="text-align: right;">Page 136</p> <p>1 ACKNOWLEDGMENT OF DEPONENT 2 3 I, _____, do 4 hereby certify that I have read the 5 foregoing pages, and that the same is 6 a correct transcription of the answers 7 given by me to the questions therein 8 propounded, except for the corrections or 9 changes in form or substance, if any, 10 noted in the attached Errata Sheet. 11 12 13 _____ 14 CHRISTINA PRAMUDJI, M.D. DATE 15 16 17 Subscribed and sworn 18 to before me this 19 ____ day of _____, 20____. 20 My commission expires: _____ 21 22 _____ 23 Notary Public 24</p>
<p style="text-align: right;">Page 135</p> <p>1 - - - - - 2 E R R A T A 3 - - - - - 4 5 PAGE LINE CHANGE 6 _____ 7 REASON: _____ 8 _____ 9 REASON: _____ 10 _____ 11 REASON: _____ 12 _____ 13 REASON: _____ 14 _____ 15 REASON: _____ 16 _____ 17 REASON: _____ 18 _____ 19 REASON: _____ 20 _____ 21 REASON: _____ 22 _____ 23 REASON: _____ 24 _____</p>	<p style="text-align: right;">Page 137</p> <p>1 THE STATE OF TEXAS: 2 COUNTY OF FT. BEND: 3 4 I, Tamara Vinson, a Certified Shorthand 5 Reporter and Notary Public in and for the State of 6 Texas, do hereby certify that the facts as stated by 7 me in the caption hereto are true; that the above and 8 foregoing answers of the witness, CHRISTINA PRAMUDJI, 9 M.D., to the interrogatories as indicated were made 10 before me by the said witness after being first duly 11 sworn to testify the truth, and same were reduced to 12 typewriting under my direction; that the above and 13 foregoing deposition as set forth in typewriting is a 14 full, true, and correct transcript of the proceedings 15 had at the time of taking of said deposition. 16 I further certify that I am not, in any 17 capacity, a regular employee of the party in whose 18 behalf this deposition is taken, nor in the regular 19 employ of his attorney; and I certify that I am not 20 interested in the cause, nor of kin or counsel to 21 either of the parties. 22 23 GIVEN UNDER MY HAND AND SEAL OF OFFICE, on 24 this, the ____ day of March, 2016. 25 26 _____ 27 Tamara Vinson, Texas CSR No. 3015 28 Expiration Date: 12-31-2016 29 30 GOLKOW TECHNOLOGIES, INC. 31 Texas CRCB Registration #690 32 440 Louisiana, Suite 910 33 Houston, Texas 77002 34 www.golkow.com</p>

35 (Pages 134 to 137)

A				
abdominal 34:20 35:7,16 36:8 68:14,15 100:9,9 101:1,5,6,9 abdominally 61:13 62:2,21 93:7 able 36:23,24 46:5 51:19 103:6 112:15 118:5 122:24 abovestyled 3:4 absolutely 28:1 43:3 48:22,24 51:22 52:1 56:6 69:24 77:19 92:21 118:16 126:14,17 accelerate 80:6 accept 45:15 acknowledging 90:7 acknowledgment 136:1 add 126:9 added 56:24 57:17 58:13 125:11 131:21,22 addition 6:7 additional 59:2 64:18 address 6:20 22:4,7 22:10 23:7,10 65:21 adequate 114:19,20 115:10 131:5 adequately 114:21 adhesions 62:22,23 100:22 advantage 39:3 adverse 59:24 afaes 4:6 afc 35:18 affairs 114:9 115:1 129:6,19 130:15 131:12,15,19 132:7,17 133:8,12	afternoon 7:5 age 129:22 130:18 ago 18:21 28:13 33:9,13 39:6 agree 9:11 10:11 11:6,15,19,24 12:20 13:1,6 17:5 23:13,15 27:19 35:7 41:3 44:17 46:14 54:22 56:22 58:3,6,22 59:5 61:12 62:12 63:13 64:3,9,19 65:18 66:8,10 70:1,3 78:6 79:11 80:23 82:7 83:19 86:16 89:15 90:9 94:1,3 94:9,11 96:3,7 102:2,17,21,22 103:10,15,21 104:2,4 110:23 111:8,12 112:4 114:24 115:5,23 116:2,7,11,12,22 117:12,18,22 119:4,5,15,17,22 120:2,8,13,18,22 121:2,4,8,13,19 122:10,19 124:7,9 127:20 128:9,14 131:22 133:10 ahead 40:19 allows 52:20 alternative 23:14 23:16 34:17 35:6 92:20 alternatives 32:15 35:8 ams 35:23 amsden 2:11 analyses 67:23 analysis 49:14 67:11,15,18 70:17 andrew 4:4 andy 7:6 9:23 19:14 34:1,1,6	angles 38:11 announce 28:15 announced 28:13 announcement 47:14 48:7 49:7 answer 13:14 18:13 22:22 34:4 40:14 42:18 58:2,5,21 59:4 71:15 72:22 78:4 80:5 82:19 106:8 115:24 117:5 119:12 120:7 121:18,23 126:18 128:23 129:1,2 130:10 answered 11:13 18:11,12 62:24 71:18 72:12 73:16 95:20 123:16 129:4 131:18 answering 34:6 answers 136:6 137:6 anterior 57:24 125:2,5,8,22 126:1,2 127:12 anticipate 8:24 49:11 98:19 103:6 112:16 122:13,17 122:24 anticipated 73:15 112:22 anybody 108:11 anymore 28:14 anyway 15:10 95:23 124:6 apart 76:8 77:3,6 apex 30:5 apical 29:24 30:3 37:19,20 38:1 50:24 57:15 101:16 apologize 107:5 apparent 104:8 appearances 5:3 applied 106:19,23	apply 109:15 appreciate 23:3 36:24 appreciates 34:10 apprise 106:15 appropriate 15:6 35:10 132:6 133:7 appropriately 56:19 approval 69:13 approved 52:17,24 53:7 69:8 approximately 88:2 area 23:22 24:3 105:24 123:11,12 124:19 125:7 126:3,11 areas 38:12 arent 52:23 109:6,6 arm 95:18 arms 125:8,9 126:10,11,20 arteries 76:15 article 104:11 articles 13:22 artisyn 36:2 asc 35:17,18 97:22 100:18 101:23 asked 19:1 22:14 40:8 71:14,19 75:20 107:5 122:2 133:18 askew 32:13 asking 79:10,11 98:15 assessment 68:6 assigns 67:22 associated 6:16 54:23 55:20 56:17 assume 108:24 109:9,16,18,23 assuming 10:5 83:17 84:7 astora 28:16 attached 3:10 7:23	136:10 attempts 121:5 attended 81:17 attorney 137:13 attributable 115:2 augmentation 64:17 august 25:2,20,23 authoritative 63:15 authoritive 63:14 available 9:11 23:18 26:10 28:22 30:22 31:1 32:4 36:15 37:9 42:1 44:14 46:17,24 47:9,10,16 48:8 49:7,24 50:10,18 98:20 124:18 125:6 127:8 avenue 4:5 avoid 38:23 102:3 102:19 aware 84:22,23 98:12,13 104:16 111:15,18 133:2 <hr/> B babbling 75:23 back 8:12 9:23 19:7 25:24 27:8 40:3 41:16 57:15 69:19 71:5 97:11 115:8 131:1,9 background 110:23 backgrounds 115:13 backtracking 53:10 bad 71:20 105:19 banks 1:20 barbara 1:9 bard 90:3 barker 2:2 based 96:14 97:2 97:17 129:21

130:17 basically 50:22 basis 75:5,13,14 123:7 bathroom 97:5 bears 57:3 82:3 began 50:20 68:14 beginning 66:1 behalf 137:12 believe 12:14 24:15 24:18,20 25:10,15 26:2 29:4 39:12 39:15 40:21 42:18 44:3 51:23 52:2 52:14 53:14 54:8 54:13,16 56:13,18 59:17 60:6 66:14 66:17,20 71:3,7 71:17,21,23 72:7 72:13,23 73:3,7 73:16,20 74:1,8 77:5,8,10,12,13 78:13,15 79:17 80:4,6,9,15 84:13 85:2,9,10,17 88:18 92:23 93:2 93:10 97:1,16 98:21 100:19,23 101:14,20 106:17 106:22 110:15 116:5 124:17 125:5 126:3,12,15 131:14 132:5,21 133:6 believed 60:3 129:6 129:20 130:15 131:13,20 believes 81:23 131:15 bend 137:2 benefit 38:21 56:24 57:17,24 58:13,18 58:19 best 37:18 39:6,11 better 63:4 64:8,16 89:11 96:13	big 18:17 80:19 bigger 126:2 billed 8:20 billing 8:24 bills 9:11 biofilm 76:10 biologic 30:12 biology 93:18 bit 39:5 50:12 53:10 73:18 87:24 106:7 bleeding 38:24 39:2 blood 94:20 blynn 2:1 body 44:22 79:9,11 83:23,24 86:1,2,6 86:13 100:15 103:20 110:6 boggs 2:7 bogus 76:16 borne 62:18 boston 29:3,4 bouncing 115:8 131:10 bound 111:17 bowel 62:22 100:17 100:22 101:15,22 box 41:10 break 40:2,4,8 72:13 85:11 86:15 97:6,10,12,15 breakdown 86:4,7 breaking 85:18 brenda 1:12 brings 37:2,6 brittle 78:17 79:5 86:8,13,23 broadly 25:4 broken 91:21 brought 7:24 8:3,5 8:5,14 16:6,13,17 bullet 57:12 58:6 59:20 61:23 62:1 butler 4:9 8:13 16:1 19:1 butlersnow 4:11	buy 49:5,23 <hr/> C <hr/> c 4:1 cadaver 32:22 calculating 84:16 calculation 46:4 caliber 61:3 call 17:1 72:16 called 35:21 90:3 110:18,19 calls 131:4 cant 10:1 18:2 19:6 19:7 24:20 28:23 29:7 31:17,20 45:6 46:7 51:9 58:5 62:17 74:18 74:18 88:17 92:17 99:13 100:5 105:6 107:7 108:20 116:16 119:12 122:6 128:23 129:2,2 131:6 capacity 137:12 caption 137:5 carbone 81:12,14 81:22 82:2 cardiac 76:14 79:17,19,23 care 51:24 52:15 53:8,9 64:20,23 112:10 113:13,23 114:5 career 107:10,15 carey 2:8 carol 2:23 carpenter 1:14 carry 100:24 cartmell 4:4 case 1:8,10,11,13 1:14,16,17,19,20 1:22,23 2:1,3,4,6 2:7,9,10,12,13,15 2:16,18,19,21,22 2:24 16:4 18:15 18:20,23 19:5	20:11,16,17 46:10 65:16 69:23 87:5 93:14 96:19 100:11 106:14 114:8,18 117:15 cases 1:7 8:12 21:13 76:23 casespecific 8:18 9:14 catherines 47:21 cathy 2:10 cause 3:4 75:11 80:6 85:16,23 86:1,17,19 96:8 101:11,13 115:3 116:6 117:18,21 137:14 causes 96:2,4 causing 86:2 cautery 94:19 caution 129:7,20 130:16 131:13,20 131:21 caviness 18:22 20:10 cavity 79:19,23 centimeter 125:23 centimeters 125:18 126:7,13,16 certain 52:19 72:19 107:2 certainly 70:12 82:4 99:21 certificate 5:9 certified 137:3 certify 136:4 137:5 137:11,13 change 74:15 131:7 135:5 changed 108:5 changes 108:3 136:9 changing 107:4 charlene 2:20 charleston 1:2 check 48:20	chemical 70:5,13 chemistry 70:2,10 choice 30:16 36:9 37:24 38:5,6,8 51:4 97:21 98:21 98:23 103:1,12 choose 13:22 102:3 102:18 chose 10:23 36:17 christina 1:13 3:1 5:5 6:3,5,7 7:1 136:14 137:6 chronic 119:24 circles 127:24 circumstance 79:8 93:20 circumstances 78:8 78:10,11 79:13 cite 13:22,24 cited 13:23 104:10 city 3:8 4:5 47:19 civil 3:9 clarify 55:2 class 66:3,4,24 67:2 67:2 68:19 69:14 129:8 classified 66:24 67:2 clean 34:7 clear 64:16 101:2 clearance 41:14,22 42:4,12 cleared 26:8 52:3,6 52:16,24 68:19,24 69:5,8 clinical 26:16 76:21 76:22 77:7,20 78:2 93:22 94:7,8 clinically 78:11 clock 129:15 close 34:23 closed 118:2 closer 81:2 cole 2:8 colleagues 82:5,22 colony 4:10
---	---	--	---	--

coloplast 35:21 36:9	124:24 127:14,16	58:9	22:1,2 23:23,24	20:10 92:5
colporrhaphy 63:16	completely 27:21 34:1 61:6 79:7 118:2	consents 56:14,15	24:4,5,7,23 25:7	criteria 50:13,14
com 4:6,11 102:7 137:24	complex 119:19	consider 30:12	25:19 26:5,6,12	csr 3:6 137:19
combine 10:24 11:5 125:1	complication 12:1 12:14 103:8 111:9 111:21 112:6,24 113:10,24 114:6 115:2	42:23 51:21 52:7 52:10 54:5 61:23 67:6 83:2,10,18 84:8 111:1,23 113:22	26:18,20 27:14 32:10 33:20,21 34:21,22 36:11 37:10,14 38:15,16 39:7 41:6,7,12,23 43:12,21,22 46:18 49:3,21 50:11 51:2 56:1,2 60:4 65:4 67:23,24 68:9,10 82:24 83:1,20 84:10,11 91:13,14 93:11,12 96:5,9,10,16,17 96:23 97:22,23 99:23 100:2 104:22,23 105:3 107:24 108:2 123:9,10,18,19 127:10 136:6 137:10	cure 71:1 75:4 76:4 curious 114:8,12 current 21:24 currently 32:4 35:23 36:8 52:16 97:21
combined 16:24 17:7,8 72:9 125:1	complications 6:15 23:23 24:3 39:1 54:22 55:5,8,20 56:9,17 61:14 62:3,14 71:19 73:21,22 74:2,10 80:16 100:17 102:4,6,8,19,24 103:4,7 107:2 109:2,11,20 110:5 110:13 111:16,18 112:16 114:22 115:12 120:11,15 121:10 122:1	consideration 105:24 106:1 109:4,16		
come 11:11 131:6		considerations 132:12 133:13		curriculum 6:9,12 23:6,10
comes 81:3 132:19		considers 83:4		cut 27:1,11 29:16 30:7 96:1 128:5
comfortable 52:13 67:8 70:6		consulted 56:3		cv 8:5 21:16,18,19 21:24 22:3,16
coming 132:11		contacted 18:15 20:15		cystocele 37:19 38:1 40:10
commentary 9:23		contain 10:19 16:2		cytotoxic 93:11,17 93:23 94:10,15,24 95:10 96:9
commercials 32:13		contained 40:21 57:9 125:23		cytotoxicity 93:19
commission 136:20		continue 34:13 50:8 51:24		
communicate 110:8		continued 48:6 49:19		D
communication 6:17		contract 59:15,18 60:7,13,15	correction 60:10	d 1:13 3:1 5:5 6:4,5 7:1 136:14 137:7
comorbidities 129:23 130:18		contracted 118:13	corrections 136:8	daphne 2:2
companies 110:16		contracting 61:2	correctly 24:15 75:2 76:18 103:16 125:18	data 44:22 52:11 69:21 74:16 76:1 76:6
company 8:7 39:19 109:2,10,11,13,19		contraction 59:13 59:15,20 60:4,9 116:3,5,7,8,12,13 116:23,23 117:2 117:12,13	correlates 11:3 68:2	database 81:11
comparable 63:16		contracts 59:16,16 59:17 60:16,19 61:7	correlation 74:12	date 25:16 26:5 28:23 37:12 41:14 41:22 42:4,12 48:21 49:2 50:3 136:14 137:20
comparator 92:16		controlled 14:2 87:15 91:4,10 92:8,15,19,23	couldnt 21:20 45:9 45:10	dated 65:22
compare 11:23 36:22 83:24 87:17 89:6,18 92:24 127:19		controversial 35:1	counsel 9:24 21:18 92:4 137:14	dates 25:7,14
compared 23:17 36:14,21 38:22 56:24 57:17 58:14 61:14 62:3,14 100:8,17 124:9 127:4,20 128:9,14		converse 75:17	counting 32:22	day 122:3 136:19 137:16
comparing 92:15 92:19 127:13,14		corporate 28:18	country 115:13	days 9:3,4 103:24 104:8
comparison 89:20 127:18		correct 7:10 11:20 12:2 13:4,5 15:22 17:10,13 19:5,11	county 137:2	deal 10:10
compartment 72:4 72:5,8,9,11,15,24 73:5,9,9 74:3			couple 28:13 33:12 36:4 107:6	dealt 70:4
			course 41:13 111:4	death 133:2,2,4
			court 1:1 4:14 9:17 19:19 20:3 33:24 34:9	decide 37:17
			crcb 137:21	deciding 130:2,6,8
			created 19:10	

130:22 decision 13:21 54:9 54:14,17 66:11 decreased 58:19 defect 29:24 30:10 defects 39:7,16 defendants 4:8 defining 55:1 definitely 38:8 58:19 71:4 deformed 61:5,9 degradation 70:24 71:6 74:24 76:9 76:16 80:3 degrade 74:19 75:6 75:16 76:13,20 77:13,19 78:1,7,9 78:10 79:13 80:7 85:11,21,22 degraded 76:14 degrades 69:22 70:15,20 74:11,17 75:19 76:2,7 77:18,24 78:6,14 78:16 86:13 degrading 85:14,17 degree 61:11 72:19 80:1 107:2 demographics 129:22 130:17 demonstrate 91:5 91:11 93:4 demonstrated 96:14 97:1,16 demonstrative 91:23 92:5 department 114:9 depend 86:11 105:19 112:1 132:13 depended 124:14 128:1 depending 38:10 103:19 128:5 depends 11:17 125:19 132:10,10	deponent 136:1 deposed 107:6 deposition 1:12 3:1 6:3 7:6,19,20 9:17 14:9 40:12 55:12 65:8 134:2 137:9 137:11,12 depth 89:14 details 10:1 determination 87:17 determine 67:11,15 70:20 88:3,23 89:10 devastating 103:9 developed 128:17 developing 98:8 device 7:7 11:19 12:1,15,20 13:9 15:21,21 24:13,21 26:3,8,12 36:13 37:8,24 38:4,6,8 38:14 39:6,11 40:9 42:20,24 43:6,12 46:23 48:7,14 49:17 50:6,9,14,15 51:4 51:4,20 52:2,16 52:23 54:10,18 66:12,15,18,21 67:3,19 68:3,9,18 68:20,24 69:5,14 71:8 80:10,16 81:24 84:14 92:16 92:19,20,24,24 98:9,21,23 99:4 100:23 101:8,11 101:14 102:1,5,20 102:24 103:1,16 103:17,22,23 104:7 106:9 107:12,16,20,24 109:3,10,19 110:1 111:10,21 112:24 113:10 114:1 123:8 133:3	devices 37:16,16 43:6 46:19 47:24 48:10 49:6 51:24 66:3,4,5,9 67:12 67:16 91:7,13 93:5 111:1,5 diabetes 94:20 didnt 14:17,24 15:7 18:5 19:4 24:19 24:21 26:3 30:10 36:4,5,22 37:4,4 39:1 49:8,10,13 50:5 75:21 77:1 79:1 82:19 89:14 89:23 90:8 111:22 113:1,11 114:1,5 122:16 difference 12:24 15:9 21:20 31:14 31:22,24 38:17 differences 11:18 37:1 different 11:7,9,11 11:15,22 12:2,12 12:21,23 15:3 18:1 20:13 31:5 36:22 37:1 38:11 38:12 71:15 72:9 73:4,9,19 77:9 79:7,20 89:8 92:24 112:12,13 113:18 119:7 diligent 111:23 dimock 2:23 dinner 81:20 direction 137:9 disagree 44:21 55:24 56:22 57:2 57:21 58:4 60:7 60:11 61:12 62:6 62:17 63:13,17,20 64:19,23 66:11 81:7 82:1 83:20 84:2,10 114:3 127:4,10 133:11 disagreed 56:7,9	disappear 76:13 disappearing 85:15 disclose 110:4 disclosed 110:14 115:5 disclosing 109:1,11 109:19 disclosure 19:12 disclosures 19:20 discomfort 86:24 discontinuance 37:13 discuss 10:10 13:17 13:17 discussed 43:8 86:9 119:8 discussing 131:9 discussions 115:8 disintegrating 77:3 77:6 dispute 10:1,2,8 dissection 100:16 101:17 distinction 53:4 118:7,19 district 1:1,1,5 division 1:2 doctor 10:13 41:14 42:19 54:9,14,17 65:1,7 69:18 80:19 102:2,17,22 103:3,11 111:11 112:8 129:7 133:15 doctors 106:15 111:1,5 115:12 130:1,21 document 1:6 7:21 7:24 40:13 65:13 65:15,19 documentation 89:2 91:17 documents 8:6,8 83:13 doesnt 59:15 63:9 74:16 75:1,6,15	75:17,18 76:12,13 76:20 77:12 100:24 101:14 131:11,14 doing 27:12 34:23 42:23 101:18 111:14 112:9 114:7 donna 2:11 dont 7:14 9:21 10:6 11:21 13:10 14:16 15:9 19:6,16 25:10 30:17,17,17 30:19,24 31:13,22 32:2 33:9 34:22 35:12 36:2,22 41:19,20,21,24 42:8,16,16 45:19 46:21 47:1 48:11 48:13,16 52:5 53:16,19 54:7 59:17 63:10 64:8 66:10 67:4,20,21 68:1,4,6 69:2,3,8 71:5 72:16 74:7 77:16,18 78:22,23 82:3 83:6,24 85:21 88:5,5,10 88:13,16 90:19,24 91:16 92:9,13 93:8,10 95:1,3 99:5 107:23,23 109:7 110:9,19 111:12 112:20 113:4 117:15 118:18 119:6 122:7,9,9,22 123:16 124:4 126:5,8,11,19 129:3 130:5,8 131:5 133:10,10 133:10,11 dozen 27:5 dr 7:5,20 15:11 23:5 40:3 81:12 81:14,22 82:2,22
--	---	---	--	--

Christina Pramudji, M.D.

Page 142

83:2,4,7,11,18,23 84:8 97:11 drafting 21:8 draw 18:2 drawing 13:18 drew 132:16 drives 8:7 16:9 due 82:2 83:22 94:18 131:22 duly 3:3 7:2 137:7 durham 1:23 dynamesh 96:22 dyspareunia 120:4	88:14 98:4 elizabeth 2:1 email 28:16,19 employ 137:13 employee 137:12 encapsulated 60:21 engage 117:7,14,17 117:23 engineering 70:5 ensure 41:8 enterocele 101:17 entire 21:3 124:19 126:23 entitled 124:3 environment 27:16 27:22 32:7 79:18 79:19 eroded 86:2 erosion 61:16 64:18 80:23 81:5,23 82:8,13,23 85:12 85:16 86:10,17,19 94:4,13,14 95:3,4 95:7,14 105:2,5,7 105:9,11,12,16,22 105:23 122:14 erosions 71:10 94:22,24 105:19 119:19 120:19,23 121:21 errata 136:10 especially 118:11 esq 4:4,9 essman 1:8 estimate 20:22 21:2 26:23 ethicon 1:3 26:5,17 35:19 36:2 40:24 41:10 45:14 46:15 46:19 47:24 49:18 53:17 63:19 67:10 67:14,22 69:10 81:17 83:9,10 98:8 106:19,22 108:10,10,12 114:10,24 122:3	122:19 129:6,11 129:19 130:15 131:12,15,19 ethicons 44:14 45:7 45:12 68:6 eugenia 2:5 event 59:24 evidence 56:23 57:13 58:13 74:10 93:10 94:15 exact 88:16 91:15 exactly 42:15 examination 5:6 7:3 examine 51:17 examining 76:24 example 11:7 13:1 28:3 79:12 86:9 exception 8:11 122:14 excise 121:5 excluding 73:22,23 excuse 107:1 exhibit 6:1,3,5,6,9 6:10,12,13,15,18 7:17,19 9:7,8,18 9:20 10:12,14 13:16 14:7,9,21 15:13 16:22 20:24 21:14,16,18,21,22 21:23 40:7,11 41:4 55:10,12 61:20,21 65:1,6,8 68:11 69:20 exist 60:4 experience 52:11 55:7 57:7 63:23 67:9 74:6 76:21 76:22 82:4 84:1 104:12 110:24 111:10 112:13 113:16,21 115:14 experienced 111:7 111:16 123:7 expert 6:5 8:15 10:17 18:15 19:2	19:12 20:16,19 24:20 70:1,9 experts 10:3,9 75:22 96:12 expiration 48:21 49:2 50:3 137:20 expired 50:4 51:20 expires 136:20 exposed 86:2 93:17 94:10 96:8 exposure 59:3 62:20,20 64:18 81:5 82:8,13,16 82:20,23 85:12,16 86:5,7 94:4,13,14 105:7,17 extent 50:5 external 38:19 extra 49:23 extrusion 73:17 80:23 81:5,23 extrusions 120:24 eyes 77:4,7	53:3 56:22 58:22 59:12 60:11,18 64:8,19 65:7,9,11 71:17,18,21 73:13 77:21 78:20 80:2 82:18,21 83:16 84:4,13 87:16 90:9 92:4,7 97:7 97:11 99:3,14,21 100:3 102:14,17 107:10,19 110:11 111:8 112:19 113:17 114:7,16 116:20,22 117:4,6 117:10 119:22 120:6,8 121:13,17 121:19 123:1,3,15 123:22 124:1,5,7 124:17 127:11 129:1,17,19 130:6 131:12,19 132:2 132:17 133:6,14 133:18,22 failure 71:24 72:1,2 72:17,24 73:4,8 73:22,23 74:3,8 failures 72:14 fair 31:21 36:7 37:23 62:6 83:11 90:16 103:14 fall 103:17 falling 77:3,6 familiar 21:13 54:7 82:11 104:21 far 26:14 70:11,11 fashion 30:3 fashioned 125:19 faster 129:15 fault 72:18 fda 6:17,18,18 45:1 45:15 52:3,17,24 53:7,12 54:10,18 55:19,24 56:9 57:22 58:4 59:24 60:2,12 62:7,13 65:19 66:2 69:13		
E				F		
e 4:1,1 135:2 earlier 25:10 32:6 42:6 75:21 119:8 127:2 early 98:14 easy 99:6 121:21 ed 39:13 edge 86:20 edges 86:16 94:19 education 40:22 41:9 educational 8:7 effect 77:20 80:3 93:22 94:9 100:15 effective 44:23 52:12 57:4 64:1 efficacious 63:22 96:14 97:2,17 efficacy 11:7,9,13 12:21 17:20 18:9 44:19 63:5,10 eight 81:2 123:20 either 24:4 26:4 30:11 37:12 41:22 42:12 73:8 110:10 125:8 137:14 elapsing 104:8 electron 77:1 elevate 28:5,8 29:10 33:2,3 38:14,20 87:23				f 1:20 fact 35:8 38:19 75:3,15 79:15,21 81:16 99:14 129:21 130:17 factors 37:21 61:24 105:23 facts 13:16,17,17 137:5 faes 4:4 5:6 7:4,6 10:11,13 13:13,15 14:14,19,23 15:2 15:9,11 18:3 19:9 19:22 20:2,4,8,9 20:12 22:17,20 23:2,5,21 25:4,9 25:22 34:9,12 35:14 36:7 37:2 39:22,23 40:3,20 44:24 45:20,24 46:9,14 52:14,22		

83:4,9,10,17,20 83:22 84:7,10 110:16 114:11 fdas 44:17 45:14 66:11 federal 3:9 20:3 feel 29:1 30:10 52:13 67:8 69:19 69:24 70:6 105:10 127:24 feeling 27:18 90:13 felt 13:18 22:22 49:9 50:18 fibers 61:4 fifteen 43:17 fifth 55:18 fight 10:10 file 1:3 find 8:10 24:20 51:19 80:21 88:7 88:11,14 106:4 fine 114:22 124:2 finish 34:2 finished 34:6 first 7:2 18:12,14 20:15 21:19 24:12 25:12 32:16,19 33:8 35:2 41:18 42:1 47:14 65:12 66:1 68:12,18,23 69:4,9 72:17 75:14 100:13 108:1 122:4 123:6 137:7 fishing 78:20,23 79:2,4 86:9 five 71:9 73:24 74:4 74:10 80:17 81:2 93:2 107:7 flash 16:9 flat 11:8,16 12:2,6 12:15,22 13:2,8 27:3,4 28:3,4 29:16,21 41:15 43:24 44:8,13 53:11,18 66:20	67:2 68:7,18 69:4 69:11 85:1 92:12 92:15 106:11 124:18 floor 59:11 60:10 81:17 flow 94:21 flubbed 130:7 following 1:7 54:10 54:18 63:14 follows 7:2 followup 84:23 foregoing 136:5 137:6,9 forget 14:16,18 15:7 forgot 33:15 forgotten 75:22 form 17:19,21 18:8 22:12,13 23:19 25:3,6,21 35:11 36:3,18 39:17 44:20 45:17,22 46:3,12 52:8,18 53:2 56:20 58:15 60:5,14 64:6,14 71:13 73:11 77:17 78:18 79:24 83:12 83:21 84:2,12 87:13 94:16 98:24 99:12,18 100:1 107:17 110:7 111:3 112:11 113:14 114:2,14 117:9,11 119:20 121:11 122:21 123:14 124:13 127:9 128:22 130:4,24 131:17 131:24 132:9,23 133:9 136:9 forming 16:3,18 17:15,17 18:6 65:16 67:6 114:17 forth 9:24 115:9 131:10 137:9	forward 27:8 found 46:22 four 55:18 89:4,9 105:16 fox 1:21 frame 84:16 free 27:1 30:3,7 69:19 frequency 107:2 frequently 50:21 front 16:10 41:4 77:3,6 ft 137:2 full 24:19,21 26:17 46:15 83:23,24 137:10 fully 34:1 36:24 further 62:18 84:20 137:11 <hr/> G <hr/> gage 4:9,11 9:21 14:16,20,24 15:4 17:21 19:14,16,19 19:23 22:12,19,21 23:4,19 25:3,6,21 33:22,24 34:4,11 35:11 36:3,18 39:17 40:18 44:20 45:17,22 46:3,12 52:8,18 53:2 56:20 58:15 59:8 60:5,14 64:6,14 65:3,5 71:13 73:11 77:17 78:18 79:24 83:12,21 84:12 87:13 90:5 94:16 97:5 98:24 99:12,18 100:1 102:11,16 107:9 107:17 110:7 111:3 112:11 113:14 114:2,14 116:18 117:9 119:20 121:11 122:21 123:14,20	123:23 124:3,13 127:9 128:22 129:15,18 130:4 130:24 131:17,24 132:9,23 133:9,24 gathering 14:3 general 9:13 11:10 11:10,24 15:17,20 17:10 18:4,15 20:19 36:16,20 generalized 9:23 generally 66:4,5 127:23 gessner 3:8 getting 80:12 give 65:11 71:15 132:14 given 136:7 137:16 giving 22:21 114:4 115:22 glance 21:19 go 13:16 30:5 39:23 40:19 41:1 50:5 59:19 61:23 84:18 84:20 85:3 89:14 119:14 123:21 131:11 133:13,16 goes 41:11,16 131:1 going 7:18 9:6,7 10:5,13 14:1,8 20:13 21:15,17 25:16 27:8,8 28:14 46:23 47:8 47:9,15 48:8 55:11,17 59:10 61:3,4,5 65:7 69:16 72:10,11,19 73:18 80:21 82:18 83:16 84:4,6 89:7 95:22 96:1 99:6 101:5 102:11,12 103:5 109:6,6,17 111:4,6 115:7,24 117:10 119:5 127:24 131:9 132:19,20	golkow 137:21,24 good 7:5 14:5 50:18 51:11 63:21 69:10 114:5 goodwin 1:4 gotta 129:12 gotten 10:2 grade 37:18,24 38:9,10,10 39:7 39:16 40:10 77:16 grades 39:11 graft 63:3 127:14 127:15,19 grafts 128:3 grams 100:4 grand 4:5 gray 105:24 great 52:1,9 greater 30:3 82:14 91:19 125:16 grossly 76:24 group 51:14 guide 110:16 guidelines 110:15 110:18,21 gut 90:13 guys 20:2,4 gyne 96:15 gynecare 6:14 gynecologists 68:14 gynemesh 10:18,21 11:3,8,16 12:2,3,5 12:13,15,22 13:2 13:8 15:16 16:19 17:4 18:6,9 20:16 22:7 23:7 26:19 26:24 27:1,3,7,10 29:21 30:6,18,23 31:1,15,23 32:4,7 41:15,17 42:13 43:24 44:4,8,13 53:10,18 54:1 66:20 67:1,7,19 68:7 69:1,4,11,22 70:7 74:11,17 76:2,7,20 84:24
---	--	--	--	---

87:3 88:1 89:12 90:11,14,22 91:6 91:11 92:12,15 93:4,6 96:15 97:3 97:18 98:10,17 99:11,17,24 100:4 106:11 108:18,21 114:18 115:2,16 119:11 123:17 124:15,18 125:2,6 125:15,23 126:22 127:14,15,19 128:1,3,5,12,17 128:18	heard 9:23 104:3,6 heather 2:13 heavier 99:10,22 held 11:12 hell 15:4,5 help 27:12 110:16 helped 16:1 helpful 114:17 helps 17:24 hereto 3:11 137:5 hermann 47:19,21 hernia 54:1 100:21 100:24 101:1,6,12 hernias 68:14 101:12 hes 117:10 high 68:3 71:2 75:5 76:4 80:11 81:8 81:11 82:4,5,6,8 84:15 105:2,7,9 105:14 106:5,7 higher 81:9 106:2 highest 14:4,5 highland 4:10 highrisk 66:5,9,12 66:15,18,21 68:8 hill 1:9 history 94:20 hold 70:9 holes 95:10 honestly 19:6,16 hospital 47:22 49:5 hospitals 28:24 47:12,18,23 49:17 49:23 hours 20:12,23 21:2,3,7,10 123:24 houston 3:8 137:23 huge 12:24,24 human 33:1 hundred 91:5,11 91:19,22 92:8 93:3 126:15 hurt 132:20 hypothetical 63:7	74:20 83:17 84:7 hypothetically 85:13,20 86:3,14 86:22 104:4	20:13 21:15,17 22:15 34:5 39:20 44:10,15 45:3,9 45:18 52:4,22,23 53:24 54:7 55:11 55:17 58:2 65:7 67:17 69:16 71:15 72:12 73:18 75:23 78:4 79:11 82:18 83:14,16 84:4,6 85:15 86:12 87:1 88:16 89:6 90:6 93:18 95:6,6,16 95:16,22 99:1 100:2 101:1 102:11 108:17 115:24 119:5,10 124:24 126:6 130:9 133:18 impact 77:7 78:2 78:12 implant 48:21 51:24 53:6 implanted 24:9,12 25:12 49:1 51:12 52:16 79:8,11 implanting 37:15 51:21 52:7 68:15 108:7,9 113:11 123:8 implants 27:18 implication 77:22 important 13:18 22:23 67:5 103:10 132:18 improper 94:19 improved 63:9 inability 117:6,7,14 incapacitating 121:15 incision 95:11,14 101:4,10 include 107:4 109:24,24 132:6 included 106:19,23 109:7 125:8,9	131:15 includes 66:4,5 including 8:6 incorrect 22:22 25:10,13 indelicate 118:20 index 5:1 6:1 indicated 39:16 40:10,16 42:21 43:24 44:4 52:23 103:23 137:7 indication 68:18,24 69:6,12,13 indications 43:1 ineloquent 87:12 infection 103:21 104:8 inflammation 93:24 inflammatory 85:23,24 86:3 inform 55:19 information 40:21 80:12 84:6 108:4 130:1,2,20,22 131:14 informed 103:1,12 inguinal 101:12 inherent 64:5,12 109:20 injury 100:21 101:15,19,22 115:4 innumerable 94:21 inserted 29:16 instance 3:2 83:19 84:9 intend 46:10 69:23 87:4 91:18 92:1 93:13 100:10 106:13 intended 133:19 intepro 89:24 97:24 98:2 intercourse 116:14 116:24 117:8,14
---	---	--	--	--

117:17,19,21,22 117:24 118:5,8,10 118:14 interested 137:14 internal 67:11,15 interrogatories 137:7 interrupt 14:24 15:6 18:5 48:24 100:2 intervention 120:24 interventions 120:10 intraabdominal 62:23 introduce 13:7 introduced 63:6 introduces 58:24 59:2,9 invasive 100:8 102:2,3,4,18,20 investigator 63:18 63:24 invoices 8:14 10:3 involved 26:15 107:11,15 isnt 80:19 94:7,13 113:20 issue 94:23 issued 15:19 45:1 53:12 56:5 66:2 issuing 55:19 ive 13:16 28:5,5 35:19,23 75:21 76:23 83:13 104:3 132:24	joy 1:8 judge 1:5 judgment 43:4,10 131:4 133:8 july 54:10,18 58:10 <hr/> K <hr/> k 1:20 kansas 4:5 katy 47:21 keep 89:2 96:1 keeping 50:2 keeps 41:1 kept 48:5 key 2:19 kin 137:14 kind 37:2,6 49:10 50:15 87:12 89:8 89:15 105:20,24 kit 13:2,7 29:7,18 32:16,19,21,22 33:2,11,18 36:12 36:17 37:17 56:16 99:8 107:20 109:3 109:10 110:6 111:10 112:17 124:20 kits 36:15,22 37:1 44:19,23 87:22 99:7,15 123:12 127:8 knew 22:24,24 109:2 111:20 115:1 122:3 know 7:14 9:6,22 10:7,9 11:21 13:10 14:3 17:23 19:6,16 24:16 26:7,14 29:1 30:17,17,18,19,24 31:3,12,14,18,22 32:2,3,12 34:22 35:14 39:10,13,18 40:24 41:14,17,20 41:21,24 42:4,8 43:23 45:18 46:19	47:23 48:3,13,17 49:11,17 52:5,9 53:17 54:7 57:6 63:10 66:23 67:1 67:4,10,14 68:1,4 68:6,23 69:2,3,7,8 69:10,16 76:12,24 77:2 78:20,23 79:1,21 80:2 81:8 81:12 82:13,21 83:4,6,13 84:18 88:20 90:20,24 91:15 92:7,11,14 92:18 93:6,19 95:7 98:8 99:3,5 99:15 100:3,6 102:23 103:4,11 104:24 105:4,21 106:18 107:1 108:4,15,18,21 109:5,21 110:2,3 110:18,19,20 111:9,11,12,22 112:2,6,7,12 113:1,11 114:1,5 115:22,24 119:14 122:2,7,9,10,19 123:11,11,16 124:4 125:1,21 126:5,11,21 129:3 130:9 132:11,15 133:3,20 knowing 103:5 111:24 knowingly 52:15 knowledge 16:23 17:24 49:1,4 52:20 113:16,21 122:23 known 109:13 115:12 kriz 1:11 <hr/> L <hr/> label 42:24 43:5,7,8 43:15,19 52:21	labs 32:23 lap 15:8 lapsed 103:18 large 14:3 29:24 30:10 81:10 121:21 launch 24:19,22 26:17 37:12 46:15 launched 24:17 25:2,4,20 26:4 41:18 law 41:4 lead 85:11,18 86:10 86:23 94:4,12 116:3,8,13,24 117:13 119:18,24 120:3,10 learn 28:15 leeway 52:20 left 99:7 131:6 legally 53:5 level 13:24 14:4,5 129:22 130:18 levels 115:13 liability 1:4 lieu 45:16 life 48:17 49:12 102:4,6,7 107:4 lifechanging 102:7 102:19,23 103:9 120:15 121:9 lighter 99:16,20 liked 98:15 limited 26:10 line 78:20,23 79:5,5 86:9 94:22 95:2,8 95:8,12,15 135:5 list 6:7 14:12,22 15:15,23 16:1,2 17:1,8,12 22:1 91:18,22 122:1 listed 16:22 22:3,6 22:15,16 23:6,9 42:12 96:2 lite 89:24 98:2 literature 8:7,8	13:11 14:1,4 23:22 24:3 39:18 55:6 56:12 57:2 59:23 60:3,12 62:10 63:21 64:15 67:9 71:4,6 74:5 76:19 82:3 83:23 84:1 89:9 96:15 97:3,18 105:21 litigation 1:5 32:13 little 16:16 29:10 39:5 42:6 50:12 53:10 73:18 106:7 113:18 live 33:1 105:22 llp 4:4,9 logan 2:20 lois 1:23 long 2:13 30:19 130:11 longer 37:9 46:17 46:23 47:9,15,16 48:8 49:6 50:9 52:24 longest 84:22,23 longterm 123:7 look 16:16 19:7 21:23 25:24 32:13 32:15 39:19,21 40:1 42:14 59:8 62:10 68:11 83:23 83:24 90:15 100:6 looked 15:8 90:19 91:1,2 looking 13:11 52:11 55:6 61:18 74:5,5 81:10 loss 37:19 38:1 50:23 lot 11:3,10 14:3 21:12 34:5 81:3 84:5,19 88:22 105:21 125:12 louisiana 137:22 low 68:3,8 71:1 75:4 76:3
---	---	--	---	--

lower 61:14 62:3,9 62:13	master 1:3 material 109:21 materials 6:7 7:24 8:3,11 16:2,7,9 21:11,12 40:22 41:1,10 91:20 matter 61:1 72:20 mdl 1:7 6:8 18:17 mean 14:21,24 17:23 18:5 20:17 20:18,19 22:17 29:20 32:11 51:12 53:22 55:2 61:1 62:12 70:3 72:1,2 75:13,18 76:13 87:8,9 100:14 118:11 125:17 126:5 131:4 133:11 meaning 22:16 55:8 meant 23:1 102:7 110:9 130:7 medical 8:9 26:19 42:20,24 43:12 52:16 53:21 60:3 60:12 66:3 67:16 93:18 107:12,16 109:10,19 111:1,5 115:1 129:6,19 130:15 131:12,15 131:19 132:7,17 133:8,12 medication 43:7 medications 43:5 meeting 10:4,5 meetings 83:8 memorial 3:7 47:19 47:19,21 memory 44:11 85:6 85:8 mention 33:15 40:20 96:22 mentioned 14:17 16:6 mesh 6:16,19 11:8	11:16 12:2,6,15 12:22 13:3,3,7,8 18:1,4 23:22 24:3 27:4,17,18,20,23 28:2,3,5 29:3,3,4 29:16,21 30:3,7 30:12,13,16 31:12 31:15,16,23 32:13 32:16 35:1,24 36:1,2,9,12,16,19 41:15 43:12,14,19 43:24 44:4,9,13 44:19,23 53:11,18 53:21,23,24 54:3 54:5,23 55:20 56:18,23,24 57:1 57:3,16,18 58:13 58:14,18,20,22 59:3,13,15,17,20 59:22 60:3,7,12 60:15,17,21,23 61:2,8,12,14,15 61:16,18,24 62:1 62:3,5,14,15,20 62:21 64:4,5,11 64:12,16,18 65:20 66:8,12,20 67:2 68:7,12,15,18,24 69:4,5,11 70:14 70:14,18,18,19,23 71:24 72:1,1,16 72:18 73:17 74:11 75:6 76:11,12,24 76:24 77:2,5,14 78:13 84:24 85:1 85:10,17 86:1,5,7 86:16,18,20,22,23 87:3,7,23 88:3,8 89:12,19,21,24 90:2,3 92:12,15 93:11 94:4,5,12 94:13,15,23 95:9 97:19,21,24 98:2 98:4,6,10,10,16 98:18,20 99:10,11 99:15,16,17,24	100:4 106:11 107:20 109:10,21 110:6 111:9 115:2 116:2,8,13,23 117:2,13 119:19 121:5 123:8,12,17 124:10,11,18,19 125:7,12,21 126:24 127:5,6,21 127:22 128:10,11 128:13,15,16,19 meshes 28:2 35:16 35:17 36:1 87:16 89:4,10 96:13,13 96:24 97:15 met 81:14 meter 100:4 methodology 88:24 micral 103:20 microscopic 70:17 77:1 microscopically 77:19 78:2 microscopy 77:1 midurethral 17:16 17:18 18:7 mind 50:2 minds 10:4,6 minimally 100:8 minute 39:6 85:5 minutes 123:20 124:4 missing 113:15,16 113:21 mississippi 4:10 missouri 4:5 mistake 25:5 moderate 68:3,8,19 moderaterisk 66:4 moment 100:5 month 47:2 49:12 morbid 100:10,14 100:19 morrow 2:22 move 13:13 63:1 69:18 82:18 95:22	117:4 120:6 121:17 123:1 133:14 moved 27:19 multiple 57:4 80:14 96:2,4 115:7 120:10,19 121:5
M			N	
m 1:13 3:1,5,5 4:9 5:5 6:4,5 7:1 18:17,17 31:6 33:16 50:6,9,15 50:17,20 51:1,4 54:18 98:9,11,15 98:17,19,23 99:4 115:20 134:2 136:14 137:7 machine 3:7 major 17:22 100:21 majority 95:2 making 13:21 28:22 46:16 118:19 manifestation 94:7 94:8 manufactured 108:10 manufacturer 36:14 march 1:14 3:4 137:16 maria 2:5,17 marie 1:20 mark 9:8 14:20 21:17 marked 7:17,18 9:20 10:12,14 13:16 14:7,9 15:3 20:24 21:14,16,22 40:7,11 55:10,11 65:6,8 69:20 market 45:21 46:2 46:11 63:6,11 99:4,8,9,16 105:1 122:5 123:6 marketing 131:22 132:8,15,19 133:5 133:7 marlex 90:2 mary 1:15		n 4:1,4 name 7:5 29:7 nancy 2:16 narrow 57:23 native 27:13 30:11 34:14,16 63:4 64:3,9,20 82:17 90:9,20 112:17 117:2 118:12 necessarily 72:17 75:17 109:14 110:24 132:1,2 necessary 103:23 necrosis 93:24,24 94:11,17,21 96:3 96:4,8 necrotized 94:1,3 94:12 need 10:10 28:2 29:2,13 38:12 39:24 44:18 49:13 50:3 71:10 90:5 103:3 105:8 129:13 131:1,11 131:14 needed 10:4 29:13 37:20,21 104:7 105:20 106:19,23 114:12 122:22 129:7 needing 10:8 needs 123:21 131:16 never 20:4 23:21 24:1,2 43:14,18 43:19 49:1 67:18 68:5 83:8 90:19		

<p>91:21 95:13 99:4 104:3,6 new 16:15 35:15 75:24 91:8 98:16 news 6:18 nice 34:7 nicely 11:12 nomenclatures 31:5 nonissue 78:3 nonmesh 58:24 nonresponsive 84:5 notary 136:23 137:4 noted 136:10 notice 6:3 7:20,23 9:16 56:5 notification 54:11 54:19 55:13 56:4 56:8 57:10 60:1 november 18:18 20:21 nuances 36:20 nudge 34:8 number 7:23 16:6 20:23 26:10 49:12 68:2 74:14 75:10 81:3 87:9,10,14 88:5,10,13,16,17 91:15 92:9,13 numbered 3:4 numbers 9:7 numerous 91:4,10 92:10 132:12</p> <hr/> <p>O</p> <p>object 13:13 17:21 22:12,13 23:19 25:3,6,21 35:11 36:3,18 39:17 44:20 45:17,22 46:3,12 52:8,18 53:2 56:20 58:15 60:5,14 63:1 64:6 64:14 71:13 73:11 77:17 78:18 79:24</p>	<p>82:18 83:12,21 84:12 87:13 94:16 98:24 99:12,18 100:1 107:17 110:7 111:3 112:11 113:14 114:2,14 117:4,9 117:10 119:20 121:11 122:21 123:14 124:13 127:9 128:22 130:4,24 131:17 131:24 132:9,23 133:9,14 objection 9:22 10:6 23:3 obstruction 62:22 100:22 obviously 18:1 50:2 68:1 occasionally 27:24 occasions 26:22 occur 38:24 78:16 103:4 104:18 109:2 110:5 117:1 117:16 120:12,17 occurred 47:3 51:8 115:3 occurs 103:21 117:2 october 59:24 offer 46:10 69:23 87:5 93:13 96:18 100:10 106:13 offered 123:17 offering 77:15 119:12 office 137:16 officially 26:4 28:20 oh 12:7 14:19 18:13 20:20 22:24 25:7 33:4 71:9 74:24 102:9 104:12,14 124:21 okay 8:20 9:6,19</p>	<p>13:13 14:8 18:3 18:13,14,19 19:9 20:9,20 21:15 26:2 27:15 28:19 29:12 30:9 31:8 31:10,21 33:14 35:17,20 37:2,6 40:18 42:16 44:12 47:20 50:8 51:16 63:13 69:17 73:1 91:3 95:21,24 101:3 102:9 104:14,16 113:6,8 113:19 118:17 122:16 123:22 125:4 127:13 128:7,8 129:13,17 133:17 olsen 1:15 once 50:17 125:11 operations 111:14 opinion 55:6 64:15 69:22 70:23 71:3 74:16 75:6,12 76:1,6,17,19 77:15,23 78:5 87:4 89:19 93:13 96:18 100:10 101:8 106:13 115:22 119:12 123:3 131:7 opinions 10:19,22 10:24 11:12 13:19 16:4,19 17:7,15 17:17,19,23 18:7 18:8 46:10 65:16 67:7 77:15 84:2 114:17 115:8 opposed 11:1 93:23 oral 1:12 3:1 order 45:1,8 53:11 53:18 66:2 74:15 77:7 103:11 105:8 orders 83:9 organ 6:16,19 17:1 17:2,9 21:4 23:11</p>	<p>27:20,24 29:17 54:24 56:16 58:9 58:23 59:1 61:13 61:15 62:2,4,15 64:10,11,21 65:21 66:9 68:16,17 77:14 90:10,21 99:9 119:9,18,23 120:3,9,14,19,22 121:4,8,14,20 122:4 128:10,15 128:20 oriented 86:12,18 outcomes 63:15 64:4,11,16 outlier 83:2,5,11,18 84:8 outline 107:14 outside 53:7 overall 81:5,23 override 133:8</p> <hr/> <p>P</p> <p>p 3:5,5 4:1,1 134:2 page 5:2 6:2 25:1,5 25:16 55:15 57:8 61:20 69:18 87:2 96:11 100:7 104:10 135:5 pages 136:5 pain 58:19 60:9 112:21 116:3,9 118:3,15 119:24 121:15 painful 116:13,24 117:18,21,23 118:6,9,24 paper 63:15 paragraph 55:18 59:19 66:1 68:12 parentheses 57:14 57:16 parenthesis 59:21 parkway 4:10 part 35:9,9,12 75:13</p>	<p>particular 10:23 111:9 129:8 131:20 parties 137:14 party 137:12 pass 38:24 passed 103:24 passes 38:15,20 39:2 patient 8:9 30:10 35:7 36:12,17 37:17,24 43:8 51:21 52:7 56:17 56:19 64:22 71:1 75:5 76:4,22 77:8 80:9 84:14,17 86:24 102:3,18,22 103:3,11 109:12 113:24 114:4 patients 27:17 29:1 32:13 36:23,23 38:5,6,9 50:14,15 50:19,20,20,23 51:11,12,15 52:10 56:4,7,15 58:9,16 58:17 70:8,8 77:20 87:11,15 105:16,22 129:24 130:3,8,20,23 paula 1:11 pause 132:14 pd 88:7 peerreviewed 23:22 24:2 pelvic 1:4 6:16,19 17:1,2,9 21:4 23:11 27:20,24 29:17 54:24 56:16 58:9,23 59:1,11 59:13 60:10 61:13 61:15 62:2,4,15 64:10,11,21 65:21 66:9 68:16,17 77:14 81:17 87:3 87:8,20 88:3,8,12 88:15 89:19 90:10</p>
--	--	---	---	--

Christina Pramudji, M.D.

Page 148

90:11,21,22 99:9 111:13 112:15,16 112:17,21 116:3,8 117:20,20 119:9 119:18,23 120:1,3 120:5,9,14,19,22 121:4,8,14,15,16 121:20 122:4,12 122:15,17 128:10 128:15,20 pelvis 35:10 72:18 124:11 127:7,23 128:19 penetrated 118:21 penny 2:14 people 26:15 112:12 percent 55:9 71:9,9 72:11 73:2,13,24 74:4,9,10 80:11 80:18,24 81:2,3,6 81:24 82:9,15,17 84:15 88:20,21 94:14 95:4 105:11 105:13 106:2 percentage 72:22 perfect 107:9,9 perfectly 115:10 131:5 perform 35:2 performed 37:8 87:10 103:2 performing 37:11 period 27:6 37:7 47:6,13 48:12 51:7 103:18 peripheral 17:23 permanent 115:4 peroxides 79:21,22 80:2,6 person 48:23 117:23 personal 82:4 perspective 38:21 52:4 phrased 67:12	physically 118:5,9 118:14,20 physician 43:9 52:14 55:3 56:13 56:14,15,19 111:22,23,24 112:5,9 113:1,2 113:11,12,23 physicians 23:18 26:11 39:10 41:6 41:11 42:1 51:14 52:20 126:21 131:2 picturing 39:20 126:6 place 95:1,5,14 placed 48:15 61:12 61:17 62:1,21 86:19 95:18 103:16 104:1 placeholder 6:11 9:10 placement 6:16 placing 61:24 plaintiffs 3:3 4:3 10:3 96:12 please 20:7 69:15 116:21 130:12 plication 58:21 plus 31:6 33:16 50:6,9,15,17,20 51:1,3 54:18 98:9 98:11,15,17,19,23 99:4 115:20 point 19:7 29:23 30:1 34:8 45:3 57:12 58:6 59:20 61:23 62:1 63:12 64:24 99:8 points 11:11 poking 86:14 polymer 70:2,6,10 polymers 70:4,7 polypropylene 77:12,14,23 78:6 78:7,13,15,17,24	79:12,16 80:3,7 85:10 86:8 87:23 poor 94:20 112:21 pop 17:17 55:21 59:22 pores 61:8,8 portions 27:11 possession 8:6 possible 112:4,14 posterior 57:16,23 58:8,17,20,20 101:18 125:2,5,9 125:22 126:2,3 127:12 potential 38:21 59:10 94:8,9 96:2 96:4,7 103:4 111:15,20 112:6 112:16 114:21 115:1 potentially 43:6 78:9 102:4,19,23 103:9 107:3 128:3 practice 24:7 26:20 43:20 48:20 53:21 54:6 70:12 107:19 practicing 43:16 pramudji 1:13 3:1 5:5 6:4,5,7 7:1,5 7:20 15:11 23:5 40:3 97:11 136:14 137:6 precaution 132:7 132:18 prefer 36:5 prefers 118:23 premarket 69:13 preparation 8:9 prepare 19:4 prepared 40:14 preparing 20:23 107:11,15 preproliferation 30:8 prerogative 43:9 54:21 prescribed 103:18	103:24 present 4:13 58:24 79:22,23 pretty 12:7,13 19:11 80:19,20 98:14 previous 21:13 79:5 previously 58:1 59:21 124:12 127:7,23 128:4,20 price 31:22,24 primarily 34:24 primary 63:24 principle 11:24 prior 7:21 8:12 18:20 26:17 27:10 35:4 92:1 104:7 priority 133:12,15 probably 9:1,3 21:1,9 27:9 29:3 29:22 30:7 31:21 52:10 76:10 83:15 124:23 125:2,10 129:12 problem 95:9 problems 53:6 71:5 procedure 3:9 23:16 35:3 36:9 56:16 92:16,20 93:1 100:19,20 102:5,20,24 103:2 procedures 32:14 58:10 proceed 40:5 97:13 103:13 proceedings 137:10 process 7:13 28:12 produce 28:14 produced 3:2 8:12 19:10 21:17 92:5 producing 10:7 28:10,11 product 22:4 23:7 29:8 30:20,22 31:4 35:19,21,23	41:5,11,15,17,21 41:22 42:1,5,13 46:5,16 48:1,18 48:21 49:2,18 50:3 53:11,13 63:3,9 64:1 85:22 98:16 104:22 106:16 108:13 132:20 133:1 products 1:4 10:24 11:2,4,11,23 15:20 17:2,3,9,10 17:17 18:1 21:5 22:7 48:4 49:12 49:13 52:1 77:15 108:7,9 119:9,11 119:13,18,23 120:3,9,14,16,19 120:23 121:5,14 121:20 122:4 prof 39:13 professional 40:22 41:1,9 43:4 professionals 114:9 114:10 122:24 131:3 profile 11:7,16 12:21 project 104:21 projection 49:10 prolapse 6:16,20 17:2,2,9 21:4 22:11 23:11,17 27:12,20,24 29:17 32:17 35:9 38:9 39:11 50:23 54:24 56:16 58:10,23 59:1 61:13,15 62:2,4,15 64:10 64:12,21 65:21 66:9 68:16,17 72:2,8,20 77:14 90:10,21 99:9 119:9,18,23 120:3 120:9,14,19,23 121:5,9,14,20
---	--	---	---	---

122:4 128:10,16 128:21 129:22 130:18 prolene 31:4,12,15 31:20,23 41:21,24 53:21,23 54:1,3 61:3,10 69:22 70:14,18 76:14 79:16 89:6,21 93:11 128:12,12 128:17,18 proliferate 10:18,20 12:4,11,20 13:2,7 15:16 16:19 17:4 17:20 18:12 29:24 30:2,4 31:6 32:20 33:15 36:21 37:8 37:16,22 38:4,13 38:22 39:15 49:16 49:22,23 50:6,8 50:13,15,17,19,20 50:22 51:1,3,5,20 54:17,18 66:17,23 67:19 68:7 70:14 70:19 72:7 80:16 80:24 81:6,24 82:9,14 84:14 85:1 88:1 91:6,12 93:5 98:11,15,17 98:22,23 106:8 111:21 112:7,24 113:10 114:1,18 115:18,20 119:10 124:10,10,20,21 124:23 125:3,3,4 125:8,9,12,16,22 126:1,2,4 127:5,6 127:7,19,21,22 128:2 properly 86:18,19 95:18 propounded 136:8 pros 121:2 prosimas 6:14 7:7 10:18,20 11:6,15 11:19,20 12:1,11	12:13,15 13:3,8 15:16 16:19 17:4 18:6,9,16,20 22:4 23:13,15 24:6,13 24:19,21 26:3,7 26:16,16 33:3,4 34:13,17 36:13,20 37:11,16,18,23 38:14,20 39:4,6 40:9,12 41:5 42:5 42:13 45:2,8,14 45:16,21 46:1,11 46:15,19,23 47:8 47:13,14,24 48:6 48:10,14,18 49:6 50:13 51:19 52:2 52:7 54:10,15 63:3,15,18,24 66:14 67:19 68:7 70:15,19 71:8,24 72:14,24 73:4,8 73:17,21 74:2,11 80:10,17 85:1 88:1 91:7,12 92:19,24 93:5 98:9,19,22 99:3 100:8,17,20,23 101:8,10,11,14,18 102:1 103:16 105:8,12 106:4,14 106:20,24 108:15 111:2,21 112:7,24 113:10 114:1,18 115:14 119:10 123:6,12 129:8,21 130:16 protegen 104:21,21 105:1,5 proven 52:12 provide 20:11 provided 15:24 41:10 124:10 127:22 128:12,19 provides 56:24 57:16 58:13 127:6 provisions 3:10	prudent 112:8 113:2 ps 10:21 11:3,8,16 12:2,3,15,22 13:2 13:8 15:16 16:20 17:4 18:6,9 20:16 22:7 23:7 26:19 26:24 27:1,3,7 29:21 31:1,15,23 32:4,7 41:15,17 42:13 43:24 44:4 44:8 53:10,18 66:20 67:1,7,19 68:7 69:1,4,11 74:11,17 76:2,7 76:20 84:24 87:3 89:12 90:11,22 91:6,11 92:12,15 93:4,6 96:16 97:3 97:18 98:10,17 99:11,17,24 100:4 106:11 108:18,21 114:19 115:2,16 119:11 123:17 124:18 125:6,15 125:24 126:22 public 54:10,19 55:13 56:4,8 57:9 60:1 136:23 137:4 publications 8:8 22:1,3,6,9,15 23:6 23:9 published 23:21 24:2 pubmed 89:1,2 pulled 61:9 purposes 110:4 119:7 pursuant 3:9 push 86:1 pushing 86:5 put 39:19 42:15 50:16 86:21 110:16 115:9 122:20 124:11 127:6,22 128:19	129:9 131:2,13,16 132:21 133:4 putting 114:22 129:20 130:16 pvsd 87:21 88:8 <hr/> Q <hr/> quality 89:10,11 question 7:14,15 11:13 16:15 18:6 18:10 20:14 22:14 22:18 34:2 35:13 37:7 40:14 43:19 49:16,22 54:13 58:3,21 59:4,7 62:24 63:7 64:9 65:12 69:15 71:14 71:14,20 72:12,21 73:16,19 74:20 75:21,24 77:9 78:5 87:12 89:8 89:24 90:7 91:1,8 95:20 99:7 102:13 113:17,20,21 115:11,16,18,20 117:6,12 119:13 122:18,18 123:16 128:7 129:2,4 130:7,10,13 131:8 questions 7:4 14:22 22:14 72:6 107:6 119:7,8 129:12,14 133:19 136:7 quick 97:5,8 quijano 2:5 quite 87:24 quote 76:9 88:17 <hr/> R <hr/> r 1:4 4:1 135:2,2 ran 49:20 randomized 14:1 87:15 91:4,10 92:8,14,18,22 range 73:14 80:19 80:21,24 81:2,7	111:5 rare 54:24 55:1,2,4 55:8,21 56:10,12 56:18 103:7,8 rate 26:2 62:20,21 74:8,9 80:24 82:4 82:8,14,16 94:14 95:4 105:9,11,12 rates 11:22 12:1,12 12:14 61:14,16,19 62:3,9,11,14 70:24 71:1,7,22 71:23 72:7,14,23 73:3,7,17,20 74:1 75:4,4,10 76:3,4 80:10,15 81:6,11 81:23 82:20,23 84:14,17 105:2,4 105:7 reach 74:14,15 reached 10:20 reaction 85:19,23 85:24 86:1,4 read 55:17 57:12 59:7 65:18 107:20 107:23,23 108:1 108:24 109:9,18 116:17,18 136:4 reading 34:5 reads 62:1 ready 40:4 97:12 real 97:7 129:15 realistically 103:6 really 13:11 28:4 33:12 34:1,23 35:4 36:23 62:17 114:15 128:23 132:18 realtime 130:9 reask 22:18 72:21 84:5 119:6 130:10 reason 10:23 39:2 75:16 132:15 135:7,9,11,13,15 135:16,18,20,22 135:24
---	--	---	---	---

Christina Pramudji, M.D.

Page 150

reasonable 54:9,14 54:16 111:24 112:8,15 113:2,5 113:12,22 114:4 reasons 94:21 131:22 132:8,15 133:5 recall 19:6 27:6 29:7,15 31:17,20 33:9 42:11 43:7 43:20 44:7,12 45:4,6,11,13,19 45:23 46:7,22 47:1,2,5,12 48:11 48:14 51:7 53:15 53:16 67:21 85:3 85:7 92:17 93:8 105:6 108:14,20 108:23 122:6 recite 45:10 reclassify 66:3,12 reconsider 74:15 75:11 reconstructive 87:4 87:8,20 88:4,8,12 88:15 89:20 90:11 90:23 record 3:10 34:7 39:24 40:4 63:2 97:12 134:1 records 8:10 19:8 83:8 rectal 101:19 rectocele 37:19 38:1 40:10 recurred 72:2 recurrence 71:1 75:4 76:3 recurrent 72:16,19 recurring 72:8 reduced 137:8 refer 21:20 69:19 91:18 119:9 referenced 6:7 references 26:1 referring 17:3	18:22 27:2 51:13 58:1 69:1 119:10 refresh 44:10 85:5 refreshing 85:7 regard 45:1 53:12 55:24 115:14 117:7 regarding 7:7 8:15 10:17,20 17:19 18:8,16 20:16 44:18 67:7 70:23 83:9 106:23 109:10 regards 68:8 89:18 registration 137:21 regular 137:12,12 regulations 114:11 regulatory 52:4 114:9 reinforce 57:5 related 71:5 129:24 130:19 relates 1:6 55:4 70:11 release 6:18 63:11 reliable 96:14 97:2 97:17 115:10 reliance 6:7 14:12 14:22 15:15 16:24 17:8,12 91:20,22 relied 16:3,18 65:16 reluctant 27:18 rely 17:15,18 18:7 75:3 76:15 109:7 relying 76:5,19 remains 64:20 remember 10:1 19:7 24:15 28:23 48:16 51:9 100:5 107:7 125:18 remind 33:22 remote 121:22 removal 103:22 remove 76:11 removed 45:21	46:1,11 76:24 104:7 105:1 reoperation 70:24 71:7,19,22,23 72:7,14,23 73:3,7 73:17,20 74:1,8,9 75:3,10 76:3 80:15 rep 28:17 108:11 repair 1:4 6:19 27:13,20,24 29:17 30:11,12 54:1,23 55:21 56:23 57:3 57:4,14,15,16 58:17,21,23 59:1 59:22 61:13 62:2 63:4 64:10,20 65:21 66:8 68:13 68:15,17 90:10,21 90:21 99:9 128:10 128:15,21 repaired 71:11 repairs 34:14,16 64:3,9 82:17 117:3 118:12 repeat 69:15 rephrase 7:15 102:12,13,15 replace 79:4 report 6:5,8 10:17 10:19 11:1 13:15 13:19,22,23 15:16 15:17 17:9,10 19:4 20:11,19,24 21:4,8,11 22:7,9 22:15 24:18,21 25:17 42:13 69:19 87:2 91:3,9 93:9 96:11,21 100:7 104:10 reported 3:6 59:23 105:4 reporter 4:14 9:17 20:6 33:24 34:9 137:4 reporters 5:9	reports 8:15,18,23 9:2,13,14 15:20 17:12 19:21 59:24 representative 108:11 represented 21:19 21:24 requests 7:24 8:1 require 120:24 required 41:4 46:6 114:10 121:6 requirement 65:20 requirements 6:19 research 46:6 reserved 5:8 134:3 residency 111:15 112:13 residual 67:18,22 68:2 resolve 121:21 resources 46:6 respect 82:2 83:22 respectfully 60:6 response 24:24 45:7,12,14 53:17 57:11 59:6 64:7 116:15 responsive 8:1 restart 43:18 restate 116:16 restorelle 35:22,22 36:6,10 97:19 result 50:18 62:3,8 62:9,13,16 120:15 results 50:18 51:11 61:13 99:2 resume 14:17 retropublic 15:21 review 14:2 44:15 65:11 89:9,16 reviewed 7:21 16:3 16:18 40:13 44:8 44:13 65:15 110:20 reviewing 21:11 rhynchart 2:14	riddell 1:12 ridgeland 4:10 right 7:15 15:21 18:22,24 19:13,18 20:2 24:11 26:17 29:7,19,21 31:17 32:9 37:13 39:20 42:3,17 58:17 70:10 75:7,8 78:7 78:10,11 79:12,23 80:8 81:16 82:9 92:17 94:22 95:2 96:22 101:9 105:6 108:23 119:1,2 127:17 129:13,14 132:24 133:24 rigorous 44:18 rise 75:11 risk 59:2,9,13,22 62:22 64:18 67:11 67:11,15,15,18,22 68:2,3,3,3,19 100:17,21,24 101:6,7,7,15,16 101:18,19,22,22 101:24 111:20 112:6,24 113:10 113:24 114:6 115:1,4 119:21 121:22 122:1 133:2,4 risks 6:20 11:20,21 13:7,8 58:24 59:10 64:4,12,17 65:22 106:15 109:1,5,8,12,17 109:20,21 110:4,8 110:13 115:12 119:4,17,23 120:2 120:9,13,18 121:9 121:14,20 122:2,3 122:11,12,14,14 122:17,19,20 123:4 133:1 road 3:8 roll 133:20
--	--	--	---	---

rule 19:20	science 11:3 70:6	seven 84:21 85:2,4	99:19 125:11	112:2 123:23
rules 3:9	scientific 29:3,4	severe 38:9 50:23	single 11:1 124:18	sorts 109:24
S	59:23 96:15 97:2	115:3 116:3,8	sit 39:9 44:3,7,12	sounds 24:11
s 1:5 4:1	97:18	severity 107:3	45:11,13 46:1	southern 1:1
sacro 35:16	score 67:22 68:2	sewing 76:15 94:19	74:7 83:14 90:16	speaking 23:3
sacrocolpopexy	scores 67:11,15	sexual 116:14,24	93:21 99:14	58:16
34:21 35:7 36:8	screen 116:19	117:7,14,17,19,24	110:11	specific 36:14 38:5
61:18 62:19 64:24	seal 137:16	118:8	sites 120:20	42:8 110:1 122:18
100:9,16 101:5	search 89:1	sharon 1:14 2:7	sitting 30:24 31:11	129:23,24 130:19
safe 44:23 52:12	searches 89:3	sharp 86:16,20	42:11 43:23 44:7	130:20
63:22	second 39:24 40:18	sheet 124:18,19	45:4 53:15 67:21	specifically 20:18
safer 96:12 97:17	55:15 59:19 65:11	125:6 126:22	69:3 88:17 122:8	22:4,7,10 23:7,10
safety 6:17,20 11:7	66:2	136:10	situation 30:16	43:1 46:22 96:21
11:16 12:21 17:19	see 15:9 24:14 37:4	shelf 48:17 49:12	112:3,5	specifics 44:16
17:24 18:4,9	38:20 39:19 40:15	shelves 47:24 49:18	situations 43:5	132:16
38:21 44:19 63:5	42:15 51:13,17,18	sherry 1:21	52:19 118:12	spent 20:23 21:8,11
63:9 65:21	53:4 55:22 57:8	shively 2:19	132:5,21 133:7	square 123:12
sale 28:22 46:24	57:19 60:8 62:1	short 40:4 97:12	six 93:2	125:7 126:15,23
47:9,10	62:10 65:23 66:6	shortening 60:9	size 125:15,17	squared 100:4
sales 28:17 108:11	68:21 70:15 71:5	shorthand 3:7	sizes 32:3 123:16	st 47:21
132:20	72:21 77:2 89:21	137:3	slight 39:3 58:18	stacked 16:10
sampling 14:5	94:24 95:1,1,10	shortly 24:14,16	slightly 12:12,23,23	stand 42:18
sandra 1:18	99:2	show 63:9 75:16	39:3 99:19	standard 51:23
satisfaction 71:2	seeing 62:19 105:11	76:9 81:1 82:10	slings 17:16 18:7	52:15 53:7,9,20
75:5 76:4,23 80:9	seen 44:24 45:7	123:20	small 71:10 81:10	53:22,24 54:3
84:14,17	53:11 62:18 65:12	showing 44:22	101:16,19 105:22	64:20,23 110:12
saw 15:8 50:18	67:18 68:5 82:10	shown 81:9,9	118:16	112:9
51:11 57:7 63:23	83:8,13 95:14,17	shows 63:22 94:14	smaller 101:22,24	standardized
83:14	104:3,6 110:22	95:3	smith 1:20	128:24 129:5
saying 22:22 58:3	selection 50:12,14	shrink 60:13,15,23	smoking 94:20	standards 106:18
62:9 71:16 75:9	sell 46:5 67:16	shrinkage 59:21	snow 4:9 8:13 16:1	106:22
95:16,16 118:3	69:11	60:4 116:2	19:1	start 16:13 35:2
says 40:15 55:18	selling 48:1 49:18	shrinking 61:2	soft 31:4,12,15,20	77:10 116:1
59:20 62:8 66:1	semantics 61:1	shrinks 60:17,19	31:23 41:21,24	started 20:20 34:23
68:12 132:19	send 9:17	shrunk 61:4,5,9	54:1 69:22 70:14	35:5 50:19
scale 121:21	sense 11:4 19:17	61:10	70:18 128:12,12	starting 75:15
scar 59:18 60:8,18	30:4 75:19 87:12	sic 17:18 93:23	128:17,18	state 3:6 19:19
60:24 61:6,10	sent 8:12	side 76:8 95:7,10	sold 41:5 46:20	39:12 69:21 70:24
116:7,12,23	sentence 66:2	sides 95:17 125:14	47:15	76:2 87:2 91:3
117:13	separate 14:20	sidetracked 29:10	sonoma 81:18	93:9 94:18 96:11
scared 32:14	separately 91:21	signature 5:8 134:3	sorry 12:10 15:6	100:7,8 102:1
118:13	119:15	significant 13:11	18:5,10 20:8	137:1,4
scarring 59:16	separating 11:1	38:17 109:12	48:24,24 88:16	stated 3:10 32:6
60:16 117:20	serious 6:15 55:19	similar 12:8,13,18	90:7 100:2 104:13	85:20 122:13
school 93:18	56:17	61:16,19 62:11,20	133:18	137:5
	set 137:9	64:4,10,17 99:2	sort 76:8 89:13	statement 57:9,21

58:4 59:5 62:7,13 63:14,17,19,20 102:21 104:5 115:6 states 1:1 39:15 40:9 41:18 42:2 stockpile 49:6 stone 2:17 stop 27:15 28:8,11 28:20 54:9,14,17 stopped 28:9 32:6 46:16 48:1 49:18 82:22 stopping 28:13 story 50:7 straight 72:22 strengthens 6:18 65:19,19 strictly 53:5 strike 13:14 16:13 17:7,16 20:13 23:14 24:1 29:13 35:14 38:17 41:8 45:12 47:6 54:15 56:14 61:11 63:1 64:2 66:24 67:12 69:16 70:22 71:22 73:18 75:22 77:8 78:14 82:19 89:7 91:7 94:1,8 95:22 108:8 110:2 113:7 115:24 116:6,11 117:4 119:5 120:6 121:3,17 123:1 124:8 128:13 133:15 strings 17:18 strip 125:23 strong 44:22 strongly 69:24 studied 64:1 70:5 87:3,7,11,18,24 88:8,12,15 89:19 90:10,14,22 93:16 93:19 97:1 115:11 115:15	studies 14:2,3,5 26:11 44:18 45:15 57:5 61:18 62:18 76:9,11 80:14,20 80:22 81:1,1,9,10 81:11 82:8,10 84:18,19,20 85:3 85:9 87:10,11,14 87:15 88:2,7,11 88:14 89:3,11,12 89:13,21 91:5,11 91:19 92:11 93:3 93:6 study 45:16 82:11 82:14,21 83:24 84:22,23 85:3 94:13 95:3 97:18 97:24 98:2,4 stuff 29:11 subject 9:16 submit 69:12 subscribed 136:17 subset 38:6 substance 17:22 93:17,23 94:10 96:9 136:9 substitute 9:18 success 76:22 sufficient 106:15 106:17 suite 4:5,10 137:22 suited 37:18 sulcus 95:18 summit 81:17 superior 63:16 supplement 29:23 30:5,7 supplementation 124:15 support 17:24 30:3 37:19,20,21 38:2 38:12 50:24 57:14 63:15 69:21 70:23 74:16 76:1,2,6,7 76:19 103:17,22 103:23 104:7	123:8 supportive 75:16 supports 71:3,4 suppose 86:15 supposed 110:13 sure 7:16 14:23 19:11 25:19 44:10 44:15 45:3,9,18 46:13 52:4 54:12 58:2 67:17 72:12 78:4 79:14 83:14 85:15 87:1 90:13 93:18 99:1 108:17 114:11 surgeon 43:3 70:4 103:16 111:13 112:15 124:14 125:19 128:1 surgeons 68:13 110:10 122:12,17 122:23 123:7 133:2 surgery 36:6 57:1 57:17 58:14 59:1 59:11,14 61:15 62:4,15 76:15 79:17 87:4,8,20 88:4,9,12,15 89:20 90:12,23 102:3,18 103:5,13 109:6 111:17 112:17 117:20 120:1,5 121:16 122:15 128:24 133:3,3 surgical 6:16,19 23:14,16 43:11,14 43:19 54:22,23 55:7,20 56:18 61:24 65:20 66:8 66:12 68:12,15 109:5,15 120:10 120:24 133:3 surprised 112:20 112:21 surrounding 94:4	94:12 116:13,23 117:13 surrounds 61:7 survey 89:13 sustain 120:15 suture 30:11 62:20 82:16,20 94:22 95:2,8,8 103:20 sutures 34:14,17 79:16,16 switch 51:10 sworn 3:3 7:2,9 136:17 137:8 syndrome 119:24 synthetic 30:13,15 30:16 63:3 64:4 64:11 system 1:4 systematic 89:9,16 <hr/> T <hr/> t 135:2 tail 125:14 take 6:3 7:6,13 41:20 42:16 43:11 61:3 85:5 97:5 105:23 106:1 109:4,16 110:10 taken 3:3 129:7 137:12 talk 36:13,16,19 56:5 talked 39:5 42:5 50:12 79:15 talking 11:18 12:3 12:5,11 52:22,23 53:4,24 82:5 85:13 95:6,6 97:15 101:1 104:12 112:2,3 tamara 3:5 4:14 137:3,19 tasting 81:20 taught 39:13 taylor 2:20 technique 22:10	23:11 72:20 94:20 112:18 128:11,16 128:18 129:5 techniques 23:17 technologies 137:21 tell 7:9 10:16 14:11 19:17 21:20 24:12 56:7 58:12 74:23 81:4 93:21 109:7 telling 75:9 tells 39:10 56:16 ten 55:9 71:9 73:1 73:13,24 74:9,10 81:2 124:5 125:17 125:18,23,23 126:7,7,12,12 tenbyten 126:22 tend 96:18 terms 13:21 35:6 63:4 89:3 106:19 125:7 terri 2:19 testified 7:2 104:20 104:24 testify 137:8 testimony 59:12 95:13 112:23 113:9 testing 70:13 texas 3:6,8 19:19 20:1 137:1,5,19 137:21,23 thank 18:14 22:18 102:16 thats 10:9 13:5,12 14:4 15:22 19:18 19:24 23:2,24 24:5,11 25:7,13 25:13,19 26:6,18 27:14 32:10 33:21 35:22 36:11 37:10 37:14 38:16 42:3 43:8,22 44:14 46:18 49:21 50:11 53:6,7,24 54:20
---	---	---	--	---

56:2 63:7,23 65:4 67:24 68:10 70:18 70:19 71:15 74:5 74:24 75:13,14,14 79:7,8 80:19,20 81:8,8 83:1,18 84:1,9,11 91:14 93:12 94:23 95:9 96:10,17 97:21,23 99:23 100:2 103:14 104:10 105:3,24 107:14 108:2 114:16 123:3,10,19 124:2 125:6 127:1 131:2 theory 13:12 76:16 theres 7:23 16:9,9 17:12 21:24 31:22 32:12 50:2 57:4 72:19 74:12,21,23 75:9 77:19,22 78:2 84:5 85:21 86:3,6 87:22 93:2 94:21 99:7 101:5 101:9 105:23 109:5,14 111:4,6 121:22 125:6,21 132:24 theyll 9:18 theyre 11:21 12:7,7 12:13 13:11 14:2 18:1 28:12 31:18 36:1 52:1 54:20 55:8 61:4 62:8,10 80:11,11 99:19 103:5 110:19 113:15,21 114:20 115:7 128:2 131:9 132:11,12 theyve 28:9,9 62:16 thing 126:20 133:22 things 43:5 52:21 52:22 78:16 79:10 109:24 115:8 131:9 132:11	think 11:10 17:24 19:15,20,23 25:22 28:12,12,23 29:1 29:6 32:7 33:14 36:22 41:16 42:5 42:7,14 44:21 49:11 52:12 53:5 53:8,8 55:7 57:2 62:9,17,24 63:5 63:21 64:15 67:5 67:12,20 69:7 71:14,18 73:15 75:20 76:10 77:18 78:9 82:2,3,5 83:6 85:14,21 86:11 91:7 95:3,20 99:19 103:3 105:10,18 106:6 107:1 110:8,10 111:13 112:1,12 112:14,15,20 113:4,5 114:20,21 114:22 115:9,23 117:15 122:12,22 123:15 124:1,5,14 124:23 125:1,10 125:17,17 129:11 130:6 131:4,4,5,6 132:18 thinking 11:22 22:15 124:24 third 57:12 thought 12:10 37:21 114:12,17 132:7 three 10:24 21:4 46:17 55:18 84:17 106:6 119:7,11,13 119:14 123:24 throwing 9:7 thumb 8:6 tightening 60:9 time 15:6,19 18:12 20:7 21:21 23:2 27:6 29:2,15,22 30:6 33:10 34:8,8	34:12 37:7,15 42:17 46:15,16,20 47:7,13 48:12 50:9 51:3,7 62:18 76:13 84:16 107:24 108:1 124:24 137:11 times 26:23 27:5 33:12 34:5 36:4 39:2 107:7 119:7 tina 2:22 tissue 27:13 30:11 34:14,16 60:8,24 61:6,10 63:4 64:3 64:9,20 82:17 85:18 86:1,4,6,15 90:10,20 93:16,20 93:22 94:3,11,12 94:18,19 96:3,4,8 96:8 112:18 117:2 118:12 titled 65:19 today 7:6,21 8:1,4 8:14 10:10 16:13 16:18 30:24 31:12 39:9 42:11 43:23 44:3,8,12 45:4,11 45:13 46:1 51:20 51:24 52:3 67:21 69:3,12 74:7 83:14 88:18 90:17 93:21 99:10,15 110:11 122:8 123:4 told 45:20 46:8 47:8 58:16,17 81:22 83:10 108:6 108:12 top 25:5 57:14 92:9 123:13 126:5 total 29:24 30:4 124:21,23 125:3,7 126:11 127:19,21 127:21 128:2 track 41:1 traditional 53:20	53:22 54:3 57:1,4 57:17 58:14,20,24 89:21 98:22 trained 43:3 131:3 training 109:5,15 112:13 transabdominal 61:17 transcript 34:5 137:10 transcription 136:6 transition 50:19 transvaginal 6:16 6:19 22:10 23:10 27:17 29:2,6 35:1 44:1,4 54:23 55:21 56:23 57:3 57:13 58:23 59:22 61:15 62:4,14 65:20 68:17 69:5 69:11 128:11,16 128:18 transvaginally 61:17 93:7 treat 73:21 74:2 120:11 treated 24:1 treating 24:3 27:12 treatment 22:11 23:11,14,16 32:17 35:6,10 64:21 72:24 73:4,8,22 73:23 74:2,8 105:20 113:12,23 114:5 trial 26:16 63:19,24 91:18,23 92:2 trials 14:2 26:11 91:4,10 92:8,15 92:19,23 tried 24:17 33:12 34:21 36:4 45:15 trim 125:12 126:19 126:20,23 127:1 trocars 13:2,3,6 101:4 true 75:18 137:5,10 truth 7:10 137:8 try 7:15 13:24 14:4 99:1 107:4 turn 55:15 57:8 61:20 tv 15:17,20,21 17:10,18 18:8 tv 15:17,21 17:10 twice 105:18 two 22:13,14 39:11 55:17 84:19 85:9 128:3 129:11,14 typewriting 137:9 137:9 typical 64:21 typically 107:20 126:23,23 127:1,5	<hr/> U <hr/> u 1:5 uhhuh 9:9,12,15 10:15 11:14 12:17 14:10 15:12,14 16:8,11,14,21 25:18 32:24 33:21 34:3 53:1 55:14 55:16 58:11 60:20 60:22 90:4,18 132:4 ultimately 10:5 47:16 99:4 ultrapro 87:21 88:11 96:22 98:10 98:20 un 118:4 unable 117:17,23 118:1,8,9,14,21 unacceptably 105:2,9,14 106:5 uncomfortable 29:1 54:20 105:10 undergo 94:11 undergrad 70:5
--	--	--	---	---

understand 7:7,9 7:14 35:12 36:24 43:11 53:3 55:4 70:7 75:2 76:18 80:5 understanding 45:24 46:4,7 110:12 understood 90:7 unidentified 59:21 unintended 85:18 85:24 uninterested 118:1 118:4 unique 11:20,20,21 13:7 united 1:1 41:18 42:2 unquote 76:9 unwilling 118:1,4 update 6:15 55:19 updated 14:17 15:5 21:19,24 108:13 108:16,19,22 uphold 29:8,9 33:5 33:6,11 98:6 upwards 105:11 usda 6:15 use 26:19 27:11,23 28:2,5 29:3,5 30:22 32:16 33:8 35:23 36:2,15 37:4,17 42:1 43:2 43:3,5,9 44:1,5 48:5,6,10 49:9,19 50:4,8,21 52:20 64:5,12 68:19 69:5,12 72:20 76:14 88:24 91:22 93:4,6 107:21,24 110:5 111:1,5 115:14 126:19,21 126:23 uses 99:10 usual 48:20 usually 95:17	125:12 utilize 128:6 utilized 84:24 <hr/> V <hr/> vagina 57:14,15 79:18,22 95:7,11 118:2,13,15 vaginal 36:16,19 60:9 103:17,22,23 104:6 123:8 various 13:16 115:13 vast 95:2 versa 34:18 versus 12:11 50:13 58:20 98:17 118:9 vessels 100:22 vice 34:17 view 34:16 viewpoint 44:17 vinson 3:6 4:14 137:3,19 virginia 1:1,17 vitae 6:9,12 23:7,10 vypro 31:8 87:21 88:3 96:22 <hr/> W <hr/> wagstaff 4:4 waited 51:10,13 wall 57:15,23 58:1 58:8 101:1,6,9 walltowall 32:12 want 14:17 15:7 32:15 34:6 39:23 42:16 59:7 63:10 63:11 69:20 96:1 103:12 116:16 130:10 133:4,10 133:11 wanted 69:10 warlick 2:10 warn 114:21 warning 47:5 131:20,21 132:6	132:18 warnings 106:14 106:20,24 wary 27:17 wasnt 18:10 19:12 25:20 30:1 79:10 89:15 113:2,12 131:22 watch 129:16 water 39:24 wave 1:7 6:8 8:15 18:17 20:19 way 31:19 33:24 72:18,22 74:20 86:21 90:20 108:4 111:18 119:13 122:7 124:7,9 127:4,20 128:9,15 128:24 129:2 133:18 wcllp 4:6 website 44:14 week 81:22 weeks 28:13 weight 99:10,16 100:3 wendy 2:4 went 21:11 122:4 123:4 west 1:1 westinhouston 3:7 weve 62:18 63:21 whats 7:18 10:14 14:8 21:15 37:7 40:11 55:11 65:8 84:22 whatsoever 110:12 whens 33:10 white 1:17 wide 111:4 widely 25:1,20 william 4:9,11 9:10 14:15 19:11 22:18 23:3 65:10 williams 2:16 wilson 2:1	wine 81:20 withdraw 102:12 102:14 117:11 witness 3:2 19:15 19:18,24 20:3 22:24 33:23 34:3 71:15 90:6 97:9 133:17,20,23 137:6,7 wolfe 1:18 woman 33:1 115:4 120:14 128:4 129:21 130:17 womans 110:6 124:11 127:6,22 128:19 women 69:21 74:16 76:1,6 120:23 129:8 wondering 98:16 wont 96:1 word 55:4 63:1 123:1 133:15 words 113:3,4 work 8:15 34:1 36:5 112:9 114:7 worked 47:12 51:18 52:9 works 70:7 108:12 worse 89:11 wouldnt 31:18 86:5 105:13 112:5 127:18 wound 59:15,16,18 60:8,16,18,24 61:6 94:18,23 95:9 112:21 116:5 116:7,12,22 117:1 117:12 writing 13:21 107:11,15 writings 107:11 written 19:4 20:11 62:16 wrong 19:11 67:13 91:7 107:14 130:9	130:9 wrongful 131:23 132:22 wrote 24:18,20 www 137:24 <hr/> X <hr/> x 49:12 <hr/> Y <hr/> y 35:24 36:1,1 yeah 15:4 19:22,24 21:1 22:19 25:11 25:13,14 33:4 34:11 39:22 71:18 73:14 77:1 79:14 80:20 81:8 84:4 90:6 97:9 102:11 102:14 104:15 106:3 113:17 116:20 124:1,1,1 124:2,2,5 125:10 126:2 127:13,14 129:18 130:14 132:19 133:23 year 18:21,21 47:2 69:7 79:6 84:17 108:22 years 33:9,13 43:15 43:17,20 46:17 49:13 70:4 84:17 84:19,21 85:2,4 108:7,9 youd 11:19 13:1 29:5 67:6 79:11 81:7 86:16 89:15 111:8 112:4 youll 9:17 102:12 youre 7:9 11:17,17 16:16 18:22 19:23 22:16 27:1 34:6 53:4 55:3 75:2,9 76:5,18 77:15 80:21 82:11 84:22 84:23 88:17 101:18 102:12
---	---	--	--	---

Christina Pramudji, M.D.

Page 155

104:16,20 109:3 111:13,13,14,17 112:2,3,18 115:22 118:3,17,19 119:11 youve 7:12 10:20 11:13 16:6,6,18 16:24 17:8 20:23 22:14 23:21 24:1 24:2,6,9 26:23 27:6 32:22 33:2 33:14,15 34:20 43:14,18,19 44:8 44:13 49:1 62:24 67:18 68:5 81:14 83:8 90:19 91:21 95:13,20,20 96:2 104:6,20 107:5,6 110:20 111:14 123:15	12cv00760 1:23 12cv00783 2:4 12cv00799 2:6 12cv00806 1:10 12cv00878 1:22 12cv00899 2:3 12cv00938 1:11 12cv00958 1:17 12cv00960 2:12 12cv01119 2:15 12cv01275 2:13 12cv01286 2:1 12cv01318 1:20 12md02327 1:3 136 5:8 138 5:9 1400 4:10 15 6:6 43:20 80:24 81:6,24 82:14,17 94:14 95:4 1950s 68:13 1970s 68:14 1990s 68:16	42:7 60:1 2009 25:23 26:4 37:12 2010 24:22 25:2,20 26:4 37:12 40:12 2011 27:9,15 29:22 34:24 35:4,5 54:10,18 55:12 81:17 2012 37:9 2013 44:8 58:10 2015 44:13 2016 1:14 3:5 65:22 137:16 20th 60:1 21 103:24 104:8 21day 103:18 22 6:9,12 23 1:14 23rd 3:4 25 3:5 88:20 105:13 134:2	5 5 6:10 9:8,18,20 100:7 50 21:2,3,7 88:20 522 44:24 45:7,14 45:16 46:7 53:11 53:18 83:9 56 6:15 5711 4:11
Z			6 6 6:12 21:18,21,22 21:23 601 4:11 64112 4:5 66 6:18 690 137:21
0			7 7 6:13 40:7,11 41:4 701 4:6 75 24:9 84:15 77002 137:23 77024 3:8
1	2 2 1:3,8,10,11,13,14 1:16,17,19,20,22 1:23 2:1,3,4,6,7,9 2:10,12,13,15,16 2:18,19,21,22,24 6:5 10:12,14 13:16 37:18,24 39:7,16 40:10 20 3:5 21:9 72:11 73:1,13 74:4,9 80:18,24 81:6,24 82:9 94:14 95:4 123:23 136:19 200 1:7 2000 70:8 2002 27:8 41:16 68:18 69:1 2005 27:10 32:18 37:8 2007 26:8 2008 24:15 25:12	3 3 5:3 6:6 14:7,9 15:13 16:22 20:24 37:18 38:1 39:7 39:16 40:10 57:8 69:18 87:2 30 21:12 105:11 106:2 300 4:5 3015 137:19 39157 4:10 3s 38:10,10	8 8 5:6 6:3,15 55:10 55:12 65:2,3 80 80:11 816 4:6
		4 4 3:5 6:9 21:14,16 61:20 96:11 123:23 134:2 40 25:5,16 41 6:13 25:1 104:10 440 137:22 4740 4:5 4s 38:9 4th 65:22	9 9 6:18 65:1,2,5,6,8 68:11 90 80:11 84:15 910 137:22 945 3:8 948 4:11